<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:FONR="http://fonar.com/20260331"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fonr-20260331.xsd" xlink:type="simple"/>
    <context id="From2025-07-01to2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-05-05_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-05</instant>
        </period>
    </context>
    <context id="AsOf2026-05-05_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-05</instant>
        </period>
    </context>
    <context id="AsOf2026-05-05_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-05</instant>
        </period>
    </context>
    <context id="AsOf2026-05-05_us-gaap_PreferredClassAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-05-05</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassANonVotingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassANonVotingPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonClassBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_CommonStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:CommonStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_ClassANonVotingPreferredStockholdersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassANonVotingPreferredStockholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_CommonClassCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_custom_ClassCCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassCCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_ClassCCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassCCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember1563870484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ClassCCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassCCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_ClassCCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassCCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CommonStockMember1563870812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ClassCCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassCCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_custom_ClassCCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">FONR:ClassCCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="AsOf2015-07-01_us-gaap_OtherInvesteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-01</instant>
        </period>
    </context>
    <context id="AsOf2015-07-01_us-gaap_NoncontrollingInterestMember_us-gaap_OtherInvesteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-01</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_OtherInvesteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_OtherInvesteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember_us-gaap_OtherInvesteesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">us-gaap:OtherInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_OtherRevenueSourceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherRevenueSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_OtherRevenueSourceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherRevenueSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_CommercialInsuranceManagedCareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:CommercialInsuranceManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_MedicareMedicaidMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:MedicareMedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_WorkersCompensationPersonalInjuryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:WorkersCompensationPersonalInjuryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_OtherRevenueSourceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherRevenueSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_OtherRevenueSourceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">FONR:OtherRevenueSourceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ClassCCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassCCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ClassCCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassCCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_ClassCCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassCCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_ClassCCommonMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassCCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_ClassAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">FONR:ClassAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_DoubtfulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:DoubtfulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_DoubtfulMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:DoubtfulMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_AdditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FONR:AdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DeductionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FONR:DeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_AdditionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FONR:AdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_DeductionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">FONR:DeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_OperatingLeasePaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">FONR:OperatingLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_FinancingLeasePaymentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">FONR:FinancingLeasePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_DiagnosticEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FONR:DiagnosticEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_DiagnosticEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FONR:DiagnosticEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_ResearchDevelopmentAndDemonstrationEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FONR:ResearchDevelopmentAndDemonstrationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_ResearchDevelopmentAndDemonstrationEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">FONR:ResearchDevelopmentAndDemonstrationEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_NoncompeteAgreementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_NoncompeteAgreementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_NoncompeteAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:NoncompeteAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2024-07-012025-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_PatentsAndCopyrightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_SoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:SoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_SoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:SoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_SoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:SoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_SoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:SoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_EmploymentContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:EmploymentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_EmploymentContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:EmploymentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_EmploymentContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:EmploymentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_EmploymentContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">FONR:EmploymentContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">FONR:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_SoftwareLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">FONR:SoftwareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_NonCompeteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">FONR:NonCompeteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">FONR:PatentsAndCopyrightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:ManufacturingAndServiceOfMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:ManufacturingAndServiceOfMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:ManufacturingAndServiceOfMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:ManufacturingAndServiceOfMedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_TotalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">FONR:TotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-26_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-26</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_srt_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-02-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2025-07-012026-03-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2024-07-012025-03-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="From2026-01-012026-03-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-03-31_custom_MagneticResonanceManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000355019</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">FONR:MagneticResonanceManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Ratio">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-07-01to2026-03-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-07-01to2026-03-31" id="Fact000004">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-07-01to2026-03-31" id="Fact000005">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2025-07-01to2026-03-31" id="Fact000006">2026</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey contextRef="From2025-07-01to2026-03-31" id="Fact000007">0000355019</dei:EntityCentralIndexKey>
    <FONR:AccountReceivableRelatedParties
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0058"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:UnearnedRevenueOnServiceContractsRelatedParty
      contextRef="AsOf2025-06-30"
      id="xdx2ixbrl0132"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl0161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2026-01-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0601"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2026-01-012026-03-31"
      id="xdx2ixbrl0602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2026-01-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0607"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0638"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0662"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0667"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0672"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0677"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0678"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0707"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0729"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0733"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2025-07-012026-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0735"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2025-07-01to2026-03-31"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0740"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-07-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0741"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0746"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0770"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:SaleNonControllingInterests
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0781"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0783"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0784"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0809"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0814"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2024-07-012025-03-31"
      id="xdx2ixbrl0817"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:SaleNonControllingInterests
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:SaleNonControllingInterests
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0822"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0826"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      id="xdx2ixbrl0832"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:AbandonedPatents
      contextRef="From2024-07-012025-03-31"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:CostOfNoncompeteContract
      contextRef="From2024-07-012025-03-31"
      id="xdx2ixbrl0910"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-07-01to2026-03-31"
      id="xdx2ixbrl0924"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="From2025-07-01to2026-03-31"
      id="xdx2ixbrl0927"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="From2025-07-01to2026-03-31"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:AccountsReceivableNetRelatedParty
      contextRef="AsOf2026-03-31_us-gaap_DoubtfulMember"
      id="xdx2ixbrl1299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NontradeReceivables
      contextRef="AsOf2026-03-31_us-gaap_DoubtfulMember"
      id="xdx2ixbrl1303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NontradeReceivables
      contextRef="AsOf2025-06-30_us-gaap_DoubtfulMember"
      id="xdx2ixbrl1319"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2026-03-31_custom_AdditionsMember"
      id="xdx2ixbrl1347"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2026-03-31_custom_DeductionsMember"
      id="xdx2ixbrl1353"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2026-03-31_custom_DeductionsMember"
      id="xdx2ixbrl1358"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2025-06-30_custom_DeductionsMember"
      id="xdx2ixbrl1373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      id="xdx2ixbrl1450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      id="xdx2ixbrl1454"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:PresentValueDiscountFinancingLease
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      id="xdx2ixbrl1470"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2025-07-01to2026-03-31"
      id="xdx2ixbrl1521"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      id="xdx2ixbrl1637"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      id="xdx2ixbrl1679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      id="xdx2ixbrl1755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      id="xdx2ixbrl1761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      id="xdx2ixbrl1767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      id="xdx2ixbrl1768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      id="xdx2ixbrl1773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      id="xdx2ixbrl1774"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      id="xdx2ixbrl1779"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      id="xdx2ixbrl1780"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:RecruitingFees
      contextRef="AsOf2026-03-31"
      id="xdx2ixbrl1832"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:RentExpenses
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      id="xdx2ixbrl1872"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SalariesAndWages
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1885"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1889"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1893"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1941"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:RentExpenses
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      id="xdx2ixbrl1976"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1989"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1993"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl1997"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2045"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:RentExpenses
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      id="xdx2ixbrl2079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SalariesAndWages
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2092"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2096"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2100"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2148"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:RentExpenses
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      id="xdx2ixbrl2185"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SalariesAndWages
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2198"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2202"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2206"
      unitRef="USD"
      xsi:nil="true"/>
    <FONR:IntersegmentNetRevenues
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      id="xdx2ixbrl2254"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-07-01to2026-03-31" id="Fact000013">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-07-01to2026-03-31" id="Fact000014">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport contextRef="From2025-07-01to2026-03-31" id="Fact000015">false</dei:DocumentTransitionReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-07-01to2026-03-31" id="Fact000016">2026-03-31</dei:DocumentPeriodEndDate>
    <dei:EntityFileNumber contextRef="From2025-07-01to2026-03-31" id="Fact000017">0-10248</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-07-01to2026-03-31" id="Fact000018">FONAR CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-07-01to2026-03-31" id="Fact000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-07-01to2026-03-31" id="Fact000020">11-2464137</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-07-01to2026-03-31" id="Fact000021">110 Marcus Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2025-07-01to2026-03-31" id="Fact000022">Melville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-07-01to2026-03-31" id="Fact000023">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-07-01to2026-03-31" id="Fact000024">11747</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-07-01to2026-03-31" id="Fact000025">(631)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-07-01to2026-03-31" id="Fact000026">694-2929</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2025-07-01to2026-03-31" id="Fact000027">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-07-01to2026-03-31" id="Fact000028">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-07-01to2026-03-31" id="Fact000029">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-07-01to2026-03-31" id="Fact000030">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-07-01to2026-03-31" id="Fact000031">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-07-01to2026-03-31" id="Fact000032">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="From2025-07-01to2026-03-31" id="Fact000033">Common Stock, $.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-07-01to2026-03-31" id="Fact000034">FONR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-07-01to2026-03-31" id="Fact000035">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-05-05_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000036"
      unitRef="Shares">6173008</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-05-05_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000037"
      unitRef="Shares">146</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-05-05_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">382513</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2026-05-05_us-gaap_PreferredClassAMember"
      decimals="INF"
      id="Fact000039"
      unitRef="Shares">313438</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000044"
      unitRef="USD">53650000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000045"
      unitRef="USD">56334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">122000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000048"
      unitRef="USD">120000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">124000</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">264000</us-gaap:AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000050"
      unitRef="USD">4717000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000051"
      unitRef="USD">5305000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <FONR:AccountReceivableRelatedParties
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000057"
      unitRef="USD">30000</FONR:AccountReceivableRelatedParties>
    <FONR:MedicalReceivable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000060"
      unitRef="USD">25592000</FONR:MedicalReceivable>
    <FONR:MedicalReceivable
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">24490000</FONR:MedicalReceivable>
    <FONR:ManagementAndOtherReceivableAllowancesForDoubtfulAccounts
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000066"
      unitRef="USD">11930000</FONR:ManagementAndOtherReceivableAllowancesForDoubtfulAccounts>
    <FONR:ManagementAndOtherReceivableAllowancesForDoubtfulAccounts
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">14296000</FONR:ManagementAndOtherReceivableAllowancesForDoubtfulAccounts>
    <us-gaap:AccruedFeesAndOtherRevenueReceivable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000063"
      unitRef="USD">48608000</us-gaap:AccruedFeesAndOtherRevenueReceivable>
    <us-gaap:AccruedFeesAndOtherRevenueReceivable
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000064"
      unitRef="USD">43401000</us-gaap:AccruedFeesAndOtherRevenueReceivable>
    <FONR:RelatedPartyReceivableAllowancesForDoubtfulAccounts
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">9320000</FONR:RelatedPartyReceivableAllowancesForDoubtfulAccounts>
    <FONR:RelatedPartyReceivableAllowancesForDoubtfulAccounts
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000075"
      unitRef="USD">7137000</FONR:RelatedPartyReceivableAllowancesForDoubtfulAccounts>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">10042000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000071"
      unitRef="USD">9748000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowances>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcess
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">2832000</us-gaap:InventoryFinishedGoodsAndWorkInProcess>
    <us-gaap:InventoryFinishedGoodsAndWorkInProcess
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000078"
      unitRef="USD">2813000</us-gaap:InventoryFinishedGoodsAndWorkInProcess>
    <FONR:PrepaidExpensesAndOtherCurrentAssetsRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000080"
      unitRef="USD">940000</FONR:PrepaidExpensesAndOtherCurrentAssetsRelatedParty>
    <FONR:PrepaidExpensesAndOtherCurrentAssetsRelatedParty
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000081"
      unitRef="USD">411000</FONR:PrepaidExpensesAndOtherCurrentAssetsRelatedParty>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000083"
      unitRef="USD">1474000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000084"
      unitRef="USD">2050000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">148007000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000087"
      unitRef="USD">144672000</us-gaap:AssetsCurrent>
    <FONR:AccountsReceivableNetLongTerm
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">3040000</FONR:AccountsReceivableNetLongTerm>
    <FONR:AccountsReceivableNetLongTerm
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000090"
      unitRef="USD">3550000</FONR:AccountsReceivableNetLongTerm>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000092"
      unitRef="USD">6195000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000093"
      unitRef="USD">6349000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000095"
      unitRef="USD">18199000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000096"
      unitRef="USD">18532000</us-gaap:PropertyPlantAndEquipmentNet>
    <FONR:NoteReceivableRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">592000</FONR:NoteReceivableRelatedParty>
    <FONR:NoteReceivableRelatedParty
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000099"
      unitRef="USD">555000</FONR:NoteReceivableRelatedParty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">35011000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000102"
      unitRef="USD">35136000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000104"
      unitRef="USD">207000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000105"
      unitRef="USD">377000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000107"
      unitRef="USD">4269000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000108"
      unitRef="USD">4269000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000110"
      unitRef="USD">2811000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000111"
      unitRef="USD">2992000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">891000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000114"
      unitRef="USD">476000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">219222000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000117"
      unitRef="USD">216908000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000122"
      unitRef="USD">2287000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000123"
      unitRef="USD">1302000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">4695000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000126"
      unitRef="USD">6975000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">4399000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000129"
      unitRef="USD">4866000</us-gaap:DeferredRevenueCurrent>
    <FONR:UnearnedRevenueOnServiceContractsRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">27000</FONR:UnearnedRevenueOnServiceContractsRelatedParty>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000134"
      unitRef="USD">3810000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000135"
      unitRef="USD">3383000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000137"
      unitRef="USD">224000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000138"
      unitRef="USD">244000</us-gaap:FinanceLeaseLiabilityCurrent>
    <FONR:CustomerDeposits
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000140"
      unitRef="USD">681000</FONR:CustomerDeposits>
    <FONR:CustomerDeposits
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000141"
      unitRef="USD">354000</FONR:CustomerDeposits>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000143"
      unitRef="USD">16123000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000144"
      unitRef="USD">17124000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000149"
      unitRef="USD">3273000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000150"
      unitRef="USD">3801000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000152"
      unitRef="USD">321000</us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000153"
      unitRef="USD">321000</us-gaap:DeferredIncomeTaxesAndOtherLiabilitiesNoncurrent>
    <FONR:AccountsPayableRelatedPartyNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000155"
      unitRef="USD">93000</FONR:AccountsPayableRelatedPartyNoncurrent>
    <FONR:AccountsPayableRelatedPartyNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000156"
      unitRef="USD">93000</FONR:AccountsPayableRelatedPartyNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000158"
      unitRef="USD">34797000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000159"
      unitRef="USD">35149000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000162"
      unitRef="USD">142000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000164"
      unitRef="USD">159000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000165"
      unitRef="USD">173000</us-gaap:OtherLiabilities>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000167"
      unitRef="USD">38643000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000168"
      unitRef="USD">39679000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000170"
      unitRef="USD">54766000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000171"
      unitRef="USD">56803000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_custom_ClassANonVotingPreferredStockMember"
      decimals="INF"
      id="Fact000176"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="INF"
      id="Fact000178"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000180"
      unitRef="Shares">453000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000182"
      unitRef="Shares">453000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000184"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000186"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000188"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000190"
      unitRef="Shares">313000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000192"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30_custom_ClassANonVotingPreferredStockMember"
      decimals="-3"
      id="Fact000194"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000196"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000198"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000200"
      unitRef="Shares">567000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000202"
      unitRef="Shares">567000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000204"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000206"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000208"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000210"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2026-03-31_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000212"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember"
      decimals="-3"
      id="Fact000214"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000216"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000218"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000220"
      unitRef="Shares">8500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000222"
      unitRef="Shares">8500000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000224"
      unitRef="Shares">6173000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000226"
      unitRef="Shares">6203000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000228"
      unitRef="Shares">6168000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000230"
      unitRef="Shares">6168000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000232"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000236"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonClassBMember"
      decimals="INF"
      id="Fact000238"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000240"
      unitRef="Shares">227000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000242"
      unitRef="Shares">227000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000244"
      unitRef="Shares">146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000246"
      unitRef="Shares">146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000248"
      unitRef="Shares">146</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonClassBMember"
      decimals="0"
      id="Fact000250"
      unitRef="Shares">146</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000252"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_us-gaap_CommonClassBMember"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2026-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000256"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-06-30_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000258"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000260"
      unitRef="Shares">567000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000262"
      unitRef="Shares">567000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000264"
      unitRef="Shares">383000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000266"
      unitRef="Shares">383000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000268"
      unitRef="Shares">383000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000270"
      unitRef="Shares">383000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-06-30_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">178292000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">178757000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">672000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">-5289000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000285"
      unitRef="Shares">4000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000287"
      unitRef="Shares">35000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">395000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000283"
      unitRef="USD">860000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">178570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">172609000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-14114000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000293"
      unitRef="USD">-12504000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">164456000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">160105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000298"
      unitRef="USD">219222000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">216908000</us-gaap:LiabilitiesAndStockholdersEquity>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000304"
      unitRef="USD">8085000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000305"
      unitRef="USD">8853000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:ProductSalesNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000307"
      unitRef="USD">75000</FONR:ProductSalesNet>
    <FONR:ProductSalesNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000308"
      unitRef="USD">55000</FONR:ProductSalesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000310"
      unitRef="USD">2162000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">2295000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000313"
      unitRef="USD">45000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">45000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">13118000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000317"
      unitRef="USD">12929000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">2987000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000320"
      unitRef="USD">2988000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000322"
      unitRef="USD">26472000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000323"
      unitRef="USD">27165000</us-gaap:Revenues>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000328"
      unitRef="USD">4781000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000329"
      unitRef="USD">4901000</us-gaap:OtherCostOfOperatingRevenue>
    <FONR:CostsRelatedToProductSales
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">277000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToProductSales
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000332"
      unitRef="USD">319000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">1163000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">1182000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">7000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000338"
      unitRef="USD">58000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000340"
      unitRef="USD">7431000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000341"
      unitRef="USD">6897000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000343"
      unitRef="USD">1572000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000344"
      unitRef="USD">1714000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000346"
      unitRef="USD">424000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000347"
      unitRef="USD">441000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000349"
      unitRef="USD">8373000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000350"
      unitRef="USD">7991000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000352"
      unitRef="USD">24028000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000353"
      unitRef="USD">23503000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000355"
      unitRef="USD">2444000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000356"
      unitRef="USD">3662000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000361"
      unitRef="USD">3000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000362"
      unitRef="USD">7000</us-gaap:InterestExpenseNonoperating>
    <FONR:InvestmentIncomeRelatedParty
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000364"
      unitRef="USD">12000</FONR:InvestmentIncomeRelatedParty>
    <FONR:InvestmentIncomeRelatedParty
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000365"
      unitRef="USD">13000</FONR:InvestmentIncomeRelatedParty>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000367"
      unitRef="USD">363000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000368"
      unitRef="USD">463000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000370"
      unitRef="USD">4000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000371"
      unitRef="USD">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000373"
      unitRef="USD">2820000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000374"
      unitRef="USD">4130000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">492000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">1006000</us-gaap:IncomeTaxExpenseBenefit>
    <FONR:ConsolidatedNetIncome
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">2328000</FONR:ConsolidatedNetIncome>
    <FONR:ConsolidatedNetIncome
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000380"
      unitRef="USD">3124000</FONR:ConsolidatedNetIncome>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">687000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">618000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000385"
      unitRef="USD">1641000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">2506000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">1537000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000390"
      unitRef="USD">2347000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="Fact000392"
      unitRef="USD">78000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-03-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="Fact000394"
      unitRef="USD">119000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2026-01-012026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">26000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-012025-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">40000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000400"
      unitRef="USDPShares">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000402"
      unitRef="USDPShares">0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000404"
      unitRef="USDPShares">0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000406"
      unitRef="USDPShares">0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000408"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2026-01-012026-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000410"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000412"
      unitRef="USDPShares">0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-012025-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000414"
      unitRef="USDPShares">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000416"
      unitRef="Shares">6169000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000418"
      unitRef="Shares">6168000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000420"
      unitRef="Shares">6296000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000422"
      unitRef="Shares">6296000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000424"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000426"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000428"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000430"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000435"
      unitRef="USD">22953000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000436"
      unitRef="USD">24284000</FONR:PatientFeeRevenueNetOfContractualAllowancesAndDiscounts>
    <FONR:ProductSalesNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000438"
      unitRef="USD">517000</FONR:ProductSalesNet>
    <FONR:ProductSalesNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000439"
      unitRef="USD">200000</FONR:ProductSalesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000441"
      unitRef="USD">6539000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000442"
      unitRef="USD">6047000</FONR:ServiceAndRepairFeesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000444"
      unitRef="USD">135000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ServiceAndRepairFeesRelatedPartiesNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000445"
      unitRef="USD">135000</FONR:ServiceAndRepairFeesRelatedPartiesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000447"
      unitRef="USD">38956000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">37447000</FONR:ManagementAndOtherFeesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000450"
      unitRef="USD">8962000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">8962000</FONR:ManagementAndOtherFeesRelatedMedicalPracticesNet>
    <us-gaap:Revenues
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000453"
      unitRef="USD">78062000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000454"
      unitRef="USD">77075000</us-gaap:Revenues>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">14724000</us-gaap:OtherCostOfOperatingRevenue>
    <us-gaap:OtherCostOfOperatingRevenue
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000460"
      unitRef="USD">14170000</us-gaap:OtherCostOfOperatingRevenue>
    <FONR:CostsRelatedToProductSales
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000462"
      unitRef="USD">816000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToProductSales
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000463"
      unitRef="USD">761000</FONR:CostsRelatedToProductSales>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000465"
      unitRef="USD">3434000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFees
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000466"
      unitRef="USD">3211000</FONR:CostsRelatedToServiceAndRepairFees>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">26000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToServiceAndRepairFeesRelatedParties
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000469"
      unitRef="USD">154000</FONR:CostsRelatedToServiceAndRepairFeesRelatedParties>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000471"
      unitRef="USD">23101000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFees
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000472"
      unitRef="USD">22008000</FONR:CostsRelatedToManagementAndOtherFees>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000474"
      unitRef="USD">4579000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000475"
      unitRef="USD">4888000</FONR:CostsRelatedToManagementAndOtherFeesRelatedMedicalPractices>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">1319000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000478"
      unitRef="USD">1124000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">21425000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000481"
      unitRef="USD">20055000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000483"
      unitRef="USD">69424000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000484"
      unitRef="USD">66371000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000486"
      unitRef="USD">8638000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000487"
      unitRef="USD">10704000</us-gaap:IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000492"
      unitRef="USD">8000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000493"
      unitRef="USD">21000</us-gaap:InterestExpenseNonoperating>
    <FONR:InvestmentIncomeRelatedParty
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000495"
      unitRef="USD">36000</FONR:InvestmentIncomeRelatedParty>
    <FONR:InvestmentIncomeRelatedParty
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000496"
      unitRef="USD">39000</FONR:InvestmentIncomeRelatedParty>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">1268000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000499"
      unitRef="USD">1626000</us-gaap:InvestmentIncomeNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000501"
      unitRef="USD">10000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000502"
      unitRef="USD">-1000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000504"
      unitRef="USD">9944000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000505"
      unitRef="USD">12347000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000507"
      unitRef="USD">2407000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">3018000</us-gaap:IncomeTaxExpenseBenefit>
    <FONR:ConsolidatedNetIncome
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000510"
      unitRef="USD">7537000</FONR:ConsolidatedNetIncome>
    <FONR:ConsolidatedNetIncome
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000511"
      unitRef="USD">9329000</FONR:ConsolidatedNetIncome>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000513"
      unitRef="USD">1576000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">1724000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">5961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">7605000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012026-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000519"
      unitRef="USD">5581000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000521"
      unitRef="USD">7122000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012026-03-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="Fact000523"
      unitRef="USD">283000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-03-31_custom_ClassANonVotingPreferredStockholdersMember"
      decimals="-3"
      id="Fact000525"
      unitRef="USD">360000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000527"
      unitRef="USD">97000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012025-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000529"
      unitRef="USD">123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012026-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000530"
      unitRef="USDPShares">0.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000531"
      unitRef="USDPShares">1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000532"
      unitRef="USDPShares">0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_custom_CommonStockholdersMember"
      decimals="INF"
      id="Fact000533"
      unitRef="USDPShares">1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012026-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000535"
      unitRef="USDPShares">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000537"
      unitRef="USDPShares">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012025-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000539"
      unitRef="USDPShares">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_us-gaap_CommonClassCMember"
      decimals="INF"
      id="Fact000541"
      unitRef="USDPShares">0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000542"
      unitRef="Shares">6169000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000543"
      unitRef="Shares">6244000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000544"
      unitRef="Shares">6296000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_custom_CommonStockholdersMember"
      decimals="-3"
      id="Fact000545"
      unitRef="Shares">6372000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000547"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000549"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000551"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_us-gaap_CommonClassCMember"
      decimals="-3"
      id="Fact000553"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000555"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000558"
      unitRef="Shares">6203000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000560"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000562"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">178757000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <FONR:CancellationOfTreasuryStockShares
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000570"
      unitRef="Shares">-31000</FONR:CancellationOfTreasuryStockShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2026-01-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000568"
      unitRef="USD">465000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember1563870812"
      decimals="-3"
      id="Fact000578"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember1563870812"
      decimals="-3"
      id="Fact000581"
      unitRef="Shares">6172000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000583"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000585"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000579"
      unitRef="USD">178292000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000587"
      unitRef="USD">-969000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000588"
      unitRef="USD">-860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000592"
      unitRef="Shares">35000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">-14067000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-12-31"
      decimals="-3"
      id="Fact000590"
      unitRef="USD">162862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000594"
      unitRef="USD">1641000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000597"
      unitRef="USD">1641000</us-gaap:NetIncomeLoss>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2026-01-012026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000600"
      unitRef="USD">-465000</FONR:CancellationOfTreasuryStock>
    <FONR:CancellationOfTreasuryStockShares
      contextRef="From2026-01-012026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000604"
      unitRef="Shares">-31000</FONR:CancellationOfTreasuryStockShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2026-01-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000608"
      unitRef="USD">734000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000609"
      unitRef="USD">734000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000613"
      unitRef="USD">687000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact000614"
      unitRef="USD">687000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000616"
      unitRef="USD">672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000621"
      unitRef="Shares">4000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000618"
      unitRef="USD">-14114000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">164456000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000623"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000626"
      unitRef="Shares">6203000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000628"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000630"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000624"
      unitRef="USD">178758000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000644"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000647"
      unitRef="Shares">6203000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000649"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000651"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">178758000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000653"
      unitRef="USD">-8525000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000654"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000658"
      unitRef="Shares">4000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000655"
      unitRef="USD">-10888000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000656"
      unitRef="USD">158951000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000660"
      unitRef="USD">2506000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000663"
      unitRef="USD">2506000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000666"
      unitRef="USD">465000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2025-01-012025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000670"
      unitRef="Shares">31000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000668"
      unitRef="USD">465000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-01-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000674"
      unitRef="USD">1351000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">1351000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000679"
      unitRef="USD">618000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact000680"
      unitRef="USD">618000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000682"
      unitRef="USD">-6019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000683"
      unitRef="USD">-860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000687"
      unitRef="Shares">35000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000684"
      unitRef="USD">-11621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">160259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember1563870484"
      decimals="-3"
      id="Fact000689"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember1563870484"
      decimals="-3"
      id="Fact000692"
      unitRef="Shares">6203000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000694"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000696"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000690"
      unitRef="USD">178757000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <FONR:CancellationOfTreasuryStockShares
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000704"
      unitRef="Shares">-31000</FONR:CancellationOfTreasuryStockShares>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2025-07-012026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000702"
      unitRef="USD">465000</FONR:CancellationOfTreasuryStock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember1563870812"
      decimals="-3"
      id="Fact000712"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_CommonStockMember1563870812"
      decimals="-3"
      id="Fact000715"
      unitRef="Shares">6172000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000717"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000719"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000713"
      unitRef="USD">178292000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000721"
      unitRef="USD">-5289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">-860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000726"
      unitRef="Shares">35000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000723"
      unitRef="USD">-12504000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000724"
      unitRef="USD">160105000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000728"
      unitRef="USD">5961000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000731"
      unitRef="USD">5961000</us-gaap:NetIncomeLoss>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2025-07-012026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000734"
      unitRef="USD">-465000</FONR:CancellationOfTreasuryStock>
    <FONR:CancellationOfTreasuryStockShares
      contextRef="From2025-07-012026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000738"
      unitRef="Shares">-31000</FONR:CancellationOfTreasuryStockShares>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-07-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000742"
      unitRef="USD">3186000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000743"
      unitRef="USD">3186000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-012026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000747"
      unitRef="USD">1576000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000748"
      unitRef="USD">1576000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000750"
      unitRef="USD">672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000751"
      unitRef="USD">-395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2026-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000755"
      unitRef="Shares">4000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000752"
      unitRef="USD">-14114000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000753"
      unitRef="USD">164456000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000757"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000760"
      unitRef="Shares">6328000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000762"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000764"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000758"
      unitRef="USD">180608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <FONR:CancellationOfTreasuryStockShares
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000775"
      unitRef="Shares">-125000</FONR:CancellationOfTreasuryStockShares>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000773"
      unitRef="USD">1963000</FONR:CancellationOfTreasuryStock>
    <FONR:SaleNonControllingInterests
      contextRef="From2024-07-012025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000778"
      unitRef="USD">113000</FONR:SaleNonControllingInterests>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000786"
      unitRef="USD">1000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000789"
      unitRef="Shares">6203000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact000791"
      unitRef="Shares">313000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_custom_ClassCCommonStockMember"
      decimals="-3"
      id="Fact000793"
      unitRef="Shares">383000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000787"
      unitRef="USD">178758000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000795"
      unitRef="USD">-13624000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">-1017000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000800"
      unitRef="Shares">45000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">-9180000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000798"
      unitRef="USD">156788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000802"
      unitRef="USD">7605000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000805"
      unitRef="USD">7605000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000808"
      unitRef="USD">1806000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000812"
      unitRef="Shares">115000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000810"
      unitRef="USD">1806000</us-gaap:StockRepurchasedDuringPeriodValue>
    <FONR:CancellationOfTreasuryStock
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000815"
      unitRef="USD">-1963000</FONR:CancellationOfTreasuryStock>
    <FONR:CancellationOfTreasuryStockShares
      contextRef="From2024-07-012025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000819"
      unitRef="Shares">-125000</FONR:CancellationOfTreasuryStockShares>
    <FONR:SaleNonControllingInterests
      contextRef="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">19000</FONR:SaleNonControllingInterests>
    <FONR:SaleNonControllingInterests
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000824"
      unitRef="USD">132000</FONR:SaleNonControllingInterests>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000828"
      unitRef="USD">4184000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000829"
      unitRef="USD">4184000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000833"
      unitRef="USD">1724000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000834"
      unitRef="USD">1724000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000836"
      unitRef="USD">-6019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000837"
      unitRef="USD">-860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-03-31_us-gaap_TreasuryStockCommonMember"
      decimals="-3"
      id="Fact000841"
      unitRef="Shares">35000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31_us-gaap_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact000838"
      unitRef="USD">-11621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000839"
      unitRef="USD">160259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000846"
      unitRef="USD">7537000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000847"
      unitRef="USD">9329000</us-gaap:ProfitLoss>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000852"
      unitRef="USD">3447000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000853"
      unitRef="USD">3536000</us-gaap:OtherDepreciationAndAmortization>
    <FONR:NetChangeInOperatingRightOfUseAssetsAndLeaseLiabilities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000855"
      unitRef="USD">-370000</FONR:NetChangeInOperatingRightOfUseAssetsAndLeaseLiabilities>
    <FONR:NetChangeInOperatingRightOfUseAssetsAndLeaseLiabilities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000856"
      unitRef="USD">-15000</FONR:NetChangeInOperatingRightOfUseAssetsAndLeaseLiabilities>
    <FONR:RecoveryProvisionForCreditLosses
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000858"
      unitRef="USD">-183000</FONR:RecoveryProvisionForCreditLosses>
    <FONR:RecoveryProvisionForCreditLosses
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000859"
      unitRef="USD">2608000</FONR:RecoveryProvisionForCreditLosses>
    <FONR:AbandonedPatents
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000861"
      unitRef="USD">3000</FONR:AbandonedPatents>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000864"
      unitRef="USD">154000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000865"
      unitRef="USD">878000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000870"
      unitRef="USD">5352000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000871"
      unitRef="USD">7140000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <FONR:IncreaseDecreaseInNotesReceivable
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000873"
      unitRef="USD">-37000</FONR:IncreaseDecreaseInNotesReceivable>
    <FONR:IncreaseDecreaseInNotesReceivable
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000874"
      unitRef="USD">-39000</FONR:IncreaseDecreaseInNotesReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000876"
      unitRef="USD">19000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000877"
      unitRef="USD">-8000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000879"
      unitRef="USD">-48000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000880"
      unitRef="USD">1093000</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000882"
      unitRef="USD">415000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000883"
      unitRef="USD">-6000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000885"
      unitRef="USD">985000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000886"
      unitRef="USD">-631000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000888"
      unitRef="USD">-3248000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000889"
      unitRef="USD">-549000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInTradingLiabilities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000891"
      unitRef="USD">-163000</us-gaap:IncreaseDecreaseInTradingLiabilities>
    <us-gaap:IncreaseDecreaseInTradingLiabilities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000892"
      unitRef="USD">-153000</us-gaap:IncreaseDecreaseInTradingLiabilities>
    <FONR:IncreaseDecreaseInCustomerDeposit
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000894"
      unitRef="USD">327000</FONR:IncreaseDecreaseInCustomerDeposit>
    <FONR:IncreaseDecreaseInCustomerDeposit
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000895"
      unitRef="USD">111000</FONR:IncreaseDecreaseInCustomerDeposit>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000897"
      unitRef="USD">-14000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000898"
      unitRef="USD">159000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000900"
      unitRef="USD">3440000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000901"
      unitRef="USD">7045000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000906"
      unitRef="USD">2435000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000907"
      unitRef="USD">3145000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <FONR:CostOfNoncompeteContract
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000909"
      unitRef="USD">500000</FONR:CostOfNoncompeteContract>
    <FONR:ProceedspurchaseFromShortTermInvestments
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000912"
      unitRef="USD">2000</FONR:ProceedspurchaseFromShortTermInvestments>
    <FONR:ProceedspurchaseFromShortTermInvestments
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000913"
      unitRef="USD">-13000</FONR:ProceedspurchaseFromShortTermInvestments>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000915"
      unitRef="USD">1000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">25000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000918"
      unitRef="USD">-2938000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000919"
      unitRef="USD">-3157000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">114000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000928"
      unitRef="USD">132000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">1806000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000933"
      unitRef="USD">3186000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000934"
      unitRef="USD">4184000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000936"
      unitRef="USD">-3186000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000937"
      unitRef="USD">-5972000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact000939"
      unitRef="USD">-2684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact000940"
      unitRef="USD">-2084000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000942"
      unitRef="USD">56334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000943"
      unitRef="USD">56341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact000945"
      unitRef="USD">53650000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact000946"
      unitRef="USD">54257000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <FONR:DescriptionOfBusinessAndBasisOfPresentationTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact000948">&lt;p id="xdx_802_ecustom--DescriptionOfBusinessAndBasisOfPresentationTextBlock_zNMwcqBqhMJ2" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 1 &#x2013; &lt;span id="xdx_82F_zxIYaY3xSHcl"&gt;DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Description of Business&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FONAR Corporation (the &#x201c;Company&#x201d; or &#x201c;FONAR&#x201d;)
is a Delaware corporation, which was incorporated on July 17, 1978. FONAR is engaged in the research, development, production and marketing
of medical scanning equipment, which uses principles of Magnetic Resonance Imaging (&#x201c;MRI&#x201d;) for the detection and diagnosis
of human diseases. In addition to the direct sale of MRI equipment, revenue is also generated from our installed-base of customers through
our service and upgrade programs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FONAR, through its wholly-owned subsidiary Health
Management Corporation of America (&#x201c;HMCA&#x201d;), provides comprehensive management services to diagnostic imaging facilities. The
services provided by the Company include development, administration, leasing of office space, facilities and medical equipment, provision
of supplies, staffing and supervision of non-medical personnel, legal services, accounting, billing and collection and the development
and implementation of practice growth and marketing strategies.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 1, 2015, the Company reorganized the segment
of our business dedicated to the management of diagnostic imaging centers. The reorganization integrated the operations of Health Management
Corporation of America and Health Diagnostics Management (&#x201c;HDM&#x201d;). Imperial Management Services, LLC contributed all of its
assets (which were utilized in the business of Health Management Corporation of America) to HDM and received a &lt;span id="xdx_904_eus-gaap--InvestmentOwnedPercentOfNetAssets_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__us-gaap--OtherInvesteesMember_z5TqAhojWUKe" title="Investment Owned, Net Assets, Percentage"&gt;24.2&lt;/span&gt;% interest in HDM.
Health Management Corporation of America retained a direct ownership interest of &lt;span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20150701__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__us-gaap--OtherInvesteesMember_zsPK066YkNcl" title="Company ownership percentage"&gt;45.8&lt;/span&gt;% in HDM, and the original investors in HDM retained
a &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20150701__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__us-gaap--OtherInvesteesMember_zcqlyfZSdqQ9" title="Retained ownership percentage"&gt;30.0&lt;/span&gt;% ownership interest in the newly expanded HDM. During the fiscal year ended June 30, 2025, the Company sold non-controlling interests
to a minority shareholder for $&lt;span id="xdx_90A_eus-gaap--ProceedsFromPaymentsToMinorityShareholders_pn3n3_c20250701__20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__us-gaap--OtherInvesteesMember_zIhoOz454x63" title="Proceeds from (Payments to) Noncontrolling Interests"&gt;132&lt;/span&gt;. Currently, the Company has a direct ownership interest of &lt;span id="xdx_906_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20260331__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__us-gaap--OtherInvesteesMember_zi7dHSmZfQ3c" title="Company ownership percentage"&gt;70.63&lt;/span&gt;% and the investors have a &lt;span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pip0_dp_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--NoncontrollingInterestMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__us-gaap--OtherInvesteesMember_zr7ZCrA7gQs9" title="Equity Method Investment, Ownership Percentage"&gt;29.37&lt;/span&gt;% ownership
interest. The entire management of diagnostic imaging centers business segment is now being conducted by HDM, operating under the name
&#x201c;Health Management Company of America&#x201d;.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Proposed Going-Private Transaction&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 23, 2025, the Company entered into an
Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) with FONAR, LLC, a Delaware limited liability company (&#x201c;Parent&#x201d;),
and FONAR Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (&#x201c;Merger Sub&#x201d;). The Merger
Agreement provides that, subject to the terms and conditions set forth in the Merger Agreement, Merger Sub will merge with and into the
Company (the &#x201c;Merger&#x201d;), with the Company continuing as the surviving corporation and a subsidiary of Parent following the
Merger. Parent and Merger Sub are each affiliated with and owned and controlled by Timothy Damadian, the Company&#x2019;s Chief Executive
Officer and Chairman of our Board of Directors. Timothy Damadian and other members of a group of 57 total (including Parent and Merger
Sub) individuals, trusts, corporations and limited liability companies (we refer to this group, collectively, as the &#x201c;Acquisition
Group&#x201d;) have proposed to acquire the Company pursuant to and on the terms and conditions set forth in the Merger Agreement.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under the Merger Agreement, at the effective time
of the Merger (the &#x201c;Effective Time&#x201d;), each share of our capital stock issued and outstanding immediately prior to the Effective
Time (other than Excluded Shares, defined below) will be converted into the right to receive cash, without interest and subject to deduction
for any required withholding tax, in an amount per share (the &#x201c;Per Share Price&#x201d;) equal to: (i) $19.00 per share of Common
Stock, (ii) $19.00 per share of Class B Common Stock, (iii) $6.34 per share of Class C Common Stock, and (iv) $10.50 per share of Class
A Non-voting Preferred Stock. Shares held by Parent, by the Company or by any of their respective subsidiaries ( including as treasury
shares) will not receive any Merger consideration (the &#x201c;Excluded Shares&#x201d;). Pursuant to the terms of the Class B Membership
Units Subscription Agreements, dated December&#160;23, 2025, between Parent and each of its equity financing sources (the &#x201c;Equity
Commitment Agreements&#x201d;), the members of the Acquisition Group who are FONAR stockholders will, immediately prior to the Merger,
cause all of their shares of Company Capital Stock and Class A Non-voting Preferred Stock to be contributed (or, alternatively, may elect
to contribute an amount of cash equal to the aggregate Per Share Price for all of their FONAR shares) to Parent in exchange for membership
units of Parent. All of such shares contributed to Parent are Excluded Shares that at the Effective Time will not receive any Merger consideration.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Consummation of the Merger is subject to the satisfaction
or waiver (to the extent permitted by applicable law) of the conditions set forth in the Merger Agreement, including: (1) the approval
by the Company&#x2019;s stockholders in favor of the adoption of the Merger Agreement providing for the Merger by (a) the affirmative vote
of shares representing a majority of the Company Capital Stock outstanding and entitled to vote, voting together as a single class, after
giving effect to the respective voting powers of each class of Company Capital Stock (the &#x201c;Company Stockholder Approval&#x201d;),
and (b) the affirmative vote of a majority of the votes cast at the Special Meeting (the &#x201c;Special Meeting&#x201d;) by disinterested
stockholders of their shares of Company Capital Stock, voting together as a single class, after giving effect to the respective voting
powers of each class of Company Capital Stock (the &#x201c;Disinterested Stockholder Approval&#x201d; and together with the Company Stockholder
Approval, the &#x201c;Requisite Company Vote&#x201d;); (2) the expiration or termination of any applicable waiting periods; (3) the consummation
of the Merger not being restrained, enjoined, rendered illegal or otherwise prohibited by any law or order of any governmental authority
of competent jurisdiction; (4) the receipt of all consents, approvals and other authorizations of any governmental entity required to
consummate the Merger and the other transactions contemplated by the Merger Agreement, free of any condition that would reasonably be
expected to have a Company Material Adverse Effect (as defined in the Merger Agreement) or a material adverse effect on Parent&#x2019;s
and Merger Sub&#x2019;s ability to consummate the transactions contemplated by the Merger Agreement; (5) the accuracy of the parties&#x2019;
representations and warranties, subject to certain qualifiers; and (6) the parties&#x2019; compliance in all material respects with their
respective pre-closing covenants, subject to the terms of the Merger Agreement.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Merger Agreement contains customary restrictions
on the Company&#x2019;s ability to solicit alternative acquisition proposals from third parties, subject to a customary &#x201c;fiduciary
out&#x201d; that permits engagement with a third party in certain circumstances involving a bona fide written Superior Proposal and compliance
with specified procedures. FONAR or Parent may terminate the Merger Agreement if the Merger has not been consummated by the &#x201c;End
Date&#x201d; of March 12, 2026, subject to an automatic extension to the later of 90 days following (a) the date the Company&#x2019;s definitive
proxy statement in connection with the Special Meeting is filed and (b) the date, if applicable, upon which any SEC or other governmental
review or investigation is completed. FONAR or Parent also may terminate the Merger Agreement (i) by mutual written consent; (ii) if any
governmental entity of competent jurisdiction shall have enacted any law or order making illegal the consummation of the Merger or the
other transactions contemplated by the Merger Agreement, and such law or order shall have become final and nonappealable (provided, however,
that such right to terminate the Merger Agreement shall not be available to any party whose breach of any representation, warranty, covenant,
or agreement set forth in the Merger Agreement has been the principal cause of the issuance, promulgation, enforcement, or entry of any
such law or order); or (iii) if the Requisite Company Vote is not obtained at the Special Meeting. In addition, Parent may terminate the
Merger Agreement if a Company Adverse Recommendation Change (as defined in the Merger Agreement) occurs, if certain non-solicitation or
stockholder meeting covenants are breached, or if other specified Company breaches occur that are not cured, and FONAR may terminate the
Merger Agreement to enter into a Company Acquisition Agreement (as defined in the Merger Agreement) with respect to a Superior Proposal
(as defined in the Merger Agreement) or for specified Parent breaches that are not cured, in each case subject to the conditions and procedures
in the Merger Agreement. Upon termination of the Merger Agreement under certain circumstances, the Company will be required to pay Parent
a termination fee equal to $450,000, as described in the previously filed Form 8-K with the SEC on December 30, 2025.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A special committee of the Board of Directors (the
&#x201c;Special Committee&#x201d;), consisting of disinterested and independent directors, approved the Merger and unanimously recommended
that the Board of Directors adopt and approve the Merger Agreement. Members of the Acquisition Group that are FONAR stockholders have
entered into voting agreements to vote their shares in favor of the Merger Proposal. The original End Date under the Merger Agreement
was March 12, 2026. Because the Company&#x2019;s definitive proxy statement in connection with the Special Meeting was not filed until
April 16, 2026, the End Date has automatically extended pursuant to the terms of the Merger Agreement to the later of 90 days following
(a) the date the Company&#x2019;s definitive proxy statement in connection with the Special Meeting was filed and (b) the date, if applicable,
upon which any government review or investigation, including without limitation, any review or investigation by the SEC , is completed.
Subject to the satisfaction or waiver of the conditions to, the Closing, the Company currently expects to complete the Merger in its fourth
fiscal quarter of 2026.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





























&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Basis of Presentation&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;These unaudited condensed consolidated financial statements
for the nine months ended March 31, 2026 have been prepared in accordance with generally accepted accounting principles in the United
States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission pertaining
to interim financial statements. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial
statements and should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s
Annual Report on Form 10-K for the year ended June 30, 2025, from which the accompanying condensed consolidated balance sheet at June
30, 2025 was derived. In the opinion of management, all adjustments considered necessary for a fair presentation of the interim financial
information have been included and are of a normal recurring nature.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</FONR:DescriptionOfBusinessAndBasisOfPresentationTextBlock>
    <us-gaap:InvestmentOwnedPercentOfNetAssets
      contextRef="AsOf2015-07-01_us-gaap_OtherInvesteesMember"
      decimals="INF"
      id="Fact000950"
      unitRef="Ratio">0.242</us-gaap:InvestmentOwnedPercentOfNetAssets>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2015-07-01_us-gaap_OtherInvesteesMember"
      decimals="INF"
      id="Fact000952"
      unitRef="Ratio">0.458</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2015-07-01_us-gaap_NoncontrollingInterestMember_us-gaap_OtherInvesteesMember"
      decimals="INF"
      id="Fact000954"
      unitRef="Ratio">0.300</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="From2025-07-012026-03-31_us-gaap_OtherInvesteesMember"
      decimals="-3"
      id="Fact000956"
      unitRef="USD">132000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-03-31_us-gaap_OtherInvesteesMember"
      decimals="INF"
      id="Fact000958"
      unitRef="Ratio">0.7063</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2026-03-31_us-gaap_NoncontrollingInterestMember_us-gaap_OtherInvesteesMember"
      decimals="INF"
      id="Fact000960"
      unitRef="Ratio">0.2937</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001009">&lt;p id="xdx_809_eus-gaap--SignificantAccountingPoliciesTextBlock_zmXqtoRIgNC8" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 2 - &lt;span id="xdx_82C_zLWriqwoZo19"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zIOKHesx4Xvg" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_860_zdCaUY65UR6e"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the unaudited condensed consolidated
financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the disclosure and reported
amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of
revenues and expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates these estimates and judgements
on an ongoing basis. The Company bases estimates and judgements on historical experience and on various other factors that are believed
to be reasonable under the circumstances. The results of operations for any interim period are not necessarily indicative of the results
of operations for a full year.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zq4U9knkjcS6" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zeP64xASAZNi"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The unaudited condensed consolidated financial statements
include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively, the &#x201c;Company&#x201d;).
All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zSc80DPSgov" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zjDyWU8lKypi"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--PatientFeeRevenuePolicyTextBlock_z4IBDcFfs6kf" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zdXXWLy8du2i"&gt;Patient fee revenue&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are to provide
diagnostic services to the patients and annual management contracts with related and unrelated parties to which the Company provides comprehensive
management services. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company&#x2019;s
performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships
with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance
companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent
upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the
third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify
payments at amounts less than the Company&#x2019;s standard charges and generally provide for payments based upon predetermined rates per
diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider
and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations
and renewals.&lt;br/&gt;
&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s patient fee revenue, net of contractual
allowances and discounts for the three and nine months ended March 31, 2026 and 2025 are summarized in the following table:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zgnewlSOr7ng" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_ziOS5r7qvCna" style="display: none"&gt;Schedule
    of patient fee revenue - net&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Three Months Ended &lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Commercial Insurance/Managed Care&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zrs1s8MXZIPd" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,043&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_z7ymXPU7q2Fa" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,251&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Medicare/Medicaid&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zOtLKMFvXJHb" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zQFynAbLqqS5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;300&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zy5NpGQzNT8e" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,222&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zzaFe1xEffl7" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,207&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_z6kMByp6Jf3e" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,497&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_zI3dCAAjdQae" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,095&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Patient Fee Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331_z6PL7ZCoQAcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,085&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331_zbuySCu6k9C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,853&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Nine Months Ended &lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Commercial Insurance/Managed Care&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_ztoJ4qu8u5Hl" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,535&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zFU8Ie6UdNuk" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,629&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Medicare/Medicaid&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zU3hZmpA03da" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;893&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zL9M0iVmsDOk" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;862&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zSsWV2KixbD7" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;14,628&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zaGT1ejD2mpj" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;14,589&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_zfvULuyh0dRg" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,897&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_z85JQojHjKh9" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,204&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Patient Fee Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331_zO5MUbax2Hkk" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;22,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331_zS5ZQykvgpVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;24,284&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AB_z1EZ14SK5Xf" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



&lt;p id="xdx_849_ecustom--ManagementAndOtherFeeReceivablePolicyTextBlock_zKuqbxcgIQZf" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_862_zV07pUNjHR3k"&gt;Management and other fees revenue&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;HMCA generates management and other fees revenues
(including management and other fees revenue from related parties) from providing comprehensive management services, including development,
administration, accounting, billing and collection services, together with office space, medical equipment, supplies and non-medical personnel
to its clients. Revenues are in the form of fees which are earned under annual management contracts with HMCA clients. Management and
other fees revenue is recognized ratably over time as the services are provided throughout the term of the contract.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue on sales contracts for scanners, included
in &#x201c;product sales&#x201d; is recognized under the percentage-of-completion method in accordance with the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification(&#x201c;ASC&#x201d;) 606 &#x201c;Revenue Recognition &#x2013; Construction-Type
and Production-Type Contracts&#x201d;. The Company manufactures its scanners under specific contracts that provide for progress payments.
Production and installation takes approximately three to six months.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue on scanner service contracts is recognized
on the straight-line method over the related contract period, usually one year.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zdztwnd6anF6" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zGCg8jsBuwv4"&gt;Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is computed
based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance
with ASC Topic 260-10, &#x201c;Participating Securities and the Two-Class method&#x201d;, the Company used the Two-Class method for calculating
basic income per share and applied the converted method in calculating diluted income per share for the three and nine months ended March
31, 2026 and 2025.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted EPS reflects the potential dilution from the
exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during
the period. For the three and nine months ended March 31, 2026 and 2025, diluted EPS for common shareholders includes 128 shares upon
conversion of Class C Common.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zvrM574Ca9ql" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zOj5Sb6NabX8" style="display: none"&gt;Schedule
    of earning per share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended March 31, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt"&gt;Basic&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net income available to common stockholders&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331_zqbXDD1S6P5f" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;1,641&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGhtC9stSmO7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;1,537&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z0fkpCo0mrXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;26&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zwcxtQrdMLYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;78&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331_zUBOTwkbOogd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;2,506&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwjt6sQghDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;2,347&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zK0C14wDgGxg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;40&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zrYS3J0XSO32" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;119&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331_zPAIhEgFA8k" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5gk377lwRac" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zD4beo0DL8pi" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z6K7LNLF9kAi" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331_znrsBtyunsy4" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKv7qqwkSbG4" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zyHXpdas9XU8" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zFQi0uWIW1Oc" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Basic income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331_zBwbDqgONxq4" title="Basic income per common share"&gt;0.24&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMBAA9yp3QD8" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zavWvE10398l" title="Basic income per common share"&gt;0.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z8p0J8VlWi5d" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331_zFHBF0f1jk1d" title="Basic income per common share"&gt;0.37&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqar1scH2De" title="Basic income per common share"&gt;0.38&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zLGc2UlOjkB" title="Basic income per common share"&gt;0.11&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zT8rDYSOG6t8" title="Basic income per common share"&gt;0.38&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWDlDtzYerOh" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zZP3r8Gojy0j" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWI1r61xr4Ub" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zQiO3Zdi5O2" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Class C Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQChCVHxoLke" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ConvertibleClassCStock_pn3n3_d0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zQFNcr2IjUz9" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConvertibleClassCStock_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziAo4awAGc0i" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConvertibleClassCStock_pn3n3_d0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zRGpkmVWsSqg" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXMoGX4mLOuh" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zoRppx4Pxm86" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za1shwXUZPZ5" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zaUpCVd9s8gh" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYUMFBgiRMU" title="Diluted income per common share"&gt;0.24&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z8Y4jdIFSfch" title="Diluted income per common share"&gt;0.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeYy1OFW9UZa" title="Diluted income per common share"&gt;0.37&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zsD0rY19nco7" title="Diluted income per common share"&gt;0.11&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;

































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Nine months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Nine months ended March 31, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt"&gt;Basic&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net income available to common stockholders&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331_z04LmGFLMMAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;5,961&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zauZSNe9bmH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;5,581&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zsrqmEkfLcea" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;97&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z5GZUugU19jk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;283&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331_zFhiPZDjBr8f" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;7,605&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIbeTaSZc0Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;7,122&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zW7OHeq4w1Md" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;123&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zIUDrXVYqFKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331_zuLD5f8HTsY4" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znIp0wFlcx53" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zDXVqSV9rMyj" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zQAvq3Cew8lk" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331_zsjfawybmvHc" title="Weighted average shares outstanding"&gt;6,941&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMYsxpVWbOu1" title="Weighted average shares outstanding"&gt;6,245&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zeBbAwA3QsZh" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zza5gf52vhe6" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Basic income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331_zS9XSRM7KW7j" title="Basic income per common share"&gt;0.87&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVUoHVu5zAO3" title="Basic income per common share"&gt;0.90&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zGOcUyrT5sNf" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zsbqNJ4pL9hg" title="Basic income per common share"&gt;0.90&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331_zGi6UWtZezlh" title="Basic income per common share"&gt;1.10&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBz3BpMzUgmh" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z5tomHvhXYd" title="Basic income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zd7Ue3RNIb1d" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZu09MHcacEh" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zEIPrvVpscV7" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0F0yHtTAAz3" title="Weighted average shares outstanding"&gt;6,244&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zC9AtzIky1m2" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Class C Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zefxALFYNEzi" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_d0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zIFgLU1EDVCe" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCmegAWzYZM9" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_d0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zJxn3TJksWX6" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5VdtCroURY4" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zdOKIptyS0I8" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIzUCgdjVsbh" title="Total Denominator for diluted earnings per share"&gt;6,372&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z47LkNDl9FNc" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pip0_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkCK3q86wss6" title="Diluted income per common share"&gt;0.89&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z6YRXXxV1Es2" title="Diluted income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4AWUcCPYxpd" title="Diluted income per common share"&gt;1.12&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zukxtMQEeAOf" title="Diluted income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zW9Im6ECFVE5" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfVf9ZIsJ76g" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_zgDQF5xEmCf7"&gt;Recent Accounting Standards or Updates Not Yet Adopted&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Income Taxes&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, The Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Codification (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (740): &#x201c;Improvements
to Income Tax Disclosures&#x201d;, which enhances transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid and to improve the effectiveness of income tax disclosures. The ASU
will be effective for our annual financial statements starting in fiscal 2026 and interim periods beginning in the first quarter of fiscal
2027, with early adoption permitted. We are currently evaluating the impact of this accounting standard, but do not expect it to have
a material impact on our income tax disclosures.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03, &#x201c;Income
Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&#x201d; (Subtopic 220-40): Disaggregation of
Income Statement Expenses&#x201d;. This ASU requires disaggregation of certain income statement expense captions into specified categories
to be disclosed within the notes to the condensed consolidated financial statements, but does not change the expense captions on the income
statement. The amendments in this ASU are to be applied prospectively, although retrospective application is permitted, and is effective
for annual financial statements starting in fiscal 2028 and interim periods starting in fiscal 2029, with early adoption permitted. The
Company is currently evaluating the effect that the adoption of ASU 2024-03 will have on our disclosures.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB, the Emerging Issues Task Force and the SEC have
issued certain other accounting standards, updates, and regulations as of March 31, 2026 that will become effective in subsequent periods;
however, management does not believe that any of those updates would have significantly affected our financial accounting measures or
disclosures had they been in effect during 2026, 2025 or 2024, and it does not believe that any of those standards will have a significant
impact on our unaudited consolidated condensed financial statements at the time they become effective.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-07-01to2026-03-31" id="Fact001011">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zIOKHesx4Xvg" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_860_zdCaUY65UR6e"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of the unaudited condensed consolidated
financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the disclosure and reported
amounts of assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of
revenues and expenses during the reporting period.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company evaluates these estimates and judgements
on an ongoing basis. The Company bases estimates and judgements on historical experience and on various other factors that are believed
to be reasonable under the circumstances. The results of operations for any interim period are not necessarily indicative of the results
of operations for a full year.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001013">&lt;p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zq4U9knkjcS6" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_86C_zeP64xASAZNi"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The unaudited condensed consolidated financial statements
include the accounts of FONAR Corporation, its majority and wholly-owned subsidiaries and partnerships (collectively, the &#x201c;Company&#x201d;).
All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001015">&lt;p id="xdx_846_eus-gaap--RevenueRecognitionPolicyTextBlock_zSc80DPSgov" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_863_zjDyWU8lKypi"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <FONR:PatientFeeRevenuePolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001017">&lt;p id="xdx_84B_ecustom--PatientFeeRevenuePolicyTextBlock_z4IBDcFfs6kf" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_866_zdXXWLy8du2i"&gt;Patient fee revenue&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s revenues generally relate to net
patient fees&#160;received from various payers and patients themselves under contracts in which our performance obligations are to provide
diagnostic services to the patients and annual management contracts with related and unrelated parties to which the Company provides comprehensive
management services. Revenues are recorded during the period our obligations to provide diagnostic services are satisfied. The Company&#x2019;s
performance obligations for diagnostic services are generally satisfied over a period of less than one day. The contractual relationships
with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance
companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent
upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the
third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify
payments at amounts less than the Company&#x2019;s standard charges and generally provide for payments based upon predetermined rates per
diagnostic services or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider
and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations
and renewals.&lt;br/&gt;
&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s patient fee revenue, net of contractual
allowances and discounts for the three and nine months ended March 31, 2026 and 2025 are summarized in the following table:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zgnewlSOr7ng" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_ziOS5r7qvCna" style="display: none"&gt;Schedule
    of patient fee revenue - net&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Three Months Ended &lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Commercial Insurance/Managed Care&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zrs1s8MXZIPd" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,043&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_z7ymXPU7q2Fa" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,251&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Medicare/Medicaid&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zOtLKMFvXJHb" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zQFynAbLqqS5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;300&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zy5NpGQzNT8e" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,222&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zzaFe1xEffl7" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,207&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_z6kMByp6Jf3e" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,497&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_zI3dCAAjdQae" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,095&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Patient Fee Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331_z6PL7ZCoQAcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,085&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331_zbuySCu6k9C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,853&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Nine Months Ended &lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Commercial Insurance/Managed Care&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_ztoJ4qu8u5Hl" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,535&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zFU8Ie6UdNuk" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,629&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Medicare/Medicaid&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zU3hZmpA03da" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;893&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zL9M0iVmsDOk" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;862&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zSsWV2KixbD7" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;14,628&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zaGT1ejD2mpj" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;14,589&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_zfvULuyh0dRg" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,897&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_z85JQojHjKh9" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,204&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Patient Fee Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331_zO5MUbax2Hkk" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;22,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331_zS5ZQykvgpVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;24,284&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AB_z1EZ14SK5Xf" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;



</FONR:PatientFeeRevenuePolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001035">&lt;table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_zgnewlSOr7ng" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Patient Fee Revenue Recognition - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_ziOS5r7qvCna" style="display: none"&gt;Schedule
    of patient fee revenue - net&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Three Months Ended &lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Commercial Insurance/Managed Care&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zrs1s8MXZIPd" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,043&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_z7ymXPU7q2Fa" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,251&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Medicare/Medicaid&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zOtLKMFvXJHb" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;323&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zQFynAbLqqS5" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;300&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zy5NpGQzNT8e" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,222&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zzaFe1xEffl7" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,207&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_z6kMByp6Jf3e" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;1,497&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_zI3dCAAjdQae" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;2,095&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Patient Fee Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_ecustom--NetPatientFeeRevenue_pn3n3_c20260101__20260331_z6PL7ZCoQAcd" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,085&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetPatientFeeRevenue_pn3n3_c20250101__20250331_zbuySCu6k9C5" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;8,853&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the Nine Months Ended &lt;br/&gt;March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Commercial Insurance/Managed Care&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_ztoJ4qu8u5Hl" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,535&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--CommercialInsuranceManagedCareMember_zFU8Ie6UdNuk" style="width: 12%; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,629&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Medicare/Medicaid&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zU3hZmpA03da" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;893&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--MedicareMedicaidMember_zL9M0iVmsDOk" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;862&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Workers&#x2019; Compensation/Personal Injury&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zSsWV2KixbD7" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;14,628&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--WorkersCompensationPersonalInjuryMember_zaGT1ejD2mpj" style="text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;14,589&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Other&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_zfvULuyh0dRg" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;3,897&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331__us-gaap--HealthCareOrganizationRevenueSourcesAxis__custom--OtherRevenueSourceMember_z85JQojHjKh9" style="border-bottom: Black 1pt solid; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;5,204&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net Patient Fee Revenue&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetPatientFeeRevenue_pn3n3_c20250701__20260331_zO5MUbax2Hkk" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;22,953&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetPatientFeeRevenue_pn3n3_c20240701__20250331_zS5ZQykvgpVh" style="border-bottom: Black 2.5pt double; text-align: right" title="Patient Fee Revenue, net of contractual allowances and discounts"&gt;24,284&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <FONR:NetPatientFeeRevenue
      contextRef="From2026-01-012026-03-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="Fact001037"
      unitRef="USD">1043000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-01-012025-03-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="Fact001039"
      unitRef="USD">1251000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2026-01-012026-03-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="Fact001041"
      unitRef="USD">323000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-01-012025-03-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="Fact001043"
      unitRef="USD">300000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2026-01-012026-03-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="Fact001045"
      unitRef="USD">5222000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-01-012025-03-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="Fact001047"
      unitRef="USD">5207000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2026-01-012026-03-31_custom_OtherRevenueSourceMember"
      decimals="-3"
      id="Fact001049"
      unitRef="USD">1497000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-01-012025-03-31_custom_OtherRevenueSourceMember"
      decimals="-3"
      id="Fact001051"
      unitRef="USD">2095000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact001053"
      unitRef="USD">8085000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact001055"
      unitRef="USD">8853000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-07-012026-03-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="Fact001057"
      unitRef="USD">3535000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2024-07-012025-03-31_custom_CommercialInsuranceManagedCareMember"
      decimals="-3"
      id="Fact001059"
      unitRef="USD">3629000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-07-012026-03-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="Fact001061"
      unitRef="USD">893000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2024-07-012025-03-31_custom_MedicareMedicaidMember"
      decimals="-3"
      id="Fact001063"
      unitRef="USD">862000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-07-012026-03-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="Fact001065"
      unitRef="USD">14628000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2024-07-012025-03-31_custom_WorkersCompensationPersonalInjuryMember"
      decimals="-3"
      id="Fact001067"
      unitRef="USD">14589000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-07-012026-03-31_custom_OtherRevenueSourceMember"
      decimals="-3"
      id="Fact001069"
      unitRef="USD">3897000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2024-07-012025-03-31_custom_OtherRevenueSourceMember"
      decimals="-3"
      id="Fact001071"
      unitRef="USD">5204000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001073"
      unitRef="USD">22953000</FONR:NetPatientFeeRevenue>
    <FONR:NetPatientFeeRevenue
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001075"
      unitRef="USD">24284000</FONR:NetPatientFeeRevenue>
    <FONR:ManagementAndOtherFeeReceivablePolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001077">&lt;p id="xdx_849_ecustom--ManagementAndOtherFeeReceivablePolicyTextBlock_zKuqbxcgIQZf" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_862_zV07pUNjHR3k"&gt;Management and other fees revenue&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;HMCA generates management and other fees revenues
(including management and other fees revenue from related parties) from providing comprehensive management services, including development,
administration, accounting, billing and collection services, together with office space, medical equipment, supplies and non-medical personnel
to its clients. Revenues are in the form of fees which are earned under annual management contracts with HMCA clients. Management and
other fees revenue is recognized ratably over time as the services are provided throughout the term of the contract.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue on sales contracts for scanners, included
in &#x201c;product sales&#x201d; is recognized under the percentage-of-completion method in accordance with the Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) Accounting Standards Codification(&#x201c;ASC&#x201d;) 606 &#x201c;Revenue Recognition &#x2013; Construction-Type
and Production-Type Contracts&#x201d;. The Company manufactures its scanners under specific contracts that provide for progress payments.
Production and installation takes approximately three to six months.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Revenue on scanner service contracts is recognized
on the straight-line method over the related contract period, usually one year.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</FONR:ManagementAndOtherFeeReceivablePolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001093">&lt;p id="xdx_843_eus-gaap--EarningsPerSharePolicyTextBlock_zdztwnd6anF6" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_864_zGCg8jsBuwv4"&gt;Earnings Per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is computed
based upon the weighted average number of shares of common stock and stock equivalents outstanding, net of common stock. In accordance
with ASC Topic 260-10, &#x201c;Participating Securities and the Two-Class method&#x201d;, the Company used the Two-Class method for calculating
basic income per share and applied the converted method in calculating diluted income per share for the three and nine months ended March
31, 2026 and 2025.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Diluted EPS reflects the potential dilution from the
exercise or conversion of all dilutive securities into common stock based on the average market price of common shares outstanding during
the period. For the three and nine months ended March 31, 2026 and 2025, diluted EPS for common shareholders includes 128 shares upon
conversion of Class C Common.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zvrM574Ca9ql" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zOj5Sb6NabX8" style="display: none"&gt;Schedule
    of earning per share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended March 31, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt"&gt;Basic&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net income available to common stockholders&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331_zqbXDD1S6P5f" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;1,641&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGhtC9stSmO7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;1,537&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z0fkpCo0mrXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;26&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zwcxtQrdMLYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;78&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331_zUBOTwkbOogd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;2,506&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwjt6sQghDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;2,347&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zK0C14wDgGxg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;40&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zrYS3J0XSO32" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;119&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331_zPAIhEgFA8k" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5gk377lwRac" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zD4beo0DL8pi" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z6K7LNLF9kAi" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331_znrsBtyunsy4" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKv7qqwkSbG4" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zyHXpdas9XU8" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zFQi0uWIW1Oc" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Basic income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331_zBwbDqgONxq4" title="Basic income per common share"&gt;0.24&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMBAA9yp3QD8" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zavWvE10398l" title="Basic income per common share"&gt;0.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z8p0J8VlWi5d" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331_zFHBF0f1jk1d" title="Basic income per common share"&gt;0.37&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqar1scH2De" title="Basic income per common share"&gt;0.38&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zLGc2UlOjkB" title="Basic income per common share"&gt;0.11&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zT8rDYSOG6t8" title="Basic income per common share"&gt;0.38&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWDlDtzYerOh" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zZP3r8Gojy0j" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWI1r61xr4Ub" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zQiO3Zdi5O2" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Class C Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQChCVHxoLke" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ConvertibleClassCStock_pn3n3_d0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zQFNcr2IjUz9" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConvertibleClassCStock_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziAo4awAGc0i" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConvertibleClassCStock_pn3n3_d0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zRGpkmVWsSqg" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXMoGX4mLOuh" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zoRppx4Pxm86" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za1shwXUZPZ5" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zaUpCVd9s8gh" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYUMFBgiRMU" title="Diluted income per common share"&gt;0.24&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z8Y4jdIFSfch" title="Diluted income per common share"&gt;0.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeYy1OFW9UZa" title="Diluted income per common share"&gt;0.37&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zsD0rY19nco7" title="Diluted income per common share"&gt;0.11&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;

































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Nine months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Nine months ended March 31, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt"&gt;Basic&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net income available to common stockholders&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331_z04LmGFLMMAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;5,961&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zauZSNe9bmH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;5,581&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zsrqmEkfLcea" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;97&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z5GZUugU19jk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;283&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331_zFhiPZDjBr8f" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;7,605&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIbeTaSZc0Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;7,122&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zW7OHeq4w1Md" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;123&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zIUDrXVYqFKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331_zuLD5f8HTsY4" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znIp0wFlcx53" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zDXVqSV9rMyj" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zQAvq3Cew8lk" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331_zsjfawybmvHc" title="Weighted average shares outstanding"&gt;6,941&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMYsxpVWbOu1" title="Weighted average shares outstanding"&gt;6,245&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zeBbAwA3QsZh" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zza5gf52vhe6" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Basic income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331_zS9XSRM7KW7j" title="Basic income per common share"&gt;0.87&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVUoHVu5zAO3" title="Basic income per common share"&gt;0.90&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zGOcUyrT5sNf" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zsbqNJ4pL9hg" title="Basic income per common share"&gt;0.90&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331_zGi6UWtZezlh" title="Basic income per common share"&gt;1.10&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBz3BpMzUgmh" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z5tomHvhXYd" title="Basic income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zd7Ue3RNIb1d" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZu09MHcacEh" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zEIPrvVpscV7" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0F0yHtTAAz3" title="Weighted average shares outstanding"&gt;6,244&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zC9AtzIky1m2" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Class C Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zefxALFYNEzi" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_d0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zIFgLU1EDVCe" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCmegAWzYZM9" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_d0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zJxn3TJksWX6" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5VdtCroURY4" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zdOKIptyS0I8" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIzUCgdjVsbh" title="Total Denominator for diluted earnings per share"&gt;6,372&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z47LkNDl9FNc" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pip0_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkCK3q86wss6" title="Diluted income per common share"&gt;0.89&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z6YRXXxV1Es2" title="Diluted income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4AWUcCPYxpd" title="Diluted income per common share"&gt;1.12&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zukxtMQEeAOf" title="Diluted income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zW9Im6ECFVE5" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001095">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zvrM574Ca9ql" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share - (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zOj5Sb6NabX8" style="display: none"&gt;Schedule
    of earning per share&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Three months ended March 31, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt"&gt;Basic&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net income available to common stockholders&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331_zqbXDD1S6P5f" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;1,641&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGhtC9stSmO7" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;1,537&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_989_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z0fkpCo0mrXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;26&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zwcxtQrdMLYf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;78&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331_zUBOTwkbOogd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;2,506&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvwjt6sQghDh" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;2,347&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zK0C14wDgGxg" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;40&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98E_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zrYS3J0XSO32" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;119&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331_zPAIhEgFA8k" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5gk377lwRac" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zD4beo0DL8pi" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z6K7LNLF9kAi" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331_znrsBtyunsy4" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKv7qqwkSbG4" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zyHXpdas9XU8" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zFQi0uWIW1Oc" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Basic income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331_zBwbDqgONxq4" title="Basic income per common share"&gt;0.24&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMBAA9yp3QD8" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zavWvE10398l" title="Basic income per common share"&gt;0.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z8p0J8VlWi5d" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331_zFHBF0f1jk1d" title="Basic income per common share"&gt;0.37&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkqar1scH2De" title="Basic income per common share"&gt;0.38&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zLGc2UlOjkB" title="Basic income per common share"&gt;0.11&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zT8rDYSOG6t8" title="Basic income per common share"&gt;0.38&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWDlDtzYerOh" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zZP3r8Gojy0j" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWI1r61xr4Ub" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zQiO3Zdi5O2" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Class C Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQChCVHxoLke" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_ecustom--ConvertibleClassCStock_pn3n3_d0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zQFNcr2IjUz9" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConvertibleClassCStock_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziAo4awAGc0i" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_905_ecustom--ConvertibleClassCStock_pn3n3_d0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zRGpkmVWsSqg" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXMoGX4mLOuh" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zoRppx4Pxm86" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za1shwXUZPZ5" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zaUpCVd9s8gh" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYUMFBgiRMU" title="Diluted income per common share"&gt;0.24&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pip0_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z8Y4jdIFSfch" title="Diluted income per common share"&gt;0.07&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeYy1OFW9UZa" title="Diluted income per common share"&gt;0.37&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pip0_c20250101__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zsD0rY19nco7" title="Diluted income per common share"&gt;0.11&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;

































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Nine months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="15" style="border-bottom: Black 1pt solid; text-align: center"&gt;Nine months ended March 31, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class C Common Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Class A Preferred Stock&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 28%; text-indent: -10pt"&gt;Basic&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Numerator:&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Net income available to common stockholders&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_981_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331_z04LmGFLMMAd" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;5,961&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zauZSNe9bmH3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;5,581&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zsrqmEkfLcea" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;97&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_984_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_z5GZUugU19jk" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;283&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331_zFhiPZDjBr8f" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;7,605&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_980_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIbeTaSZc0Vf" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;7,122&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zW7OHeq4w1Md" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;123&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_ecustom--NetIncomeLossAvailableToCommonStockholderBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zIUDrXVYqFKl" style="border-bottom: Black 2.5pt double; text-align: right" title="Net income available to common stockholders"&gt;360&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331_zuLD5f8HTsY4" title="Weighted average shares outstanding"&gt;6,865&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znIp0wFlcx53" title="Weighted average shares outstanding"&gt;6,169&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zDXVqSV9rMyj" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zQAvq3Cew8lk" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331_zsjfawybmvHc" title="Weighted average shares outstanding"&gt;6,941&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMYsxpVWbOu1" title="Weighted average shares outstanding"&gt;6,245&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zeBbAwA3QsZh" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zza5gf52vhe6" title="Weighted average shares outstanding"&gt;313&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Basic income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331_zS9XSRM7KW7j" title="Basic income per common share"&gt;0.87&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVUoHVu5zAO3" title="Basic income per common share"&gt;0.90&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zGOcUyrT5sNf" title="Basic income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zsbqNJ4pL9hg" title="Basic income per common share"&gt;0.90&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331_zGi6UWtZezlh" title="Basic income per common share"&gt;1.10&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBz3BpMzUgmh" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z5tomHvhXYd" title="Basic income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassAPreferredStockMember_zd7Ue3RNIb1d" title="Basic income per common share"&gt;1.14&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Denominator:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Weighted average shares outstanding&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZu09MHcacEh" title="Weighted average shares outstanding"&gt;6,168&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zEIPrvVpscV7" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0F0yHtTAAz3" title="Weighted average shares outstanding"&gt;6,244&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zC9AtzIky1m2" title="Weighted average shares outstanding"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Convertible Class C Stock&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zefxALFYNEzi" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--ConvertibleClassCStock_pn3n3_d0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zIFgLU1EDVCe" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_ecustom--ConvertibleClassCStock_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCmegAWzYZM9" title="Convertible Class C Stock"&gt;128&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_ecustom--ConvertibleClassCStock_pn3n3_d0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zJxn3TJksWX6" title="Convertible Class C Stock"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total Denominator for diluted earnings per share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5VdtCroURY4" title="Total Denominator for diluted earnings per share"&gt;6,296&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zdOKIptyS0I8" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIzUCgdjVsbh" title="Total Denominator for diluted earnings per share"&gt;6,372&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--WeightedAverageNumberOfDilutedEarningsPerShare_pn3n3_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z47LkNDl9FNc" title="Total Denominator for diluted earnings per share"&gt;383&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Diluted income per common share&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--EarningsPerShareDiluted_pip0_c20250701__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkCK3q86wss6" title="Diluted income per common share"&gt;0.89&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20250701__20260331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_z6YRXXxV1Es2" title="Diluted income per common share"&gt;0.25&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20250331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4AWUcCPYxpd" title="Diluted income per common share"&gt;1.12&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20250331__us-gaap--StatementClassOfStockAxis__custom--ClassCCommonMember_zukxtMQEeAOf" title="Diluted income per common share"&gt;0.32&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact001097"
      unitRef="USD">1641000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001099"
      unitRef="USD">1537000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001101"
      unitRef="USD">26000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2026-01-012026-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001103"
      unitRef="USD">78000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact001105"
      unitRef="USD">2506000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001107"
      unitRef="USD">2347000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001109"
      unitRef="USD">40000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-01-012025-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001111"
      unitRef="USD">119000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact001113"
      unitRef="Shares">6865000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001115"
      unitRef="Shares">6169000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001117"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2026-01-012026-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001119"
      unitRef="Shares">313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact001121"
      unitRef="Shares">6865000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001123"
      unitRef="Shares">6169000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001125"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-012025-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001127"
      unitRef="Shares">313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001129"
      unitRef="USDPShares">0.24</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001131"
      unitRef="USDPShares">0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001133"
      unitRef="USDPShares">0.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2026-01-012026-03-31_custom_ClassAPreferredStockMember"
      decimals="INF"
      id="Fact001135"
      unitRef="USDPShares">0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001137"
      unitRef="USDPShares">0.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001139"
      unitRef="USDPShares">0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001141"
      unitRef="USDPShares">0.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-01-012025-03-31_custom_ClassAPreferredStockMember"
      decimals="INF"
      id="Fact001143"
      unitRef="USDPShares">0.38</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001145"
      unitRef="Shares">6168000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001147"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001149"
      unitRef="Shares">6168000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001151"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <FONR:ConvertibleClassCStock
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001153"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001155"
      unitRef="Shares">0</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001157"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001159"
      unitRef="Shares">0</FONR:ConvertibleClassCStock>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001161"
      unitRef="Shares">6296000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001163"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001165"
      unitRef="Shares">6296000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001167"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001169"
      unitRef="USDPShares">0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2026-01-012026-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001171"
      unitRef="USDPShares">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001173"
      unitRef="USDPShares">0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-012025-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001175"
      unitRef="USDPShares">0.11</us-gaap:EarningsPerShareDiluted>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001192"
      unitRef="USD">5961000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001194"
      unitRef="USD">5581000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001196"
      unitRef="USD">97000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2025-07-012026-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001198"
      unitRef="USD">283000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001200"
      unitRef="USD">7605000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001202"
      unitRef="USD">7122000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001204"
      unitRef="USD">123000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <FONR:NetIncomeLossAvailableToCommonStockholderBasic
      contextRef="From2024-07-012025-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001206"
      unitRef="USD">360000</FONR:NetIncomeLossAvailableToCommonStockholderBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001208"
      unitRef="Shares">6865000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001210"
      unitRef="Shares">6169000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001212"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012026-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001214"
      unitRef="Shares">313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001216"
      unitRef="Shares">6941000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001218"
      unitRef="Shares">6245000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001220"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012025-03-31_custom_ClassAPreferredStockMember"
      decimals="-3"
      id="Fact001222"
      unitRef="Shares">313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-07-01to2026-03-31"
      decimals="INF"
      id="Fact001224"
      unitRef="USDPShares">0.87</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001226"
      unitRef="USDPShares">0.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001228"
      unitRef="USDPShares">0.25</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2025-07-012026-03-31_custom_ClassAPreferredStockMember"
      decimals="INF"
      id="Fact001230"
      unitRef="USDPShares">0.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2024-07-012025-03-31"
      decimals="INF"
      id="Fact001232"
      unitRef="USDPShares">1.10</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001234"
      unitRef="USDPShares">1.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001236"
      unitRef="USDPShares">0.32</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="From2024-07-012025-03-31_custom_ClassAPreferredStockMember"
      decimals="INF"
      id="Fact001238"
      unitRef="USDPShares">1.14</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001240"
      unitRef="Shares">6168000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001242"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001244"
      unitRef="Shares">6244000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001246"
      unitRef="Shares">383000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <FONR:ConvertibleClassCStock
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001248"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001250"
      unitRef="Shares">0</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001252"
      unitRef="Shares">128000</FONR:ConvertibleClassCStock>
    <FONR:ConvertibleClassCStock
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001254"
      unitRef="Shares">0</FONR:ConvertibleClassCStock>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001256"
      unitRef="Shares">6296000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001258"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact001260"
      unitRef="Shares">6372000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <FONR:WeightedAverageNumberOfDilutedEarningsPerShare
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="-3"
      id="Fact001262"
      unitRef="Shares">383000</FONR:WeightedAverageNumberOfDilutedEarningsPerShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001264"
      unitRef="USDPShares">0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012026-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001266"
      unitRef="USDPShares">0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001268"
      unitRef="USDPShares">1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012025-03-31_custom_ClassCCommonMember"
      decimals="INF"
      id="Fact001270"
      unitRef="USDPShares">0.32</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001272">&lt;p id="xdx_84C_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zfVf9ZIsJ76g" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_860_zgDQF5xEmCf7"&gt;Recent Accounting Standards or Updates Not Yet Adopted&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Income Taxes&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, The Financial Accounting Standards
Board (&#x201c;FASB&#x201d;) issued Accounting Standards Codification (&#x201c;ASU&#x201d;) 2023-09, &#x201c;Income Taxes (740): &#x201c;Improvements
to Income Tax Disclosures&#x201d;, which enhances transparency about income tax information through improvements to income tax disclosures
primarily related to the rate reconciliation and income taxes paid and to improve the effectiveness of income tax disclosures. The ASU
will be effective for our annual financial statements starting in fiscal 2026 and interim periods beginning in the first quarter of fiscal
2027, with early adoption permitted. We are currently evaluating the impact of this accounting standard, but do not expect it to have
a material impact on our income tax disclosures.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2024, the FASB issued ASU 2024-03, &#x201c;Income
Statement &#x2013; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures&#x201d; (Subtopic 220-40): Disaggregation of
Income Statement Expenses&#x201d;. This ASU requires disaggregation of certain income statement expense captions into specified categories
to be disclosed within the notes to the condensed consolidated financial statements, but does not change the expense captions on the income
statement. The amendments in this ASU are to be applied prospectively, although retrospective application is permitted, and is effective
for annual financial statements starting in fiscal 2028 and interim periods starting in fiscal 2029, with early adoption permitted. The
Company is currently evaluating the effect that the adoption of ASU 2024-03 will have on our disclosures.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;FASB, the Emerging Issues Task Force and the SEC have
issued certain other accounting standards, updates, and regulations as of March 31, 2026 that will become effective in subsequent periods;
however, management does not believe that any of those updates would have significantly affected our financial accounting measures or
disclosures had they been in effect during 2026, 2025 or 2024, and it does not believe that any of those standards will have a significant
impact on our unaudited consolidated condensed financial statements at the time they become effective.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001290">&lt;p id="xdx_802_eus-gaap--LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_zcSebJM7VsLg" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 3 &#x2013; &lt;span id="xdx_828_z5m0d549yet5"&gt;ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE
AND MANAGEMENT AND OTHER FEES RECEIVABLE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Receivables, net are comprised of the following at
March 31, 2026 and June 30, 2025:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_znxSePny1sBa" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_z5KcwNT1Hvl2" style="display: none"&gt;Schedule
    of financing receivable noncurrent allowance for credit loss&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20260331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_z9uDUlZm2Mya" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20260331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_zy4JYWUiL10j" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20260331_za5yYiZxvLTh" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for credit losses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccountsReceivableNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;4,841&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;124&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;4,717&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--AccountsReceivableNetRelatedParty_iI_pn3n3_zD7Iygzp9I2l" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts receivable - related party&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--NontradeReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Medical receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,592&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,592&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--ManagementAndOtherFeesNonRelatedParties_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,538&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,930&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;48,608&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance_iI_pn3n3_zlqyMwtj7Lwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,362&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,320&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,042&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20250630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_zDJYpzCen4c1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20250630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_zoFX7j2CMrN3" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20250630_zJ36hYpt1GWl" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for credit losses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--AccountsReceivableNet_iI_pn3n3_z2WzWk1YKG9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;5,569&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;264&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;5,305&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--NontradeReceivables_iI_pn3n3_zKUEESccTpWa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Medical receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,490&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1319"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,490&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ManagementAndOtherFeesNonRelatedParties_iI_pn3n3_z4ssiUUeo5ql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;57,697&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,296&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;43,401&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance_iI_pn3n3_zHhL8FDRkGYa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,885&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,137&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,748&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zLDGe3jElyKe" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s customers are concentrated in the healthcare industry.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Accounts Receivable&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Credit risk with respect to the Company&#x2019;s accounts
receivable related to product sales and service and repair fees is limited due to the customer advances received prior to the commencement
of work performed and the billing of amounts to customers as sub-assemblies are completed. Service and repair fees are billed on a monthly
or quarterly basis and the Company does not continue providing these services if accounts receivable become past due. The Company has
established a current expected credit loss (&#x201c;CECL&#x201d;) to address the risk that a portion of these fees will not be paid. The
Company controls credit risk with respect to accounts receivable from service and repair fees through its credit evaluation process, credit
limits, monitoring procedures and reasonably short collection terms. The Company performs ongoing credit authorizations before a product
sales contract is entered into or service and repair fees are provided.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following tables presents information related
to the allowance for credit losses that relate to accounts and management and other fees receivable:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_pn3n3_zaqqWcRr4mL5" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - allowance for credit losses that relate to accounts and management and other fees receivable (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zPLUM3WPca7g" style="display: none"&gt;schedule of Allowance For Credit Losses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250630_zTF3m5fQtHU5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdditionsMember_zQbLLQYoZek1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DeductionsMember_z3aDNCarmnz9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20260331_zM238lmS4lP9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="17" style="text-align: center"&gt;Summary of Allowance For Credit Losses&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Description&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Balance&lt;br/&gt; June 30, &lt;br/&gt;
2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Additions (Recovery)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Deductions&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Balance &lt;br/&gt; March 31, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--AccountsAndNotesReceivables_iI_zCRSbZmqnX23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;264&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;(140&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;124&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--ManagementAndOtherFeesReceivable_iI_z4mNeKww8m17" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,296&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,366&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;11,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--ManagementAndOtherFeesReceivableRelatedMedicalPractices_iI_z6P1vN8HAeb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable - related medical practices&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;7,137&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,183&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1358"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,320&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240630_z4HHE9Jmibgb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdditionsMember_zpb3nqRrUnW9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DeductionsMember_z1qETW1UNvT6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250331_z9qGaOHBccgh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Balance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Additions (Recovery)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Deductions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccountsAndNotesReceivables_iI_z597CjRD3KFl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;166&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ManagementAndOtherFeesReceivable_iI_zRbLhWHURYL9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(126&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ManagementAndOtherFeesReceivableRelatedMedicalPractices_iI_z1e6OojaqVM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable - related medical practices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1373"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zAYrHajVz5U6" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long Term-Accounts Receivable&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long term-accounts receivable balances at March 31,
2026 and June 30, 2025 amounted to $&lt;span id="xdx_903_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_pn3n3_c20250701__20260331_zbp3USOweSUf" title="Long term-accounts receivable"&gt;3,040&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--IncreaseDecreaseInAccountsAndOtherReceivables_pn3n3_c20240701__20250630_zaItx5f6eQTf" title="Long term-accounts receivable"&gt;3,550&lt;/span&gt;, respectively. The Company will generate revenue from long-term, non-cancellable
contracts to provide service and repair services. Future revenue to be recognized over the following four years as of March 31, 2026 is
as follows:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LongTermPurchaseCommitmentTextBlock_pn3n3_zN9VCyVDPqMb" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Future Revenue (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zGDguxXobgZ5" style="display: none"&gt;Schedule
    of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20260331_zlT3kxEeE6e5" style="width: 43%; text-align: right" title="2026"&gt;1,491&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20260331_zFaltzaUiG8d" style="text-align: right" title="2027"&gt;1,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ContractReceivableDueThreeToFourYears_iI_pn3n3_c20260331_zuwnw6caXUu8" style="text-align: right" title="2028"&gt;622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2031&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ContractReceivableDueFourToFiveYears_iI_pn3n3_c20260331_zJuQitSMbzv9" style="border-bottom: Black 1pt solid; text-align: right" title="2029"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_iI_pn3n3_c20260331_zRuLN2jakbse" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;3,273&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z8x8yJEIk4zl" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_zJHvOhegQ943" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_867_zgrr9SEf5fhi"&gt;Medical Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Medical receivables are due under fee-for-service
contracts from third-party payors, such as hospitals, government sponsored healthcare programs, patient&#x2019;s legal counsel and directly
from patients. Substantially all the revenue relates to patients residing in Florida. Medical receivables are recorded at net realizable
value based on the estimated amounts the Company expects to receive from patients and third-party payers. The medical receivable is reduced
by an allowance for contractual adjustments based on the historical experience with each payor class at each location.&lt;/p&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Management and Other Fees Receivable&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"&gt;Management
fees receivable is related to management fees outstanding from the related and non-related centers under management agreements. The Company
has established a CECL reserve to address the risk that a portion of the contractually obligated management fees receivable from the PCs
may not be paid. The PCs may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected
fees from third-party payers and patients. The Company&#x2019;s management fees are collateralized, individually and collectively, by the
assets of the PCs. The CECL reserve is determined based on the difference between the management fee receivable and the current amount
of outstanding fees estimated to be collected by the PCs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s considerations into the estimate
of the PCs&#x2019; fee collection is based on a combination of factors. As each management agreement specifies the Company&#x2019;s ultimate
collateral for unpaid management fees are the patient fee receivables owned by each PC, the Company considers the historical loss rates
to pools of receivables with similar risks characteristics, aging of the patient fee receivables, and the financial condition of each
PC. In addition, the Company subjectively adjusts its estimated expected credit losses for current and forward-looking economic conditions
which would include trends seen within the industry and newly enacted regulations. The Company also incorporates qualitative factors,
such as changes in the nature and volume of receivables, regulatory changes, and other relevant factors. Specifically, insurance carriers
covering automobile no-fault and workers&#x2019; compensation claims incur longer payment cycles, rigorous informational requirements and
certain other disallowed claims.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company combines an objective and subjective loss-rate
methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss
rates to pools of receivables with similar risk characteristics (i.e., various insurance payors) and then subjectively adjusting for current
and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulations. The Company
also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant
factors. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to
the Company.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For LLCs owned by the Company, approximately &lt;span id="xdx_90C_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20260101__20260331_zzkC7b2SLDea" title="Revenues"&gt;64.6&lt;/span&gt;%
and &lt;span id="xdx_901_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20250101__20250331_zkYLrQnNcVs8" title="Revenues"&gt;58.8&lt;/span&gt;% of net revenues were derived from no-fault and personal injury protection for the three months ended March 31, 2026 and 2025,
respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For LLCs owned by the Company, approximately &lt;span id="xdx_90A_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20250701__20260331_z9w9GgViuqOa" title="Revenues"&gt;63.7&lt;/span&gt;%
and &lt;span id="xdx_901_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20240701__20250331_z3lF6Gm3b6q1" title="Revenues"&gt;60.1&lt;/span&gt;% of net revenues were derived from no-fault and personal injury protection for the nine months ended March 31, 2026 and 2025,
respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Net revenues from management and other fees charged
to the related PCs accounted for approximately &lt;span id="xdx_90B_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20260101__20260331_zuaxUtBStmQb" title="Net revenues"&gt;11.2&lt;/span&gt;% and &lt;span id="xdx_908_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20250101__20250331_zwIwiMce3wt6" title="Net revenues"&gt;11.0&lt;/span&gt;% of the consolidated net revenues for the three months ended March 31, 2026
and 2025, respectively. Net revenues from management and other fees charged to the related PCs accounted for approximately &lt;span id="xdx_905_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20250701__20260331_zV5YsFwJpkIj" title="Net revenues"&gt;11.4&lt;/span&gt;% and &lt;span id="xdx_905_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20240701__20250331_zO6tPtl0GNE1" title="Net revenues"&gt;11.6&lt;/span&gt;%
of the consolidated net revenues for the nine months ended March 31, 2026 and 2025.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001292">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock_pn3n3_znxSePny1sBa" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Long Term Accounts Receivable (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BA_z5KcwNT1Hvl2" style="display: none"&gt;Schedule
    of financing receivable noncurrent allowance for credit loss&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49D_20260331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_z9uDUlZm2Mya" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20260331__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_zy4JYWUiL10j" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_499_20260331_za5yYiZxvLTh" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for credit losses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--AccountsReceivableNet_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;4,841&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;124&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;4,717&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--AccountsReceivableNetRelatedParty_iI_pn3n3_zD7Iygzp9I2l" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounts receivable - related party&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1299"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;30&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_eus-gaap--NontradeReceivables_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Medical receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,592&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1303"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;25,592&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--ManagementAndOtherFeesNonRelatedParties_iI_pn3n3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;60,538&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,930&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;48,608&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance_iI_pn3n3_zlqyMwtj7Lwd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;19,362&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,320&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,042&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20250630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--AccountsReceivableMember_zDJYpzCen4c1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20250630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--DoubtfulMember_zoFX7j2CMrN3" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20250630_zJ36hYpt1GWl" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross Receivable&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Allowance for credit losses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--AccountsReceivableNet_iI_pn3n3_z2WzWk1YKG9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;5,569&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;264&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; width: 11%; text-align: right"&gt;5,305&lt;/td&gt;
&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_eus-gaap--NontradeReceivables_iI_pn3n3_zKUEESccTpWa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Medical receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,490&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1319"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;24,490&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ManagementAndOtherFeesNonRelatedParties_iI_pn3n3_z4ssiUUeo5ql" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;57,697&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;14,296&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;43,401&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance_iI_pn3n3_zHhL8FDRkGYa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable from related medical practices (&#x201c;PC&#x2019;s&#x201d;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,885&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,137&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;9,748&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfCreditLossesRelatedToFinancingReceivablesNoncurrentTableTextBlock>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-03-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001294"
      unitRef="USD">4841000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-03-31_us-gaap_DoubtfulMember"
      decimals="-3"
      id="Fact001295"
      unitRef="USD">124000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001296"
      unitRef="USD">4717000</us-gaap:AccountsReceivableNet>
    <FONR:AccountsReceivableNetRelatedParty
      contextRef="AsOf2026-03-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001298"
      unitRef="USD">30000</FONR:AccountsReceivableNetRelatedParty>
    <FONR:AccountsReceivableNetRelatedParty
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001300"
      unitRef="USD">30000</FONR:AccountsReceivableNetRelatedParty>
    <us-gaap:NontradeReceivables
      contextRef="AsOf2026-03-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001302"
      unitRef="USD">25592000</us-gaap:NontradeReceivables>
    <us-gaap:NontradeReceivables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001304"
      unitRef="USD">25592000</us-gaap:NontradeReceivables>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2026-03-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001306"
      unitRef="USD">60538000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2026-03-31_us-gaap_DoubtfulMember"
      decimals="-3"
      id="Fact001307"
      unitRef="USD">11930000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001308"
      unitRef="USD">48608000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance
      contextRef="AsOf2026-03-31_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001310"
      unitRef="USD">19362000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance
      contextRef="AsOf2026-03-31_us-gaap_DoubtfulMember"
      decimals="-3"
      id="Fact001311"
      unitRef="USD">9320000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001312"
      unitRef="USD">10042000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001314"
      unitRef="USD">5569000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30_us-gaap_DoubtfulMember"
      decimals="-3"
      id="Fact001315"
      unitRef="USD">264000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001316"
      unitRef="USD">5305000</us-gaap:AccountsReceivableNet>
    <us-gaap:NontradeReceivables
      contextRef="AsOf2025-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001318"
      unitRef="USD">24490000</us-gaap:NontradeReceivables>
    <us-gaap:NontradeReceivables
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001320"
      unitRef="USD">24490000</us-gaap:NontradeReceivables>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2025-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001322"
      unitRef="USD">57697000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2025-06-30_us-gaap_DoubtfulMember"
      decimals="-3"
      id="Fact001323"
      unitRef="USD">14296000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagementAndOtherFeesNonRelatedParties
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001324"
      unitRef="USD">43401000</FONR:ManagementAndOtherFeesNonRelatedParties>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance
      contextRef="AsOf2025-06-30_us-gaap_AccountsReceivableMember"
      decimals="-3"
      id="Fact001326"
      unitRef="USD">16885000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance
      contextRef="AsOf2025-06-30_us-gaap_DoubtfulMember"
      decimals="-3"
      id="Fact001327"
      unitRef="USD">7137000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance>
    <FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001328"
      unitRef="USD">9748000</FONR:ManagmentAndOtherFeesReceivableRelatedMedicalPracticesNetAllowance>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001344">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--AccountsReceivableAllowanceForCreditLossTableTextBlock_pn3n3_zaqqWcRr4mL5" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - allowance for credit losses that relate to accounts and management and other fees receivable (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_zPLUM3WPca7g" style="display: none"&gt;schedule of Allowance For Credit Losses&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250630_zTF3m5fQtHU5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49C_20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdditionsMember_zQbLLQYoZek1" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DeductionsMember_z3aDNCarmnz9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20260331_zM238lmS4lP9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td colspan="17" style="text-align: center"&gt;Summary of Allowance For Credit Losses&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Description&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Balance&lt;br/&gt; June 30, &lt;br/&gt;
2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Additions (Recovery)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Deductions&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Balance &lt;br/&gt; March 31, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--AccountsAndNotesReceivables_iI_zCRSbZmqnX23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;264&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;(140&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;124&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--ManagementAndOtherFeesReceivable_iI_z4mNeKww8m17" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,296&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,366&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1353"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;11,930&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--ManagementAndOtherFeesReceivableRelatedMedicalPractices_iI_z6P1vN8HAeb2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable - related medical practices&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;7,137&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,183&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1358"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,320&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240630_z4HHE9Jmibgb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AdditionsMember_zpb3nqRrUnW9" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DeductionsMember_z1qETW1UNvT6" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49D_20250331_z9qGaOHBccgh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Balance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center"&gt;Balance&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt;
2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Additions (Recovery)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Deductions&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, 2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--AccountsAndNotesReceivables_iI_z597CjRD3KFl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Accounts receivable&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;166&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;107&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;264&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ManagementAndOtherFeesReceivable_iI_zRbLhWHURYL9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,370&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,052&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(126&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;14,296&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--ManagementAndOtherFeesReceivableRelatedMedicalPractices_iI_z1e6OojaqVM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Management and other fees receivable - related medical practices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,110&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,027&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1373"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,137&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001346"
      unitRef="USD">264000</FONR:AccountsAndNotesReceivables>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2026-03-31_custom_DeductionsMember"
      decimals="-3"
      id="Fact001348"
      unitRef="USD">-140000</FONR:AccountsAndNotesReceivables>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001349"
      unitRef="USD">124000</FONR:AccountsAndNotesReceivables>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001351"
      unitRef="USD">14296000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2026-03-31_custom_AdditionsMember"
      decimals="-3"
      id="Fact001352"
      unitRef="USD">-2366000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001354"
      unitRef="USD">11930000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001356"
      unitRef="USD">7137000</FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2026-03-31_custom_AdditionsMember"
      decimals="-3"
      id="Fact001357"
      unitRef="USD">2183000</FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001359"
      unitRef="USD">9320000</FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact001361"
      unitRef="USD">166000</FONR:AccountsAndNotesReceivables>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2025-06-30_custom_AdditionsMember"
      decimals="-3"
      id="Fact001362"
      unitRef="USD">107000</FONR:AccountsAndNotesReceivables>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2025-06-30_custom_DeductionsMember"
      decimals="-3"
      id="Fact001363"
      unitRef="USD">-9000</FONR:AccountsAndNotesReceivables>
    <FONR:AccountsAndNotesReceivables
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001364"
      unitRef="USD">264000</FONR:AccountsAndNotesReceivables>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact001366"
      unitRef="USD">12370000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2025-06-30_custom_AdditionsMember"
      decimals="-3"
      id="Fact001367"
      unitRef="USD">2052000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2025-06-30_custom_DeductionsMember"
      decimals="-3"
      id="Fact001368"
      unitRef="USD">-126000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivable
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001369"
      unitRef="USD">14296000</FONR:ManagementAndOtherFeesReceivable>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact001371"
      unitRef="USD">6110000</FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2025-06-30_custom_AdditionsMember"
      decimals="-3"
      id="Fact001372"
      unitRef="USD">1027000</FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices>
    <FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices
      contextRef="AsOf2025-03-31"
      decimals="-3"
      id="Fact001374"
      unitRef="USD">7137000</FONR:ManagementAndOtherFeesReceivableRelatedMedicalPractices>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001392"
      unitRef="USD">3040000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="From2024-07-012025-06-30"
      decimals="-3"
      id="Fact001394"
      unitRef="USD">3550000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:LongTermPurchaseCommitmentTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001396">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--LongTermPurchaseCommitmentTextBlock_pn3n3_zN9VCyVDPqMb" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACCOUNTS RECEIVABLE, MEDICAL RECEIVABLE AND MANAGEMENT AND OTHER FEES RECEIVABLE - Future Revenue (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BD_zGDguxXobgZ5" style="display: none"&gt;Schedule
    of future revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 44%; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ContractReceivableDueOneToTwoYears_iI_pn3n3_c20260331_zlT3kxEeE6e5" style="width: 43%; text-align: right" title="2026"&gt;1,491&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ContractReceivableDueTwoToThreeYears_iI_pn3n3_c20260331_zFaltzaUiG8d" style="text-align: right" title="2027"&gt;1,119&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ContractReceivableDueThreeToFourYears_iI_pn3n3_c20260331_zuwnw6caXUu8" style="text-align: right" title="2028"&gt;622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2031&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ContractReceivableDueFourToFiveYears_iI_pn3n3_c20260331_zJuQitSMbzv9" style="border-bottom: Black 1pt solid; text-align: right" title="2029"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AccountsReceivableBilledForLongTermContractsOrPrograms_iI_pn3n3_c20260331_zRuLN2jakbse" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;3,273&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LongTermPurchaseCommitmentTextBlock>
    <us-gaap:ContractReceivableDueOneToTwoYears
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001398"
      unitRef="USD">1491000</us-gaap:ContractReceivableDueOneToTwoYears>
    <us-gaap:ContractReceivableDueTwoToThreeYears
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001400"
      unitRef="USD">1119000</us-gaap:ContractReceivableDueTwoToThreeYears>
    <us-gaap:ContractReceivableDueThreeToFourYears
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001402"
      unitRef="USD">622000</us-gaap:ContractReceivableDueThreeToFourYears>
    <us-gaap:ContractReceivableDueFourToFiveYears
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001404"
      unitRef="USD">41000</us-gaap:ContractReceivableDueFourToFiveYears>
    <us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001406"
      unitRef="USD">3273000</us-gaap:AccountsReceivableBilledForLongTermContractsOrPrograms>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001408">&lt;p id="xdx_845_eus-gaap--ReceivablesPolicyTextBlock_zJHvOhegQ943" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_867_zgrr9SEf5fhi"&gt;Medical Receivable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Medical receivables are due under fee-for-service
contracts from third-party payors, such as hospitals, government sponsored healthcare programs, patient&#x2019;s legal counsel and directly
from patients. Substantially all the revenue relates to patients residing in Florida. Medical receivables are recorded at net realizable
value based on the estimated amounts the Company expects to receive from patients and third-party payers. The medical receivable is reduced
by an allowance for contractual adjustments based on the historical experience with each payor class at each location.&lt;/p&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Management and Other Fees Receivable&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"&gt;Management
fees receivable is related to management fees outstanding from the related and non-related centers under management agreements. The Company
has established a CECL reserve to address the risk that a portion of the contractually obligated management fees receivable from the PCs
may not be paid. The PCs may be limited in their ability to pay the full management fee receivable if they do not collect sufficient expected
fees from third-party payers and patients. The Company&#x2019;s management fees are collateralized, individually and collectively, by the
assets of the PCs. The CECL reserve is determined based on the difference between the management fee receivable and the current amount
of outstanding fees estimated to be collected by the PCs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; color: #212529"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s considerations into the estimate
of the PCs&#x2019; fee collection is based on a combination of factors. As each management agreement specifies the Company&#x2019;s ultimate
collateral for unpaid management fees are the patient fee receivables owned by each PC, the Company considers the historical loss rates
to pools of receivables with similar risks characteristics, aging of the patient fee receivables, and the financial condition of each
PC. In addition, the Company subjectively adjusts its estimated expected credit losses for current and forward-looking economic conditions
which would include trends seen within the industry and newly enacted regulations. The Company also incorporates qualitative factors,
such as changes in the nature and volume of receivables, regulatory changes, and other relevant factors. Specifically, insurance carriers
covering automobile no-fault and workers&#x2019; compensation claims incur longer payment cycles, rigorous informational requirements and
certain other disallowed claims.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company combines an objective and subjective loss-rate
methodology to estimate expected credit losses based on the collateral owned by each PC. This involves objectively using historical loss
rates to pools of receivables with similar risk characteristics (i.e., various insurance payors) and then subjectively adjusting for current
and forward-looking economic conditions which would include trends seen within the industry and newly enacted regulations. The Company
also incorporates qualitative factors, such as changes in the nature and volume of the receivables, regulatory changes, and other relevant
factors. Additional Company managed entities also operate under a guaranty agreement, pursuant to which management fees are payable to
the Company.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For LLCs owned by the Company, approximately &lt;span id="xdx_90C_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20260101__20260331_zzkC7b2SLDea" title="Revenues"&gt;64.6&lt;/span&gt;%
and &lt;span id="xdx_901_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20250101__20250331_zkYLrQnNcVs8" title="Revenues"&gt;58.8&lt;/span&gt;% of net revenues were derived from no-fault and personal injury protection for the three months ended March 31, 2026 and 2025,
respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;For LLCs owned by the Company, approximately &lt;span id="xdx_90A_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20250701__20260331_z9w9GgViuqOa" title="Revenues"&gt;63.7&lt;/span&gt;%
and &lt;span id="xdx_901_ecustom--PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims_pip0_dp_c20240701__20250331_z3lF6Gm3b6q1" title="Revenues"&gt;60.1&lt;/span&gt;% of net revenues were derived from no-fault and personal injury protection for the nine months ended March 31, 2026 and 2025,
respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Net revenues from management and other fees charged
to the related PCs accounted for approximately &lt;span id="xdx_90B_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20260101__20260331_zuaxUtBStmQb" title="Net revenues"&gt;11.2&lt;/span&gt;% and &lt;span id="xdx_908_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20250101__20250331_zwIwiMce3wt6" title="Net revenues"&gt;11.0&lt;/span&gt;% of the consolidated net revenues for the three months ended March 31, 2026
and 2025, respectively. Net revenues from management and other fees charged to the related PCs accounted for approximately &lt;span id="xdx_905_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20250701__20260331_zV5YsFwJpkIj" title="Net revenues"&gt;11.4&lt;/span&gt;% and &lt;span id="xdx_905_ecustom--PercentageOfConsolidatedNetRevenueFromManagementFees_pip0_dp_c20240701__20250331_zO6tPtl0GNE1" title="Net revenues"&gt;11.6&lt;/span&gt;%
of the consolidated net revenues for the nine months ended March 31, 2026 and 2025.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ReceivablesPolicyTextBlock>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001424"
      unitRef="Ratio">0.646</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001426"
      unitRef="Ratio">0.588</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2025-07-01to2026-03-31"
      decimals="INF"
      id="Fact001428"
      unitRef="Ratio">0.637</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims
      contextRef="From2024-07-012025-03-31"
      decimals="INF"
      id="Fact001430"
      unitRef="Ratio">0.601</FONR:PercentageOfPcsNetRevenueDerivedFromNofaultAndPersonalInjuryProtectionClaims>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2026-01-012026-03-31"
      decimals="INF"
      id="Fact001432"
      unitRef="Ratio">0.112</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2025-01-012025-03-31"
      decimals="INF"
      id="Fact001434"
      unitRef="Ratio">0.110</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2025-07-01to2026-03-31"
      decimals="INF"
      id="Fact001436"
      unitRef="Ratio">0.114</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:PercentageOfConsolidatedNetRevenueFromManagementFees
      contextRef="From2024-07-012025-03-31"
      decimals="INF"
      id="Fact001438"
      unitRef="Ratio">0.116</FONR:PercentageOfConsolidatedNetRevenueFromManagementFees>
    <FONR:LesseeOperatingLeasesAndFinanceLeaseTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001440">&lt;p id="xdx_80E_ecustom--LesseeOperatingLeasesAndFinanceLeaseTextBlock_zskiFkkzZcAe" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 4 &#x2013; &lt;span id="xdx_827_zFOxThU7zjB3"&gt;OPERATING AND FINANCING LEASES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company accounts for its various operating leases
in accordance with Accounting Standards Codification (ASC) 842 &#x2013; &#x201c;Leases&#x201d;, as updated by ASU 2016-02. At the inception
of a lease, the Company recognizes right-of-use lease assets and related lease liabilities measured at present value of future lease payments
on its balance sheet. Lease expense is recognized on a straight-line basis over the term of the lease. The Company&#x2019;s most common
initial term varies in length from 2 to 19 years. Including renewal options negotiated with the landlord, we have a total span of 2 to
16 years at the facilities we lease. The Company reviewed its contracts with vendors and customers, determining that its right-of-use
lease assets consisted of only office space operating leases. In determining the right-of-use lease assets and liabilities, the Company
did recognize lease extension options which the Company feels would be reasonably exercised. Our incremental borrowing rate (&#x201c;IBR&#x201d;)
used to discount the stream of operating lease payments is closely related to the interest rates available to the Company.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;A reconciliation of operating and financing lease
payments undiscounted cash flows to lease liabilities recognized as of March 31, 2026 is as follows:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zrEGeeWCY3U3" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES - Lease Payments (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zszOmcCwI2Dg" style="display: none"&gt;Schedule
    of lessee operating leases liability maturity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;12 Months Ending &lt;br/&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Operating Lease&#160; &lt;br/&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Financing Lease Payments&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_ztJlaAE2a1ba" style="width: 26%; text-align: right" title="2026"&gt;6,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zMvSQkMnDgG9" style="width: 26%; text-align: right" title="2026"&gt;224&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zn8aCmAPWVAc" style="text-align: right" title="2027"&gt;6,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zNOGKowFPS2g" style="text-align: right" title="2027"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_z9UGbbao8Jdg" style="text-align: right" title="2028"&gt;5,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zQRbHEdc1SOj" style="text-align: right" title="2028"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1454"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zKRkQJ7iCwfb" style="text-align: right" title="2029"&gt;5,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_d0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zUJ8A6UDzLxg" style="text-align: right" title="2029"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zwcLInTMOeB" style="text-align: right" title="2030"&gt;5,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_d0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_z4SJcgpJtRv8" style="text-align: right" title="2030"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zA4PkCVZAQlg" style="text-align: right" title="Thereafter"&gt;23,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_d0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zAQmV92VpZtb" style="text-align: right" title="Thereafter"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PresentValueDiscount_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zjOLTpU9ORR2" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;(13,494&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PresentValueDiscountFinancingLease_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zjxyWWuJLDF9" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1470"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zUrnWwwfazX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability"&gt;38,607&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zUai1REFujLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zPZXXSHDncQl" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_pn3n3_zZ7qpEgXZjg2" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zykwfdMyhsLf" style="display: none"&gt;Schedule
    of weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the nine months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Operating leases - years&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_z3V4pWcTQnL9" title="Operating leases - years"&gt;9.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_ztPoZRu0zv16" title="Operating leases - years"&gt;10.4&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Finance lease - years&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_zNCXrTdf58Qb" title="Finance lease - years"&gt;0.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zTExPogdyFq5" title="Finance lease - years"&gt;1.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Weighted Average Discount Rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating leases&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20260331_z25LHyWcTXre" title="Operating leases"&gt;6.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zg8QaZ5idMSh" title="Operating leases"&gt;6.5&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Finance lease&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20260331_zmwxisyaK5zk" title="Finance lease"&gt;3.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zv1grdrPUMJg" title="Finance lease"&gt;3.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AB_zkqyBPEtKAv4" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_pn3n3_zbjlv8C8pZve" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zej8FxS3fJ9g"&gt;Components of lease expense&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_491_20250701__20260331_zakaSWqJcRWe" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49F_20240701__20250331_z5YMkHaQzq01" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the nine months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--OperatingLeaseCost_pn3n3_z6jursVVQ8b5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Operating lease cost&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,770&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,608&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--FinanceLeaseCostsAbstract_iB_zuRcQh9F7WLl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Finance lease cost:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--DepreciationOfLeasedEquipment_i01_pn3n3_zjwCl3pGvp7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation of leased equipment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;169&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;162&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_i01_pn3n3_zPHC5JL6dGEj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Interest on lease liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1521"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--FinanceLeaseCost_i01_pn3n3_zXN1kmcPgdpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total finance lease cost&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;185&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;174&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p id="xdx_8AB_zIbtuS95EZ93" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Supplemental cash flow information related to leases
was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_pn3n3_z0KMnZDDTytj" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zIzM3Q4l5H97"&gt;Supplemental cash flow information related to leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20250701__20260331_zMMWBlnjmykb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20240701__20250331_zBwYjURwSjE1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the nine months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--OperatingCashFlowsFromOperatingLeases_zdSmiGWexve5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FinancingCashFlowsFromFinancingLeases_ztU6i1whwg7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Financing cash flows from financing leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RightofuseEquipmentAssetsObtainedInExchangeForLeaseObligationsAbstract_iB_zNXAaYbuaO8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Right-of-use and equipment assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--RightofuseEquipmentAssetsObtainedInExchangeForLeaseObiligationsOperatingLeases_zRNCnowTWv3g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



























</FONR:LesseeOperatingLeasesAndFinanceLeaseTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001442">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_zrEGeeWCY3U3" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES - Lease Payments (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B0_zszOmcCwI2Dg" style="display: none"&gt;Schedule
    of lessee operating leases liability maturity&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;12 Months Ending &lt;br/&gt;March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Operating Lease&#160; &lt;br/&gt;Payments&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Financing Lease Payments&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 27%; text-align: left; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_ztJlaAE2a1ba" style="width: 26%; text-align: right" title="2026"&gt;6,204&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zMvSQkMnDgG9" style="width: 26%; text-align: right" title="2026"&gt;224&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zn8aCmAPWVAc" style="text-align: right" title="2027"&gt;6,057&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zNOGKowFPS2g" style="text-align: right" title="2027"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1450"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_z9UGbbao8Jdg" style="text-align: right" title="2028"&gt;5,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearThree_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zQRbHEdc1SOj" style="text-align: right" title="2028"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1454"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zKRkQJ7iCwfb" style="text-align: right" title="2029"&gt;5,708&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFour_iI_pn3n3_d0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zUJ8A6UDzLxg" style="text-align: right" title="2029"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;2031&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zwcLInTMOeB" style="text-align: right" title="2030"&gt;5,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearFive_iI_pn3n3_d0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_z4SJcgpJtRv8" style="text-align: right" title="2030"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zA4PkCVZAQlg" style="text-align: right" title="Thereafter"&gt;23,082&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FinanceLeaseLiabilityPaymentsDueAfterYearFive_iI_pn3n3_d0_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zAQmV92VpZtb" style="text-align: right" title="Thereafter"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Present value discount&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PresentValueDiscount_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zjOLTpU9ORR2" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;(13,494&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--PresentValueDiscountFinancingLease_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zjxyWWuJLDF9" style="border-bottom: Black 1pt solid; text-align: right" title="Present value discount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1470"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Total lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseLiability_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--OperatingLeasePaymentsMember_zUrnWwwfazX1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability"&gt;38,607&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FinanceLeaseLiability_iI_pn3n3_c20260331__us-gaap--RelatedPartyTransactionAxis__custom--FinancingLeasePaymentsMember_zUai1REFujLc" style="border-bottom: Black 2.5pt double; text-align: right" title="Total lease liability"&gt;224&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001444"
      unitRef="USD">6204000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="Fact001446"
      unitRef="USD">224000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001448"
      unitRef="USD">6057000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001452"
      unitRef="USD">5791000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001456"
      unitRef="USD">5708000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="Fact001458"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001460"
      unitRef="USD">5259000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="Fact001462"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001464"
      unitRef="USD">23082000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="Fact001466"
      unitRef="USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <FONR:PresentValueDiscount
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001468"
      unitRef="USD">-13494000</FONR:PresentValueDiscount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2026-03-31_custom_OperatingLeasePaymentsMember"
      decimals="-3"
      id="Fact001472"
      unitRef="USD">38607000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="AsOf2026-03-31_custom_FinancingLeasePaymentsMember"
      decimals="-3"
      id="Fact001474"
      unitRef="USD">224000</us-gaap:FinanceLeaseLiability>
    <FONR:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001492">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock_pn3n3_zZ7qpEgXZjg2" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B4_zykwfdMyhsLf" style="display: none"&gt;Schedule
    of weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the nine months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Operating leases - years&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_z3V4pWcTQnL9" title="Operating leases - years"&gt;9.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_ztPoZRu0zv16" title="Operating leases - years"&gt;10.4&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Finance lease - years&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20260331_zNCXrTdf58Qb" title="Finance lease - years"&gt;0.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FinanceLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20250331_zTExPogdyFq5" title="Finance lease - years"&gt;1.9&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Weighted Average Discount Rate&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Operating leases&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20260331_z25LHyWcTXre" title="Operating leases"&gt;6.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zg8QaZ5idMSh" title="Operating leases"&gt;6.5&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Finance lease&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20260331_zmwxisyaK5zk" title="Finance lease"&gt;3.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--FinanceLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20250331_zv1grdrPUMJg" title="Finance lease"&gt;3.6&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</FONR:ScheduleOfWeightedAverageRemainingLeaseTermTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-03-31" id="Fact001494">P9Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-03-31" id="Fact001496">P10Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2026-03-31" id="Fact001498">P0Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2025-03-31" id="Fact001500">P1Y10M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001502"
      unitRef="Ratio">0.066</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001504"
      unitRef="Ratio">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2026-03-31"
      decimals="INF"
      id="Fact001506"
      unitRef="Ratio">0.036</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2025-03-31"
      decimals="INF"
      id="Fact001508"
      unitRef="Ratio">0.036</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001510">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LeaseCostTableTextBlock_pn3n3_zbjlv8C8pZve" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES (Details 2)"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zej8FxS3fJ9g"&gt;Components of lease expense&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_491_20250701__20260331_zakaSWqJcRWe" style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" id="xdx_49F_20240701__20250331_z5YMkHaQzq01" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the nine months ended March 31,&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--OperatingLeaseCost_pn3n3_z6jursVVQ8b5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Operating lease cost&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,770&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;4,608&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--FinanceLeaseCostsAbstract_iB_zuRcQh9F7WLl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Finance lease cost:&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--DepreciationOfLeasedEquipment_i01_pn3n3_zjwCl3pGvp7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Depreciation of leased equipment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;169&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;162&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--FinanceLeaseInterestExpense_i01_pn3n3_zPHC5JL6dGEj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Interest on lease liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1521"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--FinanceLeaseCost_i01_pn3n3_zXN1kmcPgdpk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total finance lease cost&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;185&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;174&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001512"
      unitRef="USD">4770000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001513"
      unitRef="USD">4608000</us-gaap:OperatingLeaseCost>
    <FONR:DepreciationOfLeasedEquipment
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001518"
      unitRef="USD">169000</FONR:DepreciationOfLeasedEquipment>
    <FONR:DepreciationOfLeasedEquipment
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001519"
      unitRef="USD">162000</FONR:DepreciationOfLeasedEquipment>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001522"
      unitRef="USD">12000</us-gaap:FinanceLeaseInterestExpense>
    <FONR:FinanceLeaseCost
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001524"
      unitRef="USD">185000</FONR:FinanceLeaseCost>
    <FONR:FinanceLeaseCost
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001525"
      unitRef="USD">174000</FONR:FinanceLeaseCost>
    <FONR:SupplementalCashFlowInformationRelatedToLeasesTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001527">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_ecustom--SupplementalCashFlowInformationRelatedToLeasesTableTextBlock_pn3n3_z0KMnZDDTytj" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OPERATING &amp;amp; FINANCING LEASES (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zIzM3Q4l5H97"&gt;Supplemental cash flow information related to leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_491_20250701__20260331_zMMWBlnjmykb" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20240701__20250331_zBwYjURwSjE1" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;For the nine months ended March 31,&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2025&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--OperatingCashFlowsFromOperatingLeases_zdSmiGWexve5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,275&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;4,313&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FinancingCashFlowsFromFinancingLeases_ztU6i1whwg7k" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Financing cash flows from financing leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--RightofuseEquipmentAssetsObtainedInExchangeForLeaseObligationsAbstract_iB_zNXAaYbuaO8b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Right-of-use and equipment assets obtained in exchange for lease obligations:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--RightofuseEquipmentAssetsObtainedInExchangeForLeaseObiligationsOperatingLeases_zRNCnowTWv3g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,711&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



























</FONR:SupplementalCashFlowInformationRelatedToLeasesTableTextBlock>
    <FONR:OperatingCashFlowsFromOperatingLeases
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001529"
      unitRef="USD">4275000</FONR:OperatingCashFlowsFromOperatingLeases>
    <FONR:OperatingCashFlowsFromOperatingLeases
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001530"
      unitRef="USD">4313000</FONR:OperatingCashFlowsFromOperatingLeases>
    <FONR:FinancingCashFlowsFromFinancingLeases
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001532"
      unitRef="USD">183000</FONR:FinancingCashFlowsFromFinancingLeases>
    <FONR:FinancingCashFlowsFromFinancingLeases
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001533"
      unitRef="USD">183000</FONR:FinancingCashFlowsFromFinancingLeases>
    <FONR:RightofuseEquipmentAssetsObtainedInExchangeForLeaseObiligationsOperatingLeases
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001538"
      unitRef="USD">2711000</FONR:RightofuseEquipmentAssetsObtainedInExchangeForLeaseObiligationsOperatingLeases>
    <FONR:RightofuseEquipmentAssetsObtainedInExchangeForLeaseObiligationsOperatingLeases
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001539"
      unitRef="USD">2320000</FONR:RightofuseEquipmentAssetsObtainedInExchangeForLeaseObiligationsOperatingLeases>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001553">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zuLdX7aoI4Hi" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 5 - &lt;span id="xdx_821_zMj9ZnV34Hng"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Property and equipment, at cost, less accumulated
depreciation and amortization included in the accompanying condensed consolidated balance sheets is comprised of:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zdepZaRHBE3h" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zhkXgDzO9Jz7" style="display: none"&gt;Schedule of Property and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &#160; &lt;br/&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Diagnostic equipment&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DiagnosticEquipmentMember_zDT0yS4gryb4" style="width: 12%; text-align: right" title="Diagnostic equipment"&gt;37,291&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DiagnosticEquipmentMember_zwTyulqemo87" style="width: 12%; text-align: right" title="Diagnostic equipment"&gt;35,277&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research, development and demonstration equipment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchDevelopmentAndDemonstrationEquipmentMember_zKhbu3JGbbyc" style="text-align: right" title="Research, development and demonstration equipment"&gt;6,499&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchDevelopmentAndDemonstrationEquipmentMember_zKTsSkw6tdEk" style="text-align: right" title="Research, development and demonstration equipment"&gt;6,491&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Machinery and equipment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zFM3DoDfUKd4" style="text-align: right" title="Machinery and equipment"&gt;2,128&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zBR6Exu2ntH5" style="text-align: right" title="Machinery and equipment"&gt;2,128&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z4Y5hyBKLmpg" style="text-align: right" title="Furniture and fixtures"&gt;3,890&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9G1T4QJ0F3d" style="text-align: right" title="Furniture and fixtures"&gt;3,756&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Leasehold improvements&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z03DGGf5v3hc" style="text-align: right" title="Leasehold improvements"&gt;17,986&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zobDaz1mvv39" style="text-align: right" title="Leasehold improvements"&gt;17,707&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Building&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_ztYvQnqocIEg" style="border-bottom: Black 1pt solid; text-align: right" title="Building"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zk8grQJ2O6Uc" style="border-bottom: Black 1pt solid; text-align: right" title="Building"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331_zxp5NEuNlB6c" style="text-align: right" title="Property and equipment"&gt;68,734&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630_zrGyrvltgZO" style="text-align: right" title="Property and equipment"&gt;66,299&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Accumulated depreciation and amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iI_c20260331_zdEHu8mXol3j" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;50,535&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iI_c20250630_zv4JrUhizFx9" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;47,767&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260331_zHkajKWm9dKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;18,199&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250630_zqrUO0vXprfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;18,532&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A8_z2zOffm2d3j4" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation of property and equipment for the three
months ended March 31, 2026 and 2025 was $&lt;span id="xdx_90B_ecustom--DepreciationOfPropertyAndEquipment_pn3n3_c20260101__20260331_ztE8yY3VsWxi" title="Depreciation of property and equipment"&gt;934&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--DepreciationOfPropertyAndEquipment_pn3n3_c20250101__20250331_zgwPQezeknu" title="Depreciation of property and equipment"&gt;998&lt;/span&gt;, respectively. Depreciation of property and equipment for the nine months ended
March 31, 2026 and 2025 was $&lt;span id="xdx_90F_ecustom--DepreciationOfPropertyAndEquipment_pn3n3_c20250701__20260331_z1OKitKOYOpb" title="Depreciation of property and equipment"&gt;2,768&lt;/span&gt; and $ &lt;span id="xdx_90D_ecustom--DepreciationOfPropertyAndEquipment_pn3n3_c20240701__20250331_zML6vpsVYijf" title="Depreciation of property and equipment"&gt;2,998&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001555">&lt;table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_pn3n3_zdepZaRHBE3h" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B5_zhkXgDzO9Jz7" style="display: none"&gt;Schedule of Property and equipment&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &#160; &lt;br/&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Diagnostic equipment&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DiagnosticEquipmentMember_zDT0yS4gryb4" style="width: 12%; text-align: right" title="Diagnostic equipment"&gt;37,291&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--DiagnosticEquipmentMember_zwTyulqemo87" style="width: 12%; text-align: right" title="Diagnostic equipment"&gt;35,277&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Research, development and demonstration equipment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchDevelopmentAndDemonstrationEquipmentMember_zKhbu3JGbbyc" style="text-align: right" title="Research, development and demonstration equipment"&gt;6,499&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchDevelopmentAndDemonstrationEquipmentMember_zKTsSkw6tdEk" style="text-align: right" title="Research, development and demonstration equipment"&gt;6,491&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Machinery and equipment&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zFM3DoDfUKd4" style="text-align: right" title="Machinery and equipment"&gt;2,128&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zBR6Exu2ntH5" style="text-align: right" title="Machinery and equipment"&gt;2,128&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Furniture and fixtures&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z4Y5hyBKLmpg" style="text-align: right" title="Furniture and fixtures"&gt;3,890&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_z9G1T4QJ0F3d" style="text-align: right" title="Furniture and fixtures"&gt;3,756&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Leasehold improvements&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z03DGGf5v3hc" style="text-align: right" title="Leasehold improvements"&gt;17,986&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zobDaz1mvv39" style="text-align: right" title="Leasehold improvements"&gt;17,707&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Building&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_ztYvQnqocIEg" style="border-bottom: Black 1pt solid; text-align: right" title="Building"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingMember_zk8grQJ2O6Uc" style="border-bottom: Black 1pt solid; text-align: right" title="Building"&gt;940&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20260331_zxp5NEuNlB6c" style="text-align: right" title="Property and equipment"&gt;68,734&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20250630_zrGyrvltgZO" style="text-align: right" title="Property and equipment"&gt;66,299&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Less: Accumulated depreciation and amortization&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iI_c20260331_zdEHu8mXol3j" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;50,535&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation_iI_c20250630_zv4JrUhizFx9" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Accumulated depreciation and amortization"&gt;47,767&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20260331_zHkajKWm9dKh" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;18,199&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20250630_zqrUO0vXprfl" style="border-bottom: Black 2.5pt double; text-align: right" title="Property and equipment net"&gt;18,532&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_DiagnosticEquipmentMember"
      decimals="-3"
      id="Fact001557"
      unitRef="USD">37291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_DiagnosticEquipmentMember"
      decimals="-3"
      id="Fact001559"
      unitRef="USD">35277000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_custom_ResearchDevelopmentAndDemonstrationEquipmentMember"
      decimals="-3"
      id="Fact001561"
      unitRef="USD">6499000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_custom_ResearchDevelopmentAndDemonstrationEquipmentMember"
      decimals="-3"
      id="Fact001563"
      unitRef="USD">6491000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_MachineryAndEquipmentMember"
      decimals="-3"
      id="Fact001565"
      unitRef="USD">2128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_us-gaap_MachineryAndEquipmentMember"
      decimals="-3"
      id="Fact001567"
      unitRef="USD">2128000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact001569"
      unitRef="USD">3890000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact001571"
      unitRef="USD">3756000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact001573"
      unitRef="USD">17986000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact001575"
      unitRef="USD">17707000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31_us-gaap_BuildingMember"
      decimals="-3"
      id="Fact001577"
      unitRef="USD">940000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30_us-gaap_BuildingMember"
      decimals="-3"
      id="Fact001579"
      unitRef="USD">940000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001581"
      unitRef="USD">68734000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">66299000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001585"
      unitRef="USD">50535000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001587"
      unitRef="USD">47767000</us-gaap:PropertyPlantAndEquipmentExcludingLessorAssetUnderOperatingLeaseAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001589"
      unitRef="USD">18199000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001591"
      unitRef="USD">18532000</us-gaap:PropertyPlantAndEquipmentNet>
    <FONR:DepreciationOfPropertyAndEquipment
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact001593"
      unitRef="USD">934000</FONR:DepreciationOfPropertyAndEquipment>
    <FONR:DepreciationOfPropertyAndEquipment
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact001595"
      unitRef="USD">998000</FONR:DepreciationOfPropertyAndEquipment>
    <FONR:DepreciationOfPropertyAndEquipment
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact001597"
      unitRef="USD">2768000</FONR:DepreciationOfPropertyAndEquipment>
    <FONR:DepreciationOfPropertyAndEquipment
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact001599"
      unitRef="USD">2998000</FONR:DepreciationOfPropertyAndEquipment>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001601">&lt;p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_ziaF8mgeqJlg" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 6 - &lt;span id="xdx_826_zOhmtou1xei1"&gt;INVENTORIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventories included in the accompanying condensed
consolidated balance sheets consist of the following:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zTvcezI9Hf93" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_ztADcPF8wgig" style="display: none"&gt;Schedule
    of inventories&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20260331_zVpnVVs7FCh6" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20250630_zlItsYq48TYk" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zbbIvBSj5qEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Purchased parts, components and supplies&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,772&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,631&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zGYGg9Uowaf9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Work-in-process&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;60&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;182&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InventoryNet_iTI_mtIFGAWzdt0_zCAsgMlDWly7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total inventories&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,832&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,813&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A9_zt0rAHh6ANP3" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;































</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001603">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_pn3n3_zTvcezI9Hf93" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVENTORIES - Inventories (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding-top: 0pt; padding-right: 0pt; padding-left: 10pt; text-indent: -10pt"&gt;&lt;span id="xdx_8BE_ztADcPF8wgig" style="display: none"&gt;Schedule
    of inventories&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20260331_zVpnVVs7FCh6" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49E_20250630_zlItsYq48TYk" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &lt;br/&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherInventorySupplies_iI_maIFGAWzdt0_zbbIvBSj5qEl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Purchased parts, components and supplies&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,772&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;2,631&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--InventoryWorkInProcess_iI_maIFGAWzdt0_zGYGg9Uowaf9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Work-in-process&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;60&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;182&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_eus-gaap--InventoryNet_iTI_mtIFGAWzdt0_zCAsgMlDWly7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Total inventories&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,832&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,813&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:OtherInventorySupplies
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001605"
      unitRef="USD">2772000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001606"
      unitRef="USD">2631000</us-gaap:OtherInventorySupplies>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001608"
      unitRef="USD">60000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001609"
      unitRef="USD">182000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001611"
      unitRef="USD">2832000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001612"
      unitRef="USD">2813000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001628">&lt;p id="xdx_804_eus-gaap--IntangibleAssetsDisclosureTextBlock_zykGmZe3YdUb" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 7 &#x2013; &lt;span id="xdx_82C_zjGkgN3Y7ug"&gt;OTHER INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other intangible assets, net of accumulated amortization,
in the accompanying condensed consolidated balance sheets consist of the following:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zQSFRKM5bZAg" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zXGclvvJMLTk" style="display: none"&gt;Schedule
    of other intangible assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average useful lives&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross carrying amount &#x2013; March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated amortization &#x2013; March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net carrying amount &#x2013; March 31, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Capitalized software development costs&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z8ZsJXLgKfie"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z00hcr0iLW5l" style="width: 10%; text-align: right" title="Gross carrying amount intangible assets"&gt;7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zZ2RUuOtQ3Cc" style="width: 10%; text-align: right" title="Accumulated amortization intangible assets"&gt;(7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zwimjtg6zAuj" style="width: 10%; text-align: right" title="Net carrying amount intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1637"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software license&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zEnys7j2Telk"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zs7akzkHOYD4" style="text-align: right" title="Gross carrying amount intangible assets"&gt;1,260&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zPf2N03VwXe5" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(1,040&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zQINBMJn75Xj" style="text-align: right" title="Net carrying amount intangible assets"&gt;220&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Patents and copy rights&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zUWaH29iWmV3"&gt;15&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zN6xIu6SYJhk" style="text-align: right" title="Gross carrying amount intangible assets"&gt;5,227&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zYjVqLIMwlY5" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,358&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zFnWRmJlkiii" style="text-align: right" title="Net carrying amount intangible assets"&gt;869&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Non-compete&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MinimumMember_zx2yZ6VVW2Lj"&gt;2&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MaximumMember_zVMCHY4RJV8a"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zdqnhGiyxDVc" style="text-align: right" title="Gross carrying amount intangible assets"&gt;4,650&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zuS4XR2nxqm5" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,292&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_d0_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zUWXSA1Qaoa" style="text-align: right" title="Net carrying amount intangible assets"&gt;358&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Customer relationships&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zf7vJfnG8sDj"&gt;20&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zT4eDnrUcQwe" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying amount intangible assets"&gt;3,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zPqQi74rq8i3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization intangible assets"&gt;(2,536&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpj1wVVIR1Kg" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying amount intangible assets"&gt;1,364&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331_z1FwLoovZmWk" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying amount intangible assets"&gt;22,042&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331_zuES3E3MR8Sa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization intangible assets"&gt;(19,231&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331_z55Pbuxavs59" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount intangible assets"&gt;2,811&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average useful lives&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross carrying amount &#x2013; June 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated amortization &#x2013; June 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net carrying amount &#x2013; June 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Capitalized software development costs&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zJstXYVdTsMd"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zrl72bj6oiig" style="width: 10%; text-align: right" title="Gross carrying amount intangible assets"&gt;7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBwx30hX0de3" style="width: 10%; text-align: right" title="Accumulated amortization intangible assets"&gt;(7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_ztsvYtBpPpGg" style="width: 10%; text-align: right" title="Net carrying amount intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1679"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software license&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z3qiYh2wRxFa"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zbIeJV77kYV7" style="text-align: right" title="Gross carrying amount intangible assets"&gt;1,260&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zULrmdoZpWq1" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(756&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxYFiAxvBSAj" style="text-align: right" title="Net carrying amount intangible assets"&gt;504&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Patents and copy rights&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zRJOIJPUKLy1"&gt;15&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zIDMz0glFjKe" style="text-align: right" title="Gross carrying amount intangible assets"&gt;5,229&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zZoorzmo4Wv1" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,255&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zGAKytqqVqya" style="text-align: right" title="Net carrying amount intangible assets"&gt;974&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Non-compete&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z6AwObqhWk9e"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zFuwsIT9VEck" style="text-align: right" title="Gross carrying amount intangible assets"&gt;4,150&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zzqMr27oa7ck" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,150&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_d0_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zU6znbzehzla" style="text-align: right" title="Net carrying amount intangible assets"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Customer relationships&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGBe7HU78Qpe"&gt;20&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zci0aEoyEJf8" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying amount intangible assets"&gt;3,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoDp9crsf3Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization intangible assets"&gt;(2,386&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zkRQRXFv8gj9" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying amount intangible assets"&gt;1,514&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630_zvikYyGgX7la" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying amount intangible assets"&gt;21,544&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630_zQgJa2Wsy4B5" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization intangible assets"&gt;(18,552&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630_ztJAMf9GkFt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount intangible assets"&gt;2,992&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A5_zWlv4nmKZkW2" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

























&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;









&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of patents and copyrights for the three
months ended March 31, 2026 and 2025 amounted to $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zhOg7DDkkun6"&gt;34&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zDcVAjgzDmuf"&gt;37&lt;/span&gt;, respectively. Amortization of patents and copyrights for the nine months
ended March 31, 2026 and 2025 amounted to $&lt;span id="xdx_908_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zKfBlcAwrk2d"&gt;103&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240701__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_z6TxiINxXxf6"&gt;114&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of customer relationships for the three
months ended March 31, 2026 and 2025 amounted to $&lt;span id="xdx_904_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zr1sATeEyJKc"&gt;50&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zFpCvMooUA07"&gt;50&lt;/span&gt;, respectively. Amortization of customer relationships for the nine months
ended March 31, 2026 and 2025 amounted to $&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zzsDXmoMFIog"&gt;150&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240701__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zt1qSNOcMsIh"&gt;150&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of software license for the three months
ended March 31, 2026 and 2025 amounted to $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareLicenseMember_z4Zg5LuHrFGi"&gt;94&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareLicenseMember_zeFG01GeUqM7"&gt;94&lt;/span&gt;, respectively. Amortization of software license for the nine months ended March
31, 2026 and 2025 amounted to $&lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareLicenseMember_z7vkW9TMX9P"&gt;284&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240701__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareLicenseMember_zza6t2Vfi8W5"&gt;284&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization of employment contract for the three
months ended March 31, 2026 and 2025 amounted to $&lt;span id="xdx_90B_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--EmploymentContractMember_zKfyqhZ1qBJ6"&gt;40&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250101__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--EmploymentContractMember_zND8wRiRFIWh"&gt;0&lt;/span&gt;, respectively. Amortization of employment contract for the nine months ended
March 31, 2026 and 2025 amounted to $&lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--EmploymentContractMember_zUwKALY6Arn6"&gt;142&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pn3n3_c20240701__20250331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--EmploymentContractMember_z7UB9qNmWAoj"&gt;0&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The estimated amortization of other intangible assets
for the five years ending March 31, 2031 and thereafter is as follows:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_pn3n3_zmopjS1dmu05" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zvZrF2sWXJ9g" style="display: none"&gt;Schedule of Amortization expense&lt;/span&gt; &lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--TotalMember_zDzrIQWY36s7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareLicenseMember_zNcY8Yzz5mq8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompeteMember_zySbSIvdnyDb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zhkLojh5PQOg" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z5xfOJF0pTgh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Schedule Of Other Intangible Assets For the Years Ending March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Software License&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Non- Compete&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Patents and Copyrights&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Customer Relationships&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zWySpZdvIrek" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: center; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zzxZWvyZ3wk9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zGOyhZlON6we" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z8RbMKt25WVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1767"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zSCM2XipZItk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2031&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zErOotxYeGse" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;722&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zD8PYtTqAxse" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other intangible assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,811&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;869&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8A3_zXOmJMqrlAIl" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;































</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001630">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_pn3n3_zQSFRKM5bZAg" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8BF_zXGclvvJMLTk" style="display: none"&gt;Schedule
    of other intangible assets&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average useful lives&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross carrying amount &#x2013; March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated amortization &#x2013; March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net carrying amount &#x2013; March 31, 2026&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Capitalized software development costs&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z8ZsJXLgKfie"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_z00hcr0iLW5l" style="width: 10%; text-align: right" title="Gross carrying amount intangible assets"&gt;7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zZ2RUuOtQ3Cc" style="width: 10%; text-align: right" title="Accumulated amortization intangible assets"&gt;(7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zwimjtg6zAuj" style="width: 10%; text-align: right" title="Net carrying amount intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1637"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software license&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zEnys7j2Telk"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zs7akzkHOYD4" style="text-align: right" title="Gross carrying amount intangible assets"&gt;1,260&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zPf2N03VwXe5" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(1,040&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zQINBMJn75Xj" style="text-align: right" title="Net carrying amount intangible assets"&gt;220&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Patents and copy rights&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zUWaH29iWmV3"&gt;15&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zN6xIu6SYJhk" style="text-align: right" title="Gross carrying amount intangible assets"&gt;5,227&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zYjVqLIMwlY5" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,358&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zFnWRmJlkiii" style="text-align: right" title="Net carrying amount intangible assets"&gt;869&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Non-compete&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MinimumMember_zx2yZ6VVW2Lj"&gt;2&lt;/span&gt;-&lt;span id="xdx_905_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember__srt--RangeAxis__srt--MaximumMember_zVMCHY4RJV8a"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zdqnhGiyxDVc" style="text-align: right" title="Gross carrying amount intangible assets"&gt;4,650&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zuS4XR2nxqm5" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,292&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_d0_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zUWXSA1Qaoa" style="text-align: right" title="Net carrying amount intangible assets"&gt;358&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Customer relationships&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250701__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zf7vJfnG8sDj"&gt;20&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_987_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zT4eDnrUcQwe" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying amount intangible assets"&gt;3,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zPqQi74rq8i3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization intangible assets"&gt;(2,536&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zpj1wVVIR1Kg" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying amount intangible assets"&gt;1,364&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20260331_z1FwLoovZmWk" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying amount intangible assets"&gt;22,042&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20260331_zuES3E3MR8Sa" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization intangible assets"&gt;(19,231&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20260331_z55Pbuxavs59" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount intangible assets"&gt;2,811&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Weighted average useful lives&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Gross carrying amount &#x2013; June 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Accumulated amortization &#x2013; June 30, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Net carrying amount &#x2013; June 30, 2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Capitalized software development costs&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 10%; text-align: center"&gt;&lt;span id="xdx_904_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zJstXYVdTsMd"&gt;5&lt;/span&gt; years&lt;/td&gt;
&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zrl72bj6oiig" style="width: 10%; text-align: right" title="Gross carrying amount intangible assets"&gt;7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_986_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBwx30hX0de3" style="width: 10%; text-align: right" title="Accumulated amortization intangible assets"&gt;(7,005&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_ztsvYtBpPpGg" style="width: 10%; text-align: right" title="Net carrying amount intangible assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1679"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software license&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z3qiYh2wRxFa"&gt;3&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zbIeJV77kYV7" style="text-align: right" title="Gross carrying amount intangible assets"&gt;1,260&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zULrmdoZpWq1" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(756&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_985_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxYFiAxvBSAj" style="text-align: right" title="Net carrying amount intangible assets"&gt;504&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Patents and copy rights&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zRJOIJPUKLy1"&gt;15&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zIDMz0glFjKe" style="text-align: right" title="Gross carrying amount intangible assets"&gt;5,229&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zZoorzmo4Wv1" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,255&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zGAKytqqVqya" style="text-align: right" title="Net carrying amount intangible assets"&gt;974&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Non-compete&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_z6AwObqhWk9e"&gt;7&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zFuwsIT9VEck" style="text-align: right" title="Gross carrying amount intangible assets"&gt;4,150&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_984_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zzqMr27oa7ck" style="text-align: right" title="Accumulated amortization intangible assets"&gt;(4,150&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_d0_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--NoncompeteAgreementsMember_zU6znbzehzla" style="text-align: right" title="Net carrying amount intangible assets"&gt;&#x2014;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Customer relationships&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20240701__20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zGBe7HU78Qpe"&gt;20&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_988_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zci0aEoyEJf8" style="border-bottom: Black 1pt solid; text-align: right" title="Gross carrying amount intangible assets"&gt;3,900&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zoDp9crsf3Y8" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated amortization intangible assets"&gt;(2,386&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zkRQRXFv8gj9" style="border-bottom: Black 1pt solid; text-align: right" title="Net carrying amount intangible assets"&gt;1,514&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20250630_zvikYyGgX7la" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross carrying amount intangible assets"&gt;21,544&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20250630_zQgJa2Wsy4B5" style="border-bottom: Black 2.5pt double; text-align: right" title="Accumulated amortization intangible assets"&gt;(18,552&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pn3n3_c20250630_ztJAMf9GkFt3" style="border-bottom: Black 2.5pt double; text-align: right" title="Net carrying amount intangible assets"&gt;2,992&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-07-012026-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      id="Fact001631">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Fact001633"
      unitRef="USD">7005000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Fact001635"
      unitRef="USD">-7005000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-07-012026-03-31_us-gaap_LicenseMember"
      id="Fact001638">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31_us-gaap_LicenseMember"
      decimals="-3"
      id="Fact001640"
      unitRef="USD">1260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31_us-gaap_LicenseMember"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">-1040000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31_us-gaap_LicenseMember"
      decimals="-3"
      id="Fact001644"
      unitRef="USD">220000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-07-012026-03-31_custom_PatentsAndCopyrightsMember"
      id="Fact001645">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001647"
      unitRef="USD">5227000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001649"
      unitRef="USD">-4358000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001651"
      unitRef="USD">869000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-07-012026-03-31_us-gaap_NoncompeteAgreementsMember_srt_MinimumMember"
      id="Fact001652">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-07-012026-03-31_us-gaap_NoncompeteAgreementsMember_srt_MaximumMember"
      id="Fact001653">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="Fact001655"
      unitRef="USD">4650000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="Fact001657"
      unitRef="USD">-4292000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="Fact001659"
      unitRef="USD">358000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-07-012026-03-31_us-gaap_CustomerRelationshipsMember"
      id="Fact001660">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001662"
      unitRef="USD">3900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001664"
      unitRef="USD">-2536000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001666"
      unitRef="USD">1364000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001668"
      unitRef="USD">22042000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001670"
      unitRef="USD">-19231000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001672"
      unitRef="USD">2811000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2024-07-012025-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      id="Fact001673">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Fact001675"
      unitRef="USD">7005000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="-3"
      id="Fact001677"
      unitRef="USD">-7005000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2024-07-012025-06-30_us-gaap_LicenseMember"
      id="Fact001680">P3Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30_us-gaap_LicenseMember"
      decimals="-3"
      id="Fact001682"
      unitRef="USD">1260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30_us-gaap_LicenseMember"
      decimals="-3"
      id="Fact001684"
      unitRef="USD">-756000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_us-gaap_LicenseMember"
      decimals="-3"
      id="Fact001686"
      unitRef="USD">504000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2024-07-012025-06-30_custom_PatentsAndCopyrightsMember"
      id="Fact001687">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001689"
      unitRef="USD">5229000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001691"
      unitRef="USD">-4255000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001693"
      unitRef="USD">974000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2024-07-012025-06-30_us-gaap_NoncompeteAgreementsMember"
      id="Fact001694">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="Fact001696"
      unitRef="USD">4150000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="Fact001698"
      unitRef="USD">-4150000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_us-gaap_NoncompeteAgreementsMember"
      decimals="-3"
      id="Fact001700"
      unitRef="USD">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2024-07-012025-06-30_us-gaap_CustomerRelationshipsMember"
      id="Fact001701">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001703"
      unitRef="USD">3900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001705"
      unitRef="USD">-2386000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001707"
      unitRef="USD">1514000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001709"
      unitRef="USD">21544000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001711"
      unitRef="USD">-18552000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001713"
      unitRef="USD">2992000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001729"
      unitRef="USD">34000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001730"
      unitRef="USD">37000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-07-012026-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001731"
      unitRef="USD">103000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-07-012025-03-31_custom_PatentsAndCopyrightsMember"
      decimals="-3"
      id="Fact001732"
      unitRef="USD">114000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">50000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001734"
      unitRef="USD">50000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-07-012026-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001735"
      unitRef="USD">150000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-07-012025-03-31_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001736"
      unitRef="USD">150000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-03-31_custom_SoftwareLicenseMember"
      decimals="-3"
      id="Fact001737"
      unitRef="USD">94000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-03-31_custom_SoftwareLicenseMember"
      decimals="-3"
      id="Fact001738"
      unitRef="USD">94000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-07-012026-03-31_custom_SoftwareLicenseMember"
      decimals="-3"
      id="Fact001739"
      unitRef="USD">284000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-07-012025-03-31_custom_SoftwareLicenseMember"
      decimals="-3"
      id="Fact001740"
      unitRef="USD">284000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2026-01-012026-03-31_custom_EmploymentContractMember"
      decimals="-3"
      id="Fact001741"
      unitRef="USD">40000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-01-012025-03-31_custom_EmploymentContractMember"
      decimals="-3"
      id="Fact001742"
      unitRef="USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2025-07-012026-03-31_custom_EmploymentContractMember"
      decimals="-3"
      id="Fact001743"
      unitRef="USD">142000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2024-07-012025-03-31_custom_EmploymentContractMember"
      decimals="-3"
      id="Fact001744"
      unitRef="USD">0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001746">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_pn3n3_zmopjS1dmu05" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER INTANGIBLE ASSETS (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zvZrF2sWXJ9g" style="display: none"&gt;Schedule of Amortization expense&lt;/span&gt; &lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_498_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--TotalMember_zDzrIQWY36s7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareLicenseMember_zNcY8Yzz5mq8" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49B_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--NonCompeteMember_zySbSIvdnyDb" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndCopyrightsMember_zhkLojh5PQOg" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_490_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_z5xfOJF0pTgh" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;Schedule Of Other Intangible Assets For the Years Ending March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Software License&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Non- Compete&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Patents and Copyrights&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Customer Relationships&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_zWySpZdvIrek" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; width: 19%; text-align: center; text-indent: -10pt"&gt;2027&lt;/td&gt;&lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;704&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;220&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;125&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_zzxZWvyZ3wk9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2028&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1755"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;109&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_zGOyhZlON6we" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2029&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;337&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1761"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;97&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_z8RbMKt25WVf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2030&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;293&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1767"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_zSCM2XipZItk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;2031&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1773"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_zErOotxYeGse" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;722&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1779"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;358&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;364&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_zD8PYtTqAxse" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;Other intangible assets - net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,811&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;220&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;358&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;869&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,364&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001748"
      unitRef="USD">704000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      decimals="-3"
      id="Fact001749"
      unitRef="USD">220000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      decimals="-3"
      id="Fact001750"
      unitRef="USD">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001751"
      unitRef="USD">125000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001752"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001754"
      unitRef="USD">468000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      decimals="-3"
      id="Fact001756"
      unitRef="USD">159000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001757"
      unitRef="USD">109000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001758"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001760"
      unitRef="USD">337000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      decimals="-3"
      id="Fact001762"
      unitRef="USD">40000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001763"
      unitRef="USD">97000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001764"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001766"
      unitRef="USD">293000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001769"
      unitRef="USD">93000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001770"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001772"
      unitRef="USD">287000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001775"
      unitRef="USD">87000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001776"
      unitRef="USD">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001778"
      unitRef="USD">722000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001781"
      unitRef="USD">358000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001782"
      unitRef="USD">364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001784"
      unitRef="USD">2811000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31_custom_SoftwareLicenseMember"
      decimals="-3"
      id="Fact001785"
      unitRef="USD">220000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31_custom_NonCompeteMember"
      decimals="-3"
      id="Fact001786"
      unitRef="USD">358000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31_custom_PatentsAndCopyrightsMember1563882187"
      decimals="-3"
      id="Fact001787"
      unitRef="USD">869000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2026-03-31_us-gaap_CustomerRelationshipsMember1563882187"
      decimals="-3"
      id="Fact001788"
      unitRef="USD">1364000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001804">&lt;p id="xdx_807_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z0Dwz2KWoZ99" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 8 &#x2013; &lt;span id="xdx_828_zQFhLA70TLJ5"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities in the accompanying condensed
consolidated balance sheets consist of the following:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zlirQ60nK293" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zJEkUAT0c8m2" style="display: none"&gt;Schedule
    of other current liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_493_20260331_zRMRmAQkc5V5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20250630_zyvw8u4gtOze" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &#160; &lt;br/&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_zSjvbrIGioKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued salaries, commissions and payroll taxes&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,758&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;3,994&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zO7KK3xX2pCf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Sales tax payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;255&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;249&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--SelffundedHealthInsuranceReserve_iI_pn3n3_maOLCzdop_zoxNFQzeAFhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Self-funded health insurance reserve&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;108&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;260&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--PropertyTaxes_iI_pn3n3_maOLCzdop_znba1Sz1pXa1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Property taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;359&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;392&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--Utilities_iI_pn3n3_maOLCzdop_zyfKcJgZ1zYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Utilities&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;148&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;449&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--LegalAndOtherProfessionalFees_iI_pn3n3_maOLCzdop_zHQQUHecJORb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Legal and other professional fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;698&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;93&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zz9VKxOceuOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounting fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;124&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--SoftwareLicenses_iI_pn3n3_maOLCzdop_zZsLQKmid1pj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software licenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;245&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;442&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--RecruitingFees_iI_pn3n3_maOLCzdop_zntYiD9Stku" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Recruiting fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;136&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zr1o1Nhpgjf7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other general and administrative expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;922&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zJgOziew90i7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other current liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,695&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,975&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A2_zKgxqszYUA1b" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001806">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_pn3n3_zlirQ60nK293" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - OTHER CURRENT LIABILITIES - Other Current Liabilities - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&lt;span id="xdx_8B9_zJEkUAT0c8m2" style="display: none"&gt;Schedule
    of other current liabilities&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_493_20260331_zRMRmAQkc5V5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49A_20250630_zyvw8u4gtOze" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;March 31, &lt;br/&gt;2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;June 30, &#160; &lt;br/&gt;2025&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maOLCzdop_zSjvbrIGioKi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; width: 56%; text-align: left; text-indent: -10pt"&gt;Accrued salaries, commissions and payroll taxes&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;1,758&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 12%; text-align: right"&gt;3,994&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pn3n3_maOLCzdop_zO7KK3xX2pCf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Sales tax payable&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;255&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;249&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--SelffundedHealthInsuranceReserve_iI_pn3n3_maOLCzdop_zoxNFQzeAFhj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Self-funded health insurance reserve&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;108&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;260&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--PropertyTaxes_iI_pn3n3_maOLCzdop_znba1Sz1pXa1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Property taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;359&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;392&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--Utilities_iI_pn3n3_maOLCzdop_zyfKcJgZ1zYj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-indent: -10pt"&gt;Utilities&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;148&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;449&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_ecustom--LegalAndOtherProfessionalFees_iI_pn3n3_maOLCzdop_zHQQUHecJORb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Legal and other professional fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;698&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;93&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maOLCzdop_zz9VKxOceuOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Accounting fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;124&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--SoftwareLicenses_iI_pn3n3_maOLCzdop_zZsLQKmid1pj" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Software licenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;245&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;442&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_404_ecustom--RecruitingFees_iI_pn3n3_maOLCzdop_zntYiD9Stku" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Recruiting fees&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1832"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;136&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--OtherSundryLiabilitiesCurrent_iI_pn3n3_maOLCzdop_zr1o1Nhpgjf7" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other general and administrative expenses&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1000&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;922&lt;/td&gt;
&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_eus-gaap--OtherLiabilitiesCurrent_iTI_pn3n3_mtOLCzdop_zJgOziew90i7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Other current liabilities&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;4,695&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;6,975&lt;/td&gt;
&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001808"
      unitRef="USD">1758000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001809"
      unitRef="USD">3994000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001811"
      unitRef="USD">255000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001812"
      unitRef="USD">249000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <FONR:SelffundedHealthInsuranceReserve
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001814"
      unitRef="USD">108000</FONR:SelffundedHealthInsuranceReserve>
    <FONR:SelffundedHealthInsuranceReserve
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001815"
      unitRef="USD">260000</FONR:SelffundedHealthInsuranceReserve>
    <FONR:PropertyTaxes
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001817"
      unitRef="USD">359000</FONR:PropertyTaxes>
    <FONR:PropertyTaxes
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001818"
      unitRef="USD">392000</FONR:PropertyTaxes>
    <FONR:Utilities
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001820"
      unitRef="USD">148000</FONR:Utilities>
    <FONR:Utilities
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001821"
      unitRef="USD">449000</FONR:Utilities>
    <FONR:LegalAndOtherProfessionalFees
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001823"
      unitRef="USD">698000</FONR:LegalAndOtherProfessionalFees>
    <FONR:LegalAndOtherProfessionalFees
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001824"
      unitRef="USD">93000</FONR:LegalAndOtherProfessionalFees>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001826"
      unitRef="USD">124000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001827"
      unitRef="USD">38000</us-gaap:AccruedProfessionalFeesCurrent>
    <FONR:SoftwareLicenses
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001829"
      unitRef="USD">245000</FONR:SoftwareLicenses>
    <FONR:SoftwareLicenses
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001830"
      unitRef="USD">442000</FONR:SoftwareLicenses>
    <FONR:RecruitingFees
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001833"
      unitRef="USD">136000</FONR:RecruitingFees>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001835"
      unitRef="USD">1000000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001836"
      unitRef="USD">922000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact001838"
      unitRef="USD">4695000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact001839"
      unitRef="USD">6975000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001841">&lt;p id="xdx_806_eus-gaap--SegmentReportingDisclosureTextBlock_z5lW2ekuxjWf" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 9 - &lt;span id="xdx_821_zY1AsFjazEv"&gt;SEGMENT AND RELATED INFORMATION&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company operates in two reportable segments -
manufacturing and the service of medical equipment and management of diagnostic imaging centers. The accounting policies of the segments
are the same as those described in the summary of significant accounting policies as disclosed in the Company&#x2019;s 10-K as of June
30, 2025. All inter segment sales are market-based. The Company evaluates performance based on income or loss from operations.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our chief operating decision maker (&#x201c;CODM&#x201d;),
who is also our CEO, evaluates the financial performance of our segments based upon their respective revenue and segmented internal profit
and loss statements prepared on a basis not consistent with GAAP. The CODM considers actual to budget and current year actual to prior
year actual for revenue and other profit and loss measures on a monthly basis for evaluating performance of each segment and making decisions
about allocating capital and other resources to each segment.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Summarized financial information concerning the Company&#x2019;s
reportable segments is shown in the following table:&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_z1lHHIiLDbeg" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_z1YOML20fbi" style="display: none"&gt;Schedule
    of summarized segment financial information&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20260101__20260331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zWoZY7aMeLy9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20260101__20260331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_zyyULwXPeVNb" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20260101__20260331__srt--ProductOrServiceAxis__custom--TotalMember_z66Jbbk82xlj" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Three months ended March 31, 2026&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_zYj2q0SvEtW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 46%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,282&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;24,190&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;26,472&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_zj1LQw5SoPm1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_zPypKcNXVqz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;909&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,465&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;6,374&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--RentExpenses_zwf48qeHBVy1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1872"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,233&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,233&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zWtLj5TdjWY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;538&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,086&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,624&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_zl2gyrPbLpu9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,447&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,784&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;15,231&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_z4f1EJCIahjb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;194&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;194&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zWMqFegi5BKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;230&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1889"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;230&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zmG4bZXQ2pIf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;424&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1893"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;424&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zyJywKx3lxG3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;443&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,145&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,588&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--RentExpense_zLxCgt0sa01b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;313&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;18&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;331&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_z4hwwMRpygA6" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,323&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,131&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,454&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zXTrEjuKE5ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,079&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,294&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;8,373&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_zbs0OW5CSvSl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,950&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;19,078&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;24,028&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zRPAf58ZC31f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,668&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,112&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,444&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zmRxAMeBbo1j" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;20&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;343&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;363&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_z4nmc4sWdROb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;16&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(3&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_zHB5zdkYsa8b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,632&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,452&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,820&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zmaHncfTKADb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(379&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(113&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(492&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zcrD0Cmmtzo1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,253&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,339&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,328&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zhwjhM6BivG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;307&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1941"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;307&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_z4jNlNyPX5P2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;55&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,051&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,106&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20250101__20250331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zugUWS7VjVwg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250101__20250331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_zpiCwRcSOSDg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20250101__20250331__srt--ProductOrServiceAxis__custom--TotalMember_zWIgCQ4DDY05" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Three months ended March 31, 2025&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_zCq4hFtDUMEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 40%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,395&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;24,770&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;27,165&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_z6GVt5ymU0c2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_zffnnDTfEdFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;924&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,848&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,772&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--RentExpenses_zPvai4ipZGF5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,224&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,224&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zjq7NJFOgMH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;635&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,440&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;8,075&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_z6O2eV5Z1Qk" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,559&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,512&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;15,071&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_zJRtzjhLXVK8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;192&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;192&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zlDz7Ai6pi2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;249&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1993"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;249&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zGuCeIi0zb71" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;441&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1997"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;441&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zSoTdPRW0H0d" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;668&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,905&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,573&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--RentExpense_zDgdU1ZRmZvg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;313&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;335&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_zQLTrQ1f8yt" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;787&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,296&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,083&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zdVkyfhLts92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,768&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;6,223&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,991&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_zSbu18p4eijg" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,768&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;19,735&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;23,503&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zbsQBr5HHOw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,373&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,035&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,662&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zD8f3vKDItQ8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;25&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;438&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;463&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_zmlK1qaQavK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other income (expense)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(7&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_za60qxGPkM6e" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,336&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,466&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,130&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zRBPxSVjXPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(902&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(104&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,006&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zjTnR1e0uREi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,238&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,362&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,124&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zkxwXXVTOX6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;294&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;294&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_zN7jrG6H3XUe" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,186&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,238&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;*Amounts
eliminated in consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;**
Other segment costs include supplies, professional fees, marketing expenses, repairs and maintenance and other operational costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;







&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;FONAR CORPORATION AND SUBSIDIARIES&lt;/p&gt;


























&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20250701__20260331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zPQpwp4JgSo3" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_496_20250701__20260331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_z9LrZ37p2Ana" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20250701__20260331__srt--ProductOrServiceAxis__custom--TotalMember_zkElvWypBBw8" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Nine months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_zOcTr2wW5wqd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;7,191&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;70,871&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;78,062&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_zTwne2tH1COb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_z43EvIyT8ou4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,808&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,461&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;18,269&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--RentExpenses_z7PNgGTDvFM5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,778&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,778&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zZVOwFFmmoY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,468&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,165&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;24,633&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_zRUA39WXWiSl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,276&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;42,404&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;46,680&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_zAwlibzNjPeh" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;610&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2092"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;610&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zIi3X7TXtyTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;709&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;709&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zjATRAIwRKwa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,319&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2100"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,319&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zkHcMje3imub" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,492&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,600&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,092&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--RentExpense_z7Bpm4ulPaHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;54&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;993&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_zpjQhbk1wt7i" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,507&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;5,833&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,340&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zHCYhkPRzpK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,938&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,487&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;21,425&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_znJBEfSvQRul" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;12,533&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;56,891&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;69,424&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zNkvvHfheUqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(5,342&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;13,980&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,638&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zptjJQGdF8Tb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;61&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,207&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,268&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_zheuTT6wW6Jk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other income (expense)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;47&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(9&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_z5WGl2zF7pU5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(5,234&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,178&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,944&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ziO14N7V2gg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,163&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(244&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,407&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zLzIOuDnLdg5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(7,397&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,934&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;7,537&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zkjzIBZ5MIQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;919&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2148"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;919&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_zluaGvJIa399" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;149&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,298&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,447&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--TotalIdentifiableAssets_zKmgWtuMGS1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total identifiable assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;34,007&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;185,215&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;219,222&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;* Amounts
eliminated in consolidation&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"&gt;**
Other segment costs include supplies, professional fees, marketing expenses, repairs and maintenance and other operational costs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"&gt;&#160;&lt;/p&gt;


































&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20240701__20250331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zfuvVBVPCUYa" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20240701__20250331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_zkPCo1NAlR74" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_496_20240701__20250331__srt--ProductOrServiceAxis__custom--TotalMember_zXEYRXizbIV5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Nine months ended March 31, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_z49ZVkOlBeQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;6,382&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;70,693&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;77,075&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_zruj0akKmkO3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_zqah7WgVsAXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,736&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,419&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17,155&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--RentExpenses_z1cTqUNMWGt4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,601&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,601&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zCM6NJJXFj1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,046&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;24,436&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_zXUBj6xJwyF9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,126&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;41,066&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;45,192&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_zQI7yE5GtkP2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;561&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2198"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;561&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zdcQxp3FxGga" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;563&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;563&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zCNFJckg7ame" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,124&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2206"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,124&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zk9DxlhDRbji" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,701&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,216&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,917&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--RentExpense_zW8vhWUiC6N5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;68&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,007&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_zqPKrBa7pPOc" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,200&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,931&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,131&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zRONuTi3tGM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,840&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,215&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;20,055&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_zGd3uHS9cvb4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,090&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;56,281&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;66,371&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zoZCQq5g0H62" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(3,708&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,412&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,704&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zpMOFzAiXbth" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;83&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,543&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,626&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_zuAUpyqcbzfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other income (expense)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(21&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_z4JIdrdpzOPl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(3,587&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,934&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;12,347&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zoobm4rvMcoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,796&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(222&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(3,018&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zW9IGlJp10b9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(6,383&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,712&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,329&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zXIyktvF5G8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;881&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2254"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;881&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_zUdPlh2vmrha" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;157&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,184&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,341&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--TotalIdentifiableAssets_zNT5EKKL1e9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total identifiable assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;33,577&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;181,346&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;214,923&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;* Amounts eliminated in consolidation&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;** Other segment costs include supplies, professional
    fees, marketing expenses, repairs and maintenance and other operational costs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

























</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact001858">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_pn3n3_z1lHHIiLDbeg" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SEGMENT AND RELATED INFORMATION - Summarized Segments - (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;&lt;span id="xdx_8B7_z1YOML20fbi" style="display: none"&gt;Schedule
    of summarized segment financial information&lt;/span&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20260101__20260331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zWoZY7aMeLy9" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20260101__20260331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_zyyULwXPeVNb" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_497_20260101__20260331__srt--ProductOrServiceAxis__custom--TotalMember_z66Jbbk82xlj" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: center; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Three months ended March 31, 2026&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_zYj2q0SvEtW9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 46%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,282&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;24,190&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;26,472&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_zj1LQw5SoPm1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_zPypKcNXVqz2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;909&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,465&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;6,374&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--RentExpenses_zwf48qeHBVy1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1872"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,233&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,233&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zWtLj5TdjWY6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;538&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,086&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,624&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_zl2gyrPbLpu9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,447&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,784&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;15,231&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_z4f1EJCIahjb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;194&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;194&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zWMqFegi5BKk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;230&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1889"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;230&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zmG4bZXQ2pIf" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;424&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1893"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;424&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zyJywKx3lxG3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;443&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,145&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,588&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--RentExpense_zLxCgt0sa01b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;313&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;18&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;331&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_z4hwwMRpygA6" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,323&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,131&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,454&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zXTrEjuKE5ah" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,079&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,294&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;8,373&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_zbs0OW5CSvSl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,950&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;19,078&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;24,028&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zRPAf58ZC31f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,668&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,112&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,444&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zmRxAMeBbo1j" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;20&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;343&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;363&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_z4nmc4sWdROb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;16&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(3&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_zHB5zdkYsa8b" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,632&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,452&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,820&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zmaHncfTKADb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(379&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(113&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(492&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zcrD0Cmmtzo1" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,253&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,339&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,328&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zhwjhM6BivG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;307&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1941"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;307&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_z4jNlNyPX5P2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;55&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,051&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,106&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;



&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_49B_20250101__20250331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zugUWS7VjVwg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_491_20250101__20250331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_zpiCwRcSOSDg" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_494_20250101__20250331__srt--ProductOrServiceAxis__custom--TotalMember_zWIgCQ4DDY05" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="font-family: Times New Roman, Times, Serif; text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Three months ended March 31, 2025&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_zCq4hFtDUMEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 40%; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,395&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;24,770&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;27,165&lt;/td&gt;
&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_z6GVt5ymU0c2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; font-family: Times New Roman, Times, Serif; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_zffnnDTfEdFk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;924&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,848&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,772&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--RentExpenses_zPvai4ipZGF5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,224&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,224&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zjq7NJFOgMH7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;635&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,440&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;8,075&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_z6O2eV5Z1Qk" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,559&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;13,512&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;15,071&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_zJRtzjhLXVK8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;192&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1989"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;192&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zlDz7Ai6pi2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;249&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1993"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;249&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zGuCeIi0zb71" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;441&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1997"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;441&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zSoTdPRW0H0d" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;668&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;2,905&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,573&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_ecustom--RentExpense_zDgdU1ZRmZvg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;313&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;22&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;335&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_zQLTrQ1f8yt" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;787&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,296&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,083&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zdVkyfhLts92" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,768&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;6,223&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;7,991&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_zSbu18p4eijg" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,768&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;19,735&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;23,503&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zbsQBr5HHOw1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,373&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,035&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,662&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zD8f3vKDItQ8" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;25&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;438&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;463&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_zmlK1qaQavK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Other income (expense)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;12&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(7&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_za60qxGPkM6e" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,336&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,466&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;4,130&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zRBPxSVjXPl3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(902&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(104&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(1,006&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zjTnR1e0uREi" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;(2,238&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;)&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;5,362&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;3,124&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zkxwXXVTOX6c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;294&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2045"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;294&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_zN7jrG6H3XUe" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; font-family: Times New Roman, Times, Serif; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;52&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,186&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;1,238&lt;/td&gt;
&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;*Amounts
eliminated in consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 11pt"&gt;**
Other segment costs include supplies, professional fees, marketing expenses, repairs and maintenance and other operational costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;







&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;FONAR CORPORATION AND SUBSIDIARIES&lt;/p&gt;


























&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20250701__20260331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zPQpwp4JgSo3" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_496_20250701__20260331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_z9LrZ37p2Ana" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_498_20250701__20260331__srt--ProductOrServiceAxis__custom--TotalMember_zkElvWypBBw8" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Nine months ended March 31, 2026&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_zOcTr2wW5wqd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 40%; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;7,191&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;70,871&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 10%; text-align: right"&gt;78,062&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_zTwne2tH1COb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_z43EvIyT8ou4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,808&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,461&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;18,269&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--RentExpenses_z7PNgGTDvFM5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2079"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,778&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,778&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zZVOwFFmmoY1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,468&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,165&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;24,633&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_zRUA39WXWiSl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,276&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;42,404&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;46,680&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_zAwlibzNjPeh" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;610&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2092"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;610&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zIi3X7TXtyTl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;709&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2096"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;709&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zjATRAIwRKwa" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,319&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2100"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,319&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zkHcMje3imub" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,492&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,600&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,092&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_ecustom--RentExpense_z7Bpm4ulPaHf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;54&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;993&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_zpjQhbk1wt7i" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,507&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;5,833&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,340&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zHCYhkPRzpK4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,938&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,487&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;21,425&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_znJBEfSvQRul" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;12,533&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;56,891&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;69,424&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zNkvvHfheUqj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(5,342&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;13,980&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,638&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zptjJQGdF8Tb" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;61&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,207&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,268&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_zheuTT6wW6Jk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other income (expense)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;47&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(9&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_z5WGl2zF7pU5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(5,234&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,178&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,944&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_ziO14N7V2gg9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,163&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(244&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,407&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zLzIOuDnLdg5" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(7,397&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,934&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;7,537&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zkjzIBZ5MIQ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;919&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2148"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;919&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_zluaGvJIa399" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;149&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,298&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,447&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--TotalIdentifiableAssets_zKmgWtuMGS1b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total identifiable assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;34,007&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;185,215&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;219,222&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;* Amounts
eliminated in consolidation&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"&gt;**
Other segment costs include supplies, professional fees, marketing expenses, repairs and maintenance and other operational costs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"&gt;&#160;&lt;/p&gt;


































&lt;table cellpadding="0" cellspacing="0" style="font: 11pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_495_20240701__20250331__srt--ProductOrServiceAxis__custom--ManufacturingAndServiceOfMedicalEquipmentMember_zfuvVBVPCUYa" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_490_20240701__20250331__srt--ProductOrServiceAxis__us-gaap--HealthCareOtherMember_zkPCo1NAlR74" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td id="xdx_496_20240701__20250331__srt--ProductOrServiceAxis__custom--TotalMember_zXEYRXizbIV5" style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Manufacturing and Servicing of Medical&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;Management of Diagnostic Imaging&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
&lt;td style="border-bottom: Black 1pt solid; padding: 0pt 0pt 0pt 10pt; text-align: left; text-indent: -10pt"&gt;Nine months ended March 31, 2025&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Equipment&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Centers&lt;/td&gt;
&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
&lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;Totals&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--Revenues_z49ZVkOlBeQj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; width: 46%; text-align: left; text-indent: -10pt"&gt;Net revenues from external customers&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;6,382&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;70,693&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
&lt;td style="width: 11%; text-align: right"&gt;77,075&lt;/td&gt;
&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--CostOfSales_zruj0akKmkO3" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Cost of Sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--PaymentsToEmployees_zqah7WgVsAXg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,736&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,419&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17,155&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_ecustom--RentExpenses_z1cTqUNMWGt4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2185"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,601&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;3,601&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--OtherCostOfSalesExpenses_zCM6NJJXFj1i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other Cost of sales expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,390&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;23,046&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;24,436&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40A_ecustom--TotalCostOfSales_zXUBj6xJwyF9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Cost of sales&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,126&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;41,066&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;45,192&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Research and development&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_eus-gaap--SalariesAndWages_zQI7yE5GtkP2" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;561&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2198"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;561&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--OtherResearchAndDevelopmentCosts_zdcQxp3FxGga" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other research and development costs**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;563&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2202"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;563&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_ecustom--TotalResearchAndDevelopmentCosts_zCNFJckg7ame" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Research and development costs&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,124&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2206"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,124&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_409_ecustom--SalariesAndWagesExpenses_zk9DxlhDRbji" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Salaries and wages&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,701&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;8,216&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,917&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_408_ecustom--RentExpense_zW8vhWUiC6N5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Rent expense&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;939&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;68&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,007&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40C_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_zqPKrBa7pPOc" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other selling, general and administrative expenses**&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,200&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;6,931&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,131&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40E_ecustom--TotalSellingGeneralAndAdministrativeExpenses_zRONuTi3tGM3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total Selling, general and administrative expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;4,840&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,215&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;20,055&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--CostsAndExpenses_zGd3uHS9cvb4" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total costs and expenses&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,090&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;56,281&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;66,371&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperations_zoZCQq5g0H62" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income from operations&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(3,708&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;14,412&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;10,704&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40F_ecustom--InvestmentIncome_zpMOFzAiXbth" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Investment income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;83&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,543&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;1,626&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_407_eus-gaap--OtherIncome_zuAUpyqcbzfb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Other income (expense)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;38&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(21&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;17&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax_z4JIdrdpzOPl" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;(Loss) Income before provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(3,587&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,934&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;12,347&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zoobm4rvMcoj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Provision for income taxes&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(2,796&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(222&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;(3,018&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_405_eus-gaap--NetIncomeLoss_zW9IGlJp10b9" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Net (Loss) income&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;(6,383&lt;/td&gt;
&lt;td style="text-align: left"&gt;)&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;15,712&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;9,329&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40D_ecustom--IntersegmentNetRevenues_zXIyktvF5G8g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Intersegment net revenues *&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;881&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2254"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;881&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_40B_eus-gaap--DepreciationDepletionAndAmortization_zUdPlh2vmrha" style="vertical-align: bottom; background-color: White"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Depreciation and amortization&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;157&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,184&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: right"&gt;2,341&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_401_ecustom--TotalIdentifiableAssets_zNT5EKKL1e9k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
&lt;td style="padding: 0pt 0pt 0pt 20pt; text-align: left; text-indent: -10pt"&gt;Total identifiable assets&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;33,577&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;181,346&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="text-align: left"&gt;$&lt;/td&gt;
&lt;td style="text-align: right"&gt;214,923&lt;/td&gt;
&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;* Amounts eliminated in consolidation&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: left"&gt;** Other segment costs include supplies, professional
    fees, marketing expenses, repairs and maintenance and other operational costs.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;

























</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001860"
      unitRef="USD">2282000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001861"
      unitRef="USD">24190000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001862"
      unitRef="USD">26472000</us-gaap:Revenues>
    <us-gaap:PaymentsToEmployees
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001868"
      unitRef="USD">909000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001869"
      unitRef="USD">5465000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001870"
      unitRef="USD">6374000</us-gaap:PaymentsToEmployees>
    <FONR:RentExpenses
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001873"
      unitRef="USD">1233000</FONR:RentExpenses>
    <FONR:RentExpenses
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001874"
      unitRef="USD">1233000</FONR:RentExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001876"
      unitRef="USD">538000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001877"
      unitRef="USD">7086000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001878"
      unitRef="USD">7624000</FONR:OtherCostOfSalesExpenses>
    <FONR:TotalCostOfSales
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001880"
      unitRef="USD">1447000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001881"
      unitRef="USD">13784000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001882"
      unitRef="USD">15231000</FONR:TotalCostOfSales>
    <us-gaap:SalariesAndWages
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001884"
      unitRef="USD">194000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001886"
      unitRef="USD">194000</us-gaap:SalariesAndWages>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001888"
      unitRef="USD">230000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001890"
      unitRef="USD">230000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001892"
      unitRef="USD">424000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001894"
      unitRef="USD">424000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001896"
      unitRef="USD">443000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001897"
      unitRef="USD">3145000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001898"
      unitRef="USD">3588000</FONR:SalariesAndWagesExpenses>
    <FONR:RentExpense
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001900"
      unitRef="USD">313000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001901"
      unitRef="USD">18000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001902"
      unitRef="USD">331000</FONR:RentExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001904"
      unitRef="USD">2323000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001905"
      unitRef="USD">2131000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001906"
      unitRef="USD">4454000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001908"
      unitRef="USD">3079000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001909"
      unitRef="USD">5294000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001910"
      unitRef="USD">8373000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001912"
      unitRef="USD">4950000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001913"
      unitRef="USD">19078000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001914"
      unitRef="USD">24028000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001916"
      unitRef="USD">-2668000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001917"
      unitRef="USD">5112000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001918"
      unitRef="USD">2444000</us-gaap:IncomeLossFromContinuingOperations>
    <FONR:InvestmentIncome
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001920"
      unitRef="USD">20000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001921"
      unitRef="USD">343000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001922"
      unitRef="USD">363000</FONR:InvestmentIncome>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001924"
      unitRef="USD">16000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001925"
      unitRef="USD">-3000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001926"
      unitRef="USD">13000</us-gaap:OtherIncome>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001928"
      unitRef="USD">-2632000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001929"
      unitRef="USD">5452000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001930"
      unitRef="USD">2820000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001932"
      unitRef="USD">-379000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001933"
      unitRef="USD">-113000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001934"
      unitRef="USD">-492000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001936"
      unitRef="USD">-2253000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001937"
      unitRef="USD">5339000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001938"
      unitRef="USD">2328000</us-gaap:NetIncomeLoss>
    <FONR:IntersegmentNetRevenues
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001940"
      unitRef="USD">307000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001942"
      unitRef="USD">307000</FONR:IntersegmentNetRevenues>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2026-01-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001944"
      unitRef="USD">55000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2026-01-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001945"
      unitRef="USD">1051000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2026-01-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001946"
      unitRef="USD">1106000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001964"
      unitRef="USD">2395000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001965"
      unitRef="USD">24770000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001966"
      unitRef="USD">27165000</us-gaap:Revenues>
    <us-gaap:PaymentsToEmployees
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001972"
      unitRef="USD">924000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001973"
      unitRef="USD">4848000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001974"
      unitRef="USD">5772000</us-gaap:PaymentsToEmployees>
    <FONR:RentExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001977"
      unitRef="USD">1224000</FONR:RentExpenses>
    <FONR:RentExpenses
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001978"
      unitRef="USD">1224000</FONR:RentExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001980"
      unitRef="USD">635000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001981"
      unitRef="USD">7440000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001982"
      unitRef="USD">8075000</FONR:OtherCostOfSalesExpenses>
    <FONR:TotalCostOfSales
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001984"
      unitRef="USD">1559000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact001985"
      unitRef="USD">13512000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001986"
      unitRef="USD">15071000</FONR:TotalCostOfSales>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001988"
      unitRef="USD">192000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001990"
      unitRef="USD">192000</us-gaap:SalariesAndWages>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001992"
      unitRef="USD">249000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001994"
      unitRef="USD">249000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact001996"
      unitRef="USD">441000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact001998"
      unitRef="USD">441000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002000"
      unitRef="USD">668000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002001"
      unitRef="USD">2905000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002002"
      unitRef="USD">3573000</FONR:SalariesAndWagesExpenses>
    <FONR:RentExpense
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002004"
      unitRef="USD">313000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002005"
      unitRef="USD">22000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002006"
      unitRef="USD">335000</FONR:RentExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002008"
      unitRef="USD">787000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002009"
      unitRef="USD">3296000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002010"
      unitRef="USD">4083000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002012"
      unitRef="USD">1768000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002013"
      unitRef="USD">6223000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002014"
      unitRef="USD">7991000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002016"
      unitRef="USD">3768000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002017"
      unitRef="USD">19735000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002018"
      unitRef="USD">23503000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002020"
      unitRef="USD">-1373000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002021"
      unitRef="USD">5035000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002022"
      unitRef="USD">3662000</us-gaap:IncomeLossFromContinuingOperations>
    <FONR:InvestmentIncome
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002024"
      unitRef="USD">25000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002025"
      unitRef="USD">438000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002026"
      unitRef="USD">463000</FONR:InvestmentIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002028"
      unitRef="USD">12000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002029"
      unitRef="USD">-7000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002030"
      unitRef="USD">5000</us-gaap:OtherIncome>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002032"
      unitRef="USD">-1336000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002033"
      unitRef="USD">5466000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002034"
      unitRef="USD">4130000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002036"
      unitRef="USD">-902000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002037"
      unitRef="USD">-104000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002038"
      unitRef="USD">-1006000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002040"
      unitRef="USD">-2238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002041"
      unitRef="USD">5362000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002042"
      unitRef="USD">3124000</us-gaap:NetIncomeLoss>
    <FONR:IntersegmentNetRevenues
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002044"
      unitRef="USD">294000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002046"
      unitRef="USD">294000</FONR:IntersegmentNetRevenues>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002048"
      unitRef="USD">52000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002049"
      unitRef="USD">1186000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002050"
      unitRef="USD">1238000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002067"
      unitRef="USD">7191000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002068"
      unitRef="USD">70871000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002069"
      unitRef="USD">78062000</us-gaap:Revenues>
    <us-gaap:PaymentsToEmployees
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002075"
      unitRef="USD">2808000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002076"
      unitRef="USD">15461000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002077"
      unitRef="USD">18269000</us-gaap:PaymentsToEmployees>
    <FONR:RentExpenses
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002080"
      unitRef="USD">3778000</FONR:RentExpenses>
    <FONR:RentExpenses
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002081"
      unitRef="USD">3778000</FONR:RentExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002083"
      unitRef="USD">1468000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002084"
      unitRef="USD">23165000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002085"
      unitRef="USD">24633000</FONR:OtherCostOfSalesExpenses>
    <FONR:TotalCostOfSales
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002087"
      unitRef="USD">4276000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002088"
      unitRef="USD">42404000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002089"
      unitRef="USD">46680000</FONR:TotalCostOfSales>
    <us-gaap:SalariesAndWages
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002091"
      unitRef="USD">610000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002093"
      unitRef="USD">610000</us-gaap:SalariesAndWages>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002095"
      unitRef="USD">709000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002097"
      unitRef="USD">709000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002099"
      unitRef="USD">1319000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002101"
      unitRef="USD">1319000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002103"
      unitRef="USD">1492000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002104"
      unitRef="USD">8600000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002105"
      unitRef="USD">10092000</FONR:SalariesAndWagesExpenses>
    <FONR:RentExpense
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002107"
      unitRef="USD">939000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002108"
      unitRef="USD">54000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002109"
      unitRef="USD">993000</FONR:RentExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002111"
      unitRef="USD">4507000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002112"
      unitRef="USD">5833000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002113"
      unitRef="USD">10340000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002115"
      unitRef="USD">6938000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002116"
      unitRef="USD">14487000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002117"
      unitRef="USD">21425000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002119"
      unitRef="USD">12533000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002120"
      unitRef="USD">56891000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002121"
      unitRef="USD">69424000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002123"
      unitRef="USD">-5342000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002124"
      unitRef="USD">13980000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002125"
      unitRef="USD">8638000</us-gaap:IncomeLossFromContinuingOperations>
    <FONR:InvestmentIncome
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002127"
      unitRef="USD">61000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002128"
      unitRef="USD">1207000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002129"
      unitRef="USD">1268000</FONR:InvestmentIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002131"
      unitRef="USD">47000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002132"
      unitRef="USD">-9000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002133"
      unitRef="USD">38000</us-gaap:OtherIncome>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002135"
      unitRef="USD">-5234000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002136"
      unitRef="USD">15178000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002137"
      unitRef="USD">9944000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002139"
      unitRef="USD">-2163000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002140"
      unitRef="USD">-244000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002141"
      unitRef="USD">-2407000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002143"
      unitRef="USD">-7397000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002144"
      unitRef="USD">14934000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002145"
      unitRef="USD">7537000</us-gaap:NetIncomeLoss>
    <FONR:IntersegmentNetRevenues
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002147"
      unitRef="USD">919000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002149"
      unitRef="USD">919000</FONR:IntersegmentNetRevenues>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002151"
      unitRef="USD">149000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002152"
      unitRef="USD">3298000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002153"
      unitRef="USD">3447000</us-gaap:DepreciationDepletionAndAmortization>
    <FONR:TotalIdentifiableAssets
      contextRef="From2025-07-012026-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002155"
      unitRef="USD">34007000</FONR:TotalIdentifiableAssets>
    <FONR:TotalIdentifiableAssets
      contextRef="From2025-07-012026-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002156"
      unitRef="USD">185215000</FONR:TotalIdentifiableAssets>
    <FONR:TotalIdentifiableAssets
      contextRef="From2025-07-012026-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002157"
      unitRef="USD">219222000</FONR:TotalIdentifiableAssets>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002173"
      unitRef="USD">6382000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002174"
      unitRef="USD">70693000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002175"
      unitRef="USD">77075000</us-gaap:Revenues>
    <us-gaap:PaymentsToEmployees
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002181"
      unitRef="USD">2736000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002182"
      unitRef="USD">14419000</us-gaap:PaymentsToEmployees>
    <us-gaap:PaymentsToEmployees
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002183"
      unitRef="USD">17155000</us-gaap:PaymentsToEmployees>
    <FONR:RentExpenses
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002186"
      unitRef="USD">3601000</FONR:RentExpenses>
    <FONR:RentExpenses
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002187"
      unitRef="USD">3601000</FONR:RentExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002189"
      unitRef="USD">1390000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002190"
      unitRef="USD">23046000</FONR:OtherCostOfSalesExpenses>
    <FONR:OtherCostOfSalesExpenses
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002191"
      unitRef="USD">24436000</FONR:OtherCostOfSalesExpenses>
    <FONR:TotalCostOfSales
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002193"
      unitRef="USD">4126000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002194"
      unitRef="USD">41066000</FONR:TotalCostOfSales>
    <FONR:TotalCostOfSales
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002195"
      unitRef="USD">45192000</FONR:TotalCostOfSales>
    <us-gaap:SalariesAndWages
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002197"
      unitRef="USD">561000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002199"
      unitRef="USD">561000</us-gaap:SalariesAndWages>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002201"
      unitRef="USD">563000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:OtherResearchAndDevelopmentCosts
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002203"
      unitRef="USD">563000</FONR:OtherResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002205"
      unitRef="USD">1124000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:TotalResearchAndDevelopmentCosts
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002207"
      unitRef="USD">1124000</FONR:TotalResearchAndDevelopmentCosts>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002209"
      unitRef="USD">1701000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002210"
      unitRef="USD">8216000</FONR:SalariesAndWagesExpenses>
    <FONR:SalariesAndWagesExpenses
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002211"
      unitRef="USD">9917000</FONR:SalariesAndWagesExpenses>
    <FONR:RentExpense
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002213"
      unitRef="USD">939000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002214"
      unitRef="USD">68000</FONR:RentExpense>
    <FONR:RentExpense
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002215"
      unitRef="USD">1007000</FONR:RentExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002217"
      unitRef="USD">2200000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002218"
      unitRef="USD">6931000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002219"
      unitRef="USD">9131000</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002221"
      unitRef="USD">4840000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002222"
      unitRef="USD">15215000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <FONR:TotalSellingGeneralAndAdministrativeExpenses
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002223"
      unitRef="USD">20055000</FONR:TotalSellingGeneralAndAdministrativeExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002225"
      unitRef="USD">10090000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002226"
      unitRef="USD">56281000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002227"
      unitRef="USD">66371000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002229"
      unitRef="USD">-3708000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002230"
      unitRef="USD">14412000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002231"
      unitRef="USD">10704000</us-gaap:IncomeLossFromContinuingOperations>
    <FONR:InvestmentIncome
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002233"
      unitRef="USD">83000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002234"
      unitRef="USD">1543000</FONR:InvestmentIncome>
    <FONR:InvestmentIncome
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002235"
      unitRef="USD">1626000</FONR:InvestmentIncome>
    <us-gaap:OtherIncome
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002237"
      unitRef="USD">38000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002238"
      unitRef="USD">-21000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002239"
      unitRef="USD">17000</us-gaap:OtherIncome>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002241"
      unitRef="USD">-3587000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002242"
      unitRef="USD">15934000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002243"
      unitRef="USD">12347000</us-gaap:DiscontinuedOperationProvisionForLossGainOnDisposalBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002245"
      unitRef="USD">-2796000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002246"
      unitRef="USD">-222000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002247"
      unitRef="USD">-3018000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002249"
      unitRef="USD">-6383000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002250"
      unitRef="USD">15712000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002251"
      unitRef="USD">9329000</us-gaap:NetIncomeLoss>
    <FONR:IntersegmentNetRevenues
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002253"
      unitRef="USD">881000</FONR:IntersegmentNetRevenues>
    <FONR:IntersegmentNetRevenues
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002255"
      unitRef="USD">881000</FONR:IntersegmentNetRevenues>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002257"
      unitRef="USD">157000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002258"
      unitRef="USD">2184000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002259"
      unitRef="USD">2341000</us-gaap:DepreciationDepletionAndAmortization>
    <FONR:TotalIdentifiableAssets
      contextRef="From2024-07-012025-03-31_custom_ManufacturingAndServiceOfMedicalEquipmentMember"
      decimals="-3"
      id="Fact002261"
      unitRef="USD">33577000</FONR:TotalIdentifiableAssets>
    <FONR:TotalIdentifiableAssets
      contextRef="From2024-07-012025-03-31_us-gaap_HealthCareOtherMember"
      decimals="-3"
      id="Fact002262"
      unitRef="USD">181346000</FONR:TotalIdentifiableAssets>
    <FONR:TotalIdentifiableAssets
      contextRef="From2024-07-012025-03-31_custom_TotalMember"
      decimals="-3"
      id="Fact002263"
      unitRef="USD">214923000</FONR:TotalIdentifiableAssets>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact002276">&lt;p id="xdx_802_eus-gaap--CashFlowSupplementalDisclosuresTextBlock_zucOEgFs6Qbh" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 10 &#x2013; &lt;span id="xdx_82C_zup5nmcBG1m6"&gt;SUPPLEMENTAL CASH FLOW INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended March 31, 2026 and 2025,
the Company paid $&lt;span id="xdx_900_eus-gaap--InterestPaidNet_pn3n3_c20250701__20260331_zMlekA6gxXo3"&gt;8&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--InterestPaidNet_pn3n3_c20240701__20250331_zz5op64Z9YWk"&gt;21&lt;/span&gt; for interest, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended March 31, 2026 and 2025,
the Company paid $&lt;span id="xdx_900_eus-gaap--IncomeTaxesPaid_pn3n3_c20250701__20260331_zB6nWgmtgQf2"&gt;1,044&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--IncomeTaxesPaid_pn3n3_c20240701__20250331_zdKNQ3AZajuj"&gt;4,190&lt;/span&gt; for income taxes, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the nine months ended March 31, 2025, the Company
sold a &lt;span id="xdx_907_ecustom--RateOfInterestSold_pip0_dp_c20250701__20260331_zeDbLAP4hKjh" title="Rate of interest sold"&gt;0.197&lt;/span&gt;% interest in HDM to an employee. The interest was sold for $&lt;span id="xdx_901_eus-gaap--ConversionOfStockAmountConverted1_pn3n3_c20250701__20260331_z1acteCpoBg"&gt;132&lt;/span&gt; in a noncash transaction.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002277"
      unitRef="USD">8000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact002278"
      unitRef="USD">21000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002279"
      unitRef="USD">1044000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact002280"
      unitRef="USD">4190000</us-gaap:IncomeTaxesPaid>
    <FONR:RateOfInterestSold
      contextRef="From2025-07-01to2026-03-31"
      decimals="INF"
      id="Fact002282"
      unitRef="Ratio">0.00197</FONR:RateOfInterestSold>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002283"
      unitRef="USD">132000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact002285">&lt;p id="xdx_808_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zVDsfKHYbvVd" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 11 &#x2013; &lt;span id="xdx_82B_zOmwSxi81771"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt; &lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Litigation&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to legal proceedings and claims
arising from the ordinary course of its business, including personal injury, customer contract and employment claims. In the opinion of
management, the aggregate liability, if any, with respect to such actions, will not have a material adverse effect on the consolidated
financial position or results of operations of the Company.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 2, 2026, a Verified Stockholder Class
Action Complaint entitled Bruce Taylor v. Fonar Corporation et al., C.A. No. 2026-0142-JTL (Del. Ch.) (the &#x201c;Complaint&#x201d;), was
filed in the Delaware Court of Chancery by a putative FONAR stockholder (the &#x201c;Delaware Plaintiff&#x201d;), on behalf of himself and
all other similarly situated stockholders, against FONAR, the Parent Entities and members of the FONAR Board. The Complaint alleges that
the Parent Entities reached an &#x201c;agreement, arrangement or understanding,&#x201d; as those terms are defined in Section 203 of the
Delaware General Corporation Law (&#x201c;DGCL&#x201d;) (&#x201c;Section 203&#x201d;), among certain FONAR stockholders prior to the FONAR
Board&#x2019;s approval of the Merger, thereby triggering Section 203&#x2019;s requirement that at least 66 2/3% of the outstanding Company
Capital Stock unaffiliated with the Parent Entities vote in favor of the Merger (after giving effect to the respective voting powers of
each class of Company Capital Stock under FONAR&#x2019;s existing amended and restated certificate of incorporation). The Complaint seeks,
among other things, (1) an order declaring that the Merger is subject to Section 203&#x2019;s supermajority voting requirement, (2) an
order enjoining the vote on the Merger unless and until stockholders are informed that the Merger can close only if it is subject to Section
203&#x2019;s supermajority voting requirement, and (3) a finding that the members of the Board of Directors breached their fiduciary duties
by entering into the Merger Agreement without providing for a supermajority stockholder vote contemplated by Section 203. FONAR disputes
the Complaint&#x2019;s allegations, including the allegation that Section 203&#x2019;s supermajority voting requirement applies to the Merger.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In the ordinary course of its business, the Company
is a party to various lawsuits arising from the operations at the MRI sites and other insurance related matters, which are generally handled
by the Company&#x2019;s insurance carriers. Management believes, based in part on the advice counsel, that the ultimate resolution of these
matters will not have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations or cash
flows.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





































&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Other than as described under Note 14, there were no material changes in
litigation from that reported in our Form 10-K for the fiscal year ended June 30, 2025.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;Other Matters&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 13, 2022, the Company adopted a stock repurchase plan. The
plan has no expiration date and the Company cannot determine the number of shares which will be repurchased. On September 26, 2022, the
Board of Directors approved up to $&lt;span id="xdx_900_esrt--StockRepurchaseProgramAuthorizedAmount1_iI_pn3n3_c20220926__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zdK4EhOoLKSh"&gt;9,000&lt;/span&gt; to be repurchased under the plan which will be purchased on the publicly traded open market at
prevailing prices. The stock repurchase plan was suspended in the fourth quarter of fiscal 2025 due to the pending take private offer.
During the nine months ended March 31, 2026 and 2025, the Company repurchased &lt;span id="xdx_904_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20250701__20260331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zvESotlI0aM9"&gt;0&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_pn3n3_c20240701__20250331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zkeIz8R4Sq85"&gt;115&lt;/span&gt; shares at a cost of $&lt;span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20250701__20260331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zHgJtFF2n2H2"&gt;0&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--StockRepurchasedDuringPeriodValue_pn3n3_c20240701__20250331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zzqZJkkNA7Lk"&gt;1,806&lt;/span&gt;, respectively.
The Company cancelled &lt;span id="xdx_901_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pn3n3_c20250701__20260331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zm0m3TXSLJDi"&gt;31&lt;/span&gt; shares and &lt;span id="xdx_902_eus-gaap--StockRedeemedOrCalledDuringPeriodShares_pn3n3_c20240701__20250331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_z8IA5sliksbe"&gt;125&lt;/span&gt; shares at a cost of $&lt;span id="xdx_90F_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn3n3_c20250701__20260331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zsKX6sK8F1gj"&gt;465&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--StockRedeemedOrCalledDuringPeriodValue_pn3n3_c20240701__20250331__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zhGCk5nXVtac"&gt;1,963&lt;/span&gt; for the nine months ended March 31, 2026 and 2025, respectively.
As of March 31, 2026, the remaining balance under the repurchase plan was $&lt;span id="xdx_907_eus-gaap--StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_iI_pn3n3_c20260331_zaZdHwSlmV76"&gt;2,928&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company maintains a self-funded health insurance
program with a stop-loss umbrella policy with a third-party insurer to limit the maximum potential liability for individual claims to
$&lt;span id="xdx_90F_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpense_iI_pn3n3_c20260331_zK4j0smvRgqi"&gt;150&lt;/span&gt; per person and for a maximum potential claim liability based on member enrollment. With respect to this program, the Company considers
historical and projected medical utilization data when estimating its health insurance program liability and related expense. As of March
31, 2026 and June 30, 2025, the Company had approximately $&lt;span id="xdx_901_eus-gaap--SelfInsuranceReserve_iI_pn3n3_c20260331_zAaTvsNtKs8k"&gt;108&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--SelfInsuranceReserve_iI_pn3n3_c20250630_zaoxaQXRu7g8"&gt;260&lt;/span&gt;, respectively, in reserve for its self-funded health insurance
programs. The reserves are included in &#x201c;Other current liabilities&#x201d; in the condensed consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company regularly analyzes its reserves for incurred
but not reported claims, and for reported but not paid claims related to its reinsurance and self-funded insurance programs. The Company
believes its reserves are adequate. However, significant judgment is involved in assessing these reserves such as assessing historical
paid claims, average lags between the claims&#x2019; incurred date, reported dates and paid dates, and the frequency and severity of claims.
There may be differences between actual settlement amounts and recorded reserves and any resulting adjustments are included in expense
once a probable amount is known. There were no significant adjustments recorded in the periods covered by this report.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





























</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <srt:StockRepurchaseProgramAuthorizedAmount1
      contextRef="AsOf2022-09-26_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002303"
      unitRef="USD">9000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2025-07-012026-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002304"
      unitRef="Shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-07-012025-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002305"
      unitRef="Shares">115000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012026-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002306"
      unitRef="USD">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2024-07-012025-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002307"
      unitRef="USD">1806000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2025-07-012026-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002308"
      unitRef="Shares">31000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodShares
      contextRef="From2024-07-012025-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002309"
      unitRef="Shares">125000</us-gaap:StockRedeemedOrCalledDuringPeriodShares>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2025-07-012026-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002310"
      unitRef="USD">465000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRedeemedOrCalledDuringPeriodValue
      contextRef="From2024-07-012025-03-31_srt_BoardOfDirectorsChairmanMember"
      decimals="-3"
      id="Fact002311"
      unitRef="USD">1963000</us-gaap:StockRedeemedOrCalledDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002312"
      unitRef="USD">2928000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002313"
      unitRef="USD">150000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SelfInsuranceReserve
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002314"
      unitRef="USD">108000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact002315"
      unitRef="USD">260000</us-gaap:SelfInsuranceReserve>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact002330">&lt;p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zAlfAYFUMiRd" style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;NOTE 12 - &lt;span id="xdx_823_z0k2aW9cRsj6"&gt;INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In accordance with ASC 740-270, &#x201c;Income Taxes
&#x2013; Interim Reporting&#x201d;, the Company is required at the end of each interim period to determine the best estimate of its annual
effective tax rate and apply that rate to year-to-date ordinary income or loss. The resulting tax expense (or benefit) is adjusted for
the tax effect of specific events, if any, required to be discretely recognized in the interim period as they occur. For the nine months
ended March 31, 2026 and 2025, the Company recorded income tax expense of $&lt;span id="xdx_905_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20250701__20260331_zK4v0eWqGOqa"&gt;2,407&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20240701__20250331_zR2GMZPq6ich"&gt;3,018&lt;/span&gt;, respectively. For the nine months of fiscal
2026 and fiscal 2025, the income tax provision is comprised of a current income tax component of $&lt;span id="xdx_909_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_pn3n3_c20250701__20260331_zlxZVV9YOzh3"&gt;2,252&lt;/span&gt; and a deferred income tax component
of $&lt;span id="xdx_904_ecustom--DeferredIncomeTaxComponent_pn3n3_c20250701__20260331_zHzTUhwqhLBa" title="Deferred income tax component"&gt;155&lt;/span&gt; and a current income tax component of $&lt;span id="xdx_900_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_pn3n3_c20250101__20250331_z99BAQmhYsPf"&gt;2,140&lt;/span&gt; and a deferred income tax component of $&lt;span id="xdx_903_ecustom--DeferredIncomeTaxComponent_pn3n3_c20250101__20250331_zLR9vyXfGpCe" title="Deferred income tax component"&gt;878&lt;/span&gt;, respectively. For the three months ended
March 31, 2026 and 2025, the Company recorded income tax expense of $&lt;span id="xdx_903_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20260101__20260331_z5xZpsp0Djsd"&gt;492&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_pn3n3_c20250101__20250331_zZdENomiqEu7"&gt;1,006&lt;/span&gt;, respectively. Obligations for any liability associated
with the current income tax provision has been reduced, primarily resulting from the benefits and utilization of net operating loss carryforwards.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;ASC Topic 740 prescribes a recognition threshold and
a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a corporate
tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing
authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant
to the interpretation are referred to as unrecognized benefits. A liability is recognized (or amount of net operating loss carryforward
or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise&#x2019;s potential future obligation
to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC Topic 740. The Company
believes there are no uncertain tax positions in prior year tax filings and therefore it has not recorded a liability for unrecognized
tax benefits.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded a deferred tax asset of $&lt;span id="xdx_905_eus-gaap--DeferredTaxAssetsNet_iI_pn3n3_c20260331_zMPlnbXkYlv3"&gt;6,195&lt;/span&gt;
and a deferred tax liability of $&lt;span id="xdx_90F_eus-gaap--DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus_iI_pn3n3_c20260331_z2VncpjQ2WRe"&gt;321&lt;/span&gt; as of March 31, 2026, primarily relating to allowance for credit losses and tax credits.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company files corporate income tax returns in
the United States (federal) and in various state and local jurisdictions. In most instances, the Company is no longer subject to federal,
state and local income tax examinations by tax authorities for years prior to 2021.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Future ownership changes as determined under Section
382 of the Internal Revenue Code could further limit the utilization of net operating loss carryforwards. As of March 31, 2026, no such
changes in ownership have occurred.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 4, 2025, the One Big Beautiful Act (&#x201c;OBBA&#x201d;)
was signed into law, which enacts significant changes to the U.S. tax and related laws. Some of the provisions of the new tax law that
affect corporations include but are not limited to expensing of domestic specified research or experimental expenditures, increasing the
limit of the deduction to 30% of EBITDA, and 100% percent bonus depreciation on eligible property acquired after January 19, 2025. The
Company is currently evaluating the impact that the new tax law will have on its financial condition and results of operations.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




























</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002331"
      unitRef="USD">2407000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact002332"
      unitRef="USD">3018000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002333"
      unitRef="USD">2252000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <FONR:DeferredIncomeTaxComponent
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002335"
      unitRef="USD">155000</FONR:DeferredIncomeTaxComponent>
    <us-gaap:ExtinguishmentOfDebtGainLossNetOfTax
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact002336"
      unitRef="USD">2140000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
    <FONR:DeferredIncomeTaxComponent
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact002338"
      unitRef="USD">878000</FONR:DeferredIncomeTaxComponent>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact002339"
      unitRef="USD">492000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact002340"
      unitRef="USD">1006000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002341"
      unitRef="USD">6195000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002342"
      unitRef="USD">321000</us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityPolicyholdersSurplus>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact002356">&lt;p id="xdx_807_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z5Z4WBelKo6g" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 13 - &lt;span id="xdx_821_zDWJWdFGGWGc"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Tallahassee Magnetic Resonance Imaging, Inc., Stand
Up MRI of Boca Raton, Inc., and Stand Up MRI &amp;amp; Diagnostic Center, Inc. (all related medical practices) entered into a guaranty agreement,
pursuant to which they cross guaranteed all management fees which are payable to the Company, which have arisen under each individual
management agreement. As of March 31, 2026 and June 30, 2025, the net revenues owed to the Company was $&lt;span id="xdx_902_ecustom--NetRevenuess_iI_pn3n3_c20260331_zoSpsAmzlXtl" title="Net revenues"&gt;10,042&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--NetRevenuess_iI_pn3n3_c20250630_zfYC6eZvK82k" title="Net revenues"&gt;9,748&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Bensonhurst MRI Limited Partnership (&#x201c;Bensonhurst&#x201d;),
in which the CEO and President of the Company holds an interest, is party to an agreement with the Company for the service and maintenance
of its Upright MRI Scanner for a price of $&lt;span id="xdx_90E_ecustom--ServiceAndMaintenancePrice_iI_pn3n3_c20260331_z8MpqCaZZUfj" title="Service and maintenance price"&gt;110&lt;/span&gt; per annum. On February 1, 2024, Bensonhurst entered into a second contract with the Company
for the service and maintenance of a High-Field MRI Scanner for a price of $&lt;span id="xdx_90F_ecustom--ServiceAndMaintenancePrice_iI_pn3n3_c20240201_zgwDRtDN9a44" title="Service and maintenance price"&gt;70&lt;/span&gt; per annum. For the nine months ended March 31, 2026 and
2025, the Company recorded service and repair fees of $&lt;span id="xdx_903_ecustom--ServiceAndRepairFees_pn3n3_c20250701__20260331_zBL9hSzPRRz3" title="Service and repair fees"&gt;135&lt;/span&gt; and $&lt;span id="xdx_90E_ecustom--ServiceAndRepairFees_pn3n3_c20240701__20250331_zwpCnWQZE19c" title="Service and repair fees"&gt;135&lt;/span&gt;, respectively, from Bensonhurst. Also during the nine months ended
March 31, 2026 and 2025, the Company charged Bensonhurst $&lt;span id="xdx_90C_ecustom--ServiceAndRepairFees_pn3n3_c20260101__20260331_zOAfdI89Pelg" title="Service and repair fees"&gt;513&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--ServiceAndRepairFees_pn3n3_c20250101__20250331_zBO3pq4SB7F6" title="Service and repair fees"&gt;340&lt;/span&gt;, respectively, for reimbursable salaries and marketing expenses.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Integrity Healthcare Management, LLC, which is owned
by the CEO and President of the Company, owns a 7.1% interest in HMCA&#x2019;s Class A membership and receives distributions from the Company.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Radian Healthcare Management, LLC (&#x201c;Radian&#x201d;),
which is owned by the son-in-law of the CEO and President of the Company, provided the Company with personnel recruitment of new employees
at a fee of approximately $&lt;span id="xdx_903_ecustom--EmployeesFee_pn3n3_c20250701__20260331_z8JmppsSuxg4" title="Employees fee"&gt;125&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--EmployeesFee_pn3n3_c20240701__20250331_zcZKtVIxqHO5" title="Employees fee"&gt;150&lt;/span&gt; for the nine months ended March 31, 2026 and 2025, respectively.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 31, 2023, the Company entered into an
agreement with Magnetic Resonance Management, LLC (&#x201c;MRM&#x201d;) for the sale of a MRI scanner. MRM is owned by the CEO and President
of the Company. The sales price of the equipment was $&lt;span id="xdx_901_eus-gaap--ConvertibleNotesPayable_iI_pn3n3_c20230331__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zczIbRErTWlj" title="Convertible notes payable"&gt;577&lt;/span&gt; which is payable based upon a promissory note dated December 1, 2023. The note
bears interest at a rate of &lt;span id="xdx_901_eus-gaap--DerivativeFixedInterestRate_iI_pip0_dp_c20230331__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_z7Ts01k88iM4" title="Derivative fixed interest rate"&gt;9&lt;/span&gt;% and is payable in full at the maturity of the note in December 2028. During the nine months ended March
31, 2026 and 2025, the Company recorded $&lt;span id="xdx_908_eus-gaap--InvestmentIncomeNet_pn3n3_c20250701__20260331__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_z9TAqylgbM4h" title="Investment income"&gt;36&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--InvestmentIncomeNet_pn3n3_c20240701__20250331__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zF3ZjUNu0olf" title="Investment income"&gt;39&lt;/span&gt; in investment income, respectively, on this promissory note. Also during the three
months ended March 31, 2026 and 2025, the Company recorded $&lt;span id="xdx_900_eus-gaap--InvestmentIncomeNet_pn3n3_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zENXNlVJYMs9" title="Investment income"&gt;12&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--InvestmentIncomeNet_pn3n3_c20250101__20250331__us-gaap--TypeOfArrangementAxis__custom--MagneticResonanceManagementMember_zC9qohLBDDMe" title="Investment income"&gt;13&lt;/span&gt; in investment income, respectively. The Company has the option
but not the obligation to re-take possession of the scanner in lieu of payment upon maturity of the note.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;There were special one-time cash fee paid to the Company&#x2019;s
disinterested directors for their service on the Special Committee, which were paid in six equal monthly installments beginning in July
2025 and ending in December 2025 and were not contingent on consummation of the Merger or upon any other factor. Rick Turk received $200
as Chair of the committee and Robert Carrino received $175.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <FONR:NetRevenuess
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002358"
      unitRef="USD">10042000</FONR:NetRevenuess>
    <FONR:NetRevenuess
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact002360"
      unitRef="USD">9748000</FONR:NetRevenuess>
    <FONR:ServiceAndMaintenancePrice
      contextRef="AsOf2026-03-31"
      decimals="-3"
      id="Fact002362"
      unitRef="USD">110000</FONR:ServiceAndMaintenancePrice>
    <FONR:ServiceAndMaintenancePrice
      contextRef="AsOf2024-02-01"
      decimals="-3"
      id="Fact002364"
      unitRef="USD">70000</FONR:ServiceAndMaintenancePrice>
    <FONR:ServiceAndRepairFees
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002366"
      unitRef="USD">135000</FONR:ServiceAndRepairFees>
    <FONR:ServiceAndRepairFees
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact002368"
      unitRef="USD">135000</FONR:ServiceAndRepairFees>
    <FONR:ServiceAndRepairFees
      contextRef="From2026-01-012026-03-31"
      decimals="-3"
      id="Fact002370"
      unitRef="USD">513000</FONR:ServiceAndRepairFees>
    <FONR:ServiceAndRepairFees
      contextRef="From2025-01-012025-03-31"
      decimals="-3"
      id="Fact002372"
      unitRef="USD">340000</FONR:ServiceAndRepairFees>
    <FONR:EmployeesFee
      contextRef="From2025-07-01to2026-03-31"
      decimals="-3"
      id="Fact002374"
      unitRef="USD">125000</FONR:EmployeesFee>
    <FONR:EmployeesFee
      contextRef="From2024-07-012025-03-31"
      decimals="-3"
      id="Fact002376"
      unitRef="USD">150000</FONR:EmployeesFee>
    <us-gaap:ConvertibleNotesPayable
      contextRef="AsOf2023-03-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="Fact002378"
      unitRef="USD">577000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="AsOf2023-03-31_custom_MagneticResonanceManagementMember"
      decimals="INF"
      id="Fact002380"
      unitRef="Ratio">0.09</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2025-07-012026-03-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="Fact002382"
      unitRef="USD">36000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2024-07-012025-03-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="Fact002384"
      unitRef="USD">39000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2026-01-012026-03-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="Fact002386"
      unitRef="USD">12000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="From2025-01-012025-03-31_custom_MagneticResonanceManagementMember"
      decimals="-3"
      id="Fact002388"
      unitRef="USD">13000</us-gaap:InvestmentIncomeNet>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact002390">&lt;p id="xdx_80E_eus-gaap--SubsequentEventsTextBlock_zQ8WomiaRR9d" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;NOTE 14 - &lt;span id="xdx_821_zrjeImYYT5e7"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has evaluated events that occurred subsequent
to March 31, 2026 and through the date the condensed consolidated financial statements were issued.&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 16, 202, the Company filed a definitive proxy
statement under Regulation 14A of the Exchange Act, and a related Transaction Statement on Schedule 13E-3/A, as amended, with the SEC
in connection with the proposed Merger, for use at a special meeting of the Company&#x2019;s stockholders (the &#x201c;Special Meeting&#x201d;)
scheduled for 11:00 a.m., New York time, on May 28, 2026. At the Special Meeting, stockholders will be asked to consider and vote upon,
among other things, a proposal to adopt the Merger Agreement.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="From2025-07-01to2026-03-31" id="Fact002391">

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Rule 10b5-1 Trading Plan&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal quarter ended March 31, 2026, none
of our directors or executive officers &lt;span id="xdx_90B_eecd--Rule10b51ArrAdoptedFlag_dbT_c20250701__20260331_zyM0ndjuukqf"&gt;&lt;span id="xdx_903_eecd--NonRule10b51ArrAdoptedFlag_dbT_c20250701__20260331_zCsC0s0KbWzi"&gt;adopted&lt;/span&gt;&lt;/span&gt; or &lt;span id="xdx_90A_eecd--Rule10b51ArrTrmntdFlag_dbT_c20250701__20260331_zc37rZH9MfYh"&gt;&lt;span id="xdx_905_eecd--Rule10b51ArrTrmntdFlag_dbT_c20250701__20260331_zQzHUP33tLMk"&gt;terminated &lt;/span&gt;&lt;/span&gt;any contract, a Rule 10b5-1(c) or any &#x201c;non-Rule 10b5-1 trading arrangement&#x201d;
as each term is defined in Item 408(a) of Regulation S-K.&lt;/p&gt;

</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2025-07-01to2026-03-31" id="Fact002392">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2025-07-01to2026-03-31" id="Fact002393">true</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-07-01to2026-03-31" id="Fact002394">true</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2025-07-01to2026-03-31" id="Fact002395">true</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
